Search by Journal
- HOME
- > Search by Journal
- > Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Volume , Issue suppl.1 / 2021
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
YPL. ... which overlooks the clinical pharmacy for intention in tradition and challenge, evolution - future 齋藤秀之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1-1, 2021. |
|---|
|
|
PL. For further development and contribution to society of the clinical pharmacy: Efforts and problem of this academic conference 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 2-2, 2021. |
|---|
|
|
SL1. Evidence from the multicenter clinical studies for 25 years 小川久雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 3-3, 2021. |
|---|
|
|
SL2. From current situation and this of the organ reproduction using the bio3D printer 中山功一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 4-4, 2021. |
|---|
|
|
SL3. The pharmaceutical management and preparation development that assumed clinical pharmacy a base 佐々木均 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 5-5, 2021. |
|---|
|
|
SL4. From AIDS therapeutic drug development to the development of hepatitis B and the COVID-19 therapeutic drug 満屋裕明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 6-6, 2021. |
|---|
|
|
EL1. It is ... from the situation of the role - pharmacy school general medicine specialist who is a graduate of pharmacist in the future 駒ヶ嶺順平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 7-7, 2021. |
|---|
|
|
EL2. It is ... for practice - continuation-like pharmacy management of the POS 山本雄一郎1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 8-8, 2021. |
|---|
|
IL. Current Issues in Oncology Pharmacy Practice Management James G. Stevenson Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 9-9, 2021. |
|---|
|
|
Receiving a prize -1. Effect of pharmacokinetics and the condition of a patient change that a transporter is involved in 井関健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 11-11, 2021. |
|---|
|
|
Receiving a prize -2. A correlative study with quantity of exposure of the anticancer medicine and effective/toxicity and establishment of the individualization administration based on the quantity of exposure regulations factor 今村知世 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 12-12, 2021. |
|---|
|
|
Receiving a prize -3. Practice of the fur Matthew tical care to patients with cancer 川上和宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 13-13, 2021. |
|---|
|
|
Receiving a prize -4. Evidence construction for the side effect evasion of the cancer medical therapy that assumed pharmacokinetic approach a base 池村健治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 14-14, 2021. |
|---|
|
|
Receiving a prize -5. Research of the analysis approach of the clinical pharmacy study by the inflection of data mining technique and big data 今井俊吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 15-15, 2021. |
|---|
|
|
Receiving a prize -6. Construction of the treatment stratification marker aiming at precisely medical realization 平井啓太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 16-16, 2021. |
|---|
|
|
Receiving a prize -7. Development of the efficacy analysis study aiming at the appropriate clinical use and development of pharmaceutical products 山田安彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 18-18, 2021. |
|---|
|
|
Receiving a prize -8. Development of all phosphatide class high sensitivity high throughput assays 森田真也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 19-19, 2021. |
|---|
|
|
Receiving a prize -9. The antimicrobial individualization administration plan that planned drug resistant bacterium infection control 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 20-20, 2021. |
|---|
|
|
Receiving a prize -10. Study on exposure measures and adherence of the oral anticancer medicine in the cancer medical therapy and side effect management 小林一男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 21-21, 2021. |
|---|
|
|
Receiving a prize -11. Creation of the clinical outcome by the pharmacist specialized in a cancer 齋藤佳敬 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 22-22, 2021. |
|---|
|
|
Receiving a prize -12. Study on infection prevention of the antimicrobial based on Pharmacokinetics/pharmacodynamics and individual optimization in the treatment 横山雄太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 23-23, 2021. |
|---|
|
|
PA-1. Participation of intracerebral fatty acid - GPR40/FFAR1 in the chronic pain formation mechanism by the repeated stress exposure 相澤風花 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 25-25, 2021. |
|---|
|
|
PA-2. The elucidation of the risk factor of the Clozapine-induced hypersalivation and search of the therapy 石川修平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 26-26, 2021. |
|---|
|
|
PA-3. Practice of the clinical Pharmacometrics aiming at individual optimization of infection treatment in elderly people 石原慎之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 27-27, 2021. |
|---|
|
|
PA-4. Application to construction and genetic polymorphism variant enzymatic function analysis of the high active cytochrome P450 expression system with the mammal cell line 公文代將希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 28-28, 2021. |
|---|
|
|
PA-5. Development of the simple, quick LC-MS/MS method for absolute densitometry of human serum cetuximab using trypsin to immobilize 柴田海斗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 29-29, 2021. |
|---|
|
|
PA-6. The study on general strategy for the polypharmacy of patients with chronic kidney disease: Treatment by pre-Io fatty tuna pick effect application of the oxidative stress control 成田勇樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 30-30, 2021. |
|---|
|
|
PA-7. Study on molecular mechanism determining Human monocarboxylate transporter 1, difference in 4 (hMCT1, 4) substrate selectivity 二木悠哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 31-31, 2021. |
|---|
|
|
PA-8. Database study for the actual situation analysis and the cancellation on polypharmacy 馬渕賢幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 32-32, 2021. |
|---|
|
|
PA-9. Kinase inhibition by the fusion of a data base and the clinical data and the relative visualization of the adverse event and the clinical application 水野貴仁1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 33-33, 2021. |
|---|
|
|
PA-10. Study on pharmacokinetics of the emergency intensive care domain patients 山崎伸吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 34-34, 2021. |
|---|
|
|
PA-11. Analysis of the reaction kinetics of the drug metabolizing enzyme in the organ out of the liver and study on expression change 朝居祐貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 36-36, 2021. |
|---|
|
|
PA-12. The clinical pharmacy study that assumed drug metabolism for the proper use of the immunosuppressive drug and interaction a base 宇野貴哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 37-37, 2021. |
|---|
|
|
PA-13. Study on usefulness of the establishment of the antimicrobial proper use support system which a pharmacist leads and the intervention of the clinical pharmacy 大橋健吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 38-38, 2021. |
|---|
|
|
PA-14. Study on contribution of the pharmacist in the medical treatment management based on the protocol 片田佳希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 39-39, 2021. |
|---|
|
|
PA-15. Low BMI and the myeloablative pre-treatment regimen extend intravenous alimentation dosing period in the hematopoietic stem cell transplantation 神谷貴樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 40-40, 2021. |
|---|
|
|
PA-16. Study on usefulness elucidation of clinical information, the genetic polymorphism information for the tacrolimus individualization administration plan after the hematopoietic stem cell transplantation 末次王卓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 41-41, 2021. |
|---|
|
|
PA-17. Development of adverse event management, the individualization medical therapy that pointed to safe improvement in rare cancer treatment スタッブ由紀子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 42-42, 2021. |
|---|
|
|
PA-18. Study on drug resistance of the Haemophilus influenzae 瀬山翔史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 43-43, 2021. |
|---|
|
|
PA-19. Study on venous thromboembolism and anticoagulation in patients with cancer 平出誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 44-44, 2021. |
|---|
|
|
PA-20. Effect and relations with those CYP3A activity markers and serum Na level that CYP3A5 genotype gives to pharmacokinetics of the tolvaptan in the patients with heart failure 星川昂平1, 内藤隆文1, 阿久津駿太1, 早乙女雅夫2, 前川裕一郎2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 45-45, 2021. |
|---|
|
|
International Symposium1. Challenge and Evolution of Pharmaceutical Health Care and Sciences for the Next Decade 1 Ikuko Yano, Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 46-46, 2021. |
|---|
|
|
IS01-1. Role of pharmacist on rational drug use under the DRG payment method in the future in China Dechun Jiang Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 47-47, 2021. |
|---|
|
|
IS01-2. Evaluating Trastuzumab-Related Cardiotoxic Effects : An Example How Features of Real World Data Impact Study Design and Analytical Approaches Hsu-Chih Chien Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 48-48, 2021. |
|---|
|
|
IS01-3. Evolving model of care post haematopoietic stem cell transplantation : optimising multidisciplinary care (the PostMAN Clinic) Midori Nakagaki1, Nicole C Gavin2,3, Therese Hayes2, Rebecca Fichera4, Caroline Stewart2, Leonie Naumann5, Justine Brennan6, Natasha Perry2, Emma Foley7, Erin Crofton2, Christie Brown5, Jenni Leutenegger2, Glen A Kennedy2,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 49-49, 2021. |
|---|
|
|
IS01-4. Pharmacist interventions to improve the safety incancer patients receiving chemotherapy Mayako Uchida Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 50-50, 2021. |
|---|
|
|
International Symposium2. Challenge and Evolution of Pharmaceutical Health Care and Sciences for the Next Decade 2 Ikuko Yano, Yasuo Takeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 51-51, 2021. |
|---|
|
|
IS02-1. Pharmaceutical GS1 barcodes for patient safety : Traceability and access to drug information Koich Uemura1, Takao Orii2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 52-52, 2021. |
|---|
|
|
IS02-2. Impact of a board certified pharmacist-led antimicrobial stewardship for patients receiving antimicrobial injection Takashi Niwa Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 53-53, 2021. |
|---|
|
|
IS02-3. Evaluation of Palliative Care Pharmacists' Interventions and Outcomes Sari Nakagawa1,2, Yoshiaki Okamoto2, Chika Tokuyama1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 54-54, 2021. |
|---|
|
|
IS02-4. Challenges in the optimization of kidney disease therapy by Nephrology and Pharmacotherapy Specialists Kazuhiro Yamamoto Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 55-55, 2021. |
|---|
|
|
IS02-5. Relationship between CYP3A5 polymorphism and tacrolimus blood concentration changes in allogeneic hematopoietic stem cell transplant recipients during continuous infusion Naoki Yoshikawa, Ryuji Ikeda Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 56-56, 2021. |
|---|
|
|
Symposium 1. Term of ... organizer regarding palliative treatment as the approach in consideration of renal function in the cancer medical care from ... chemotherapy seamlessly 岸本真, 上ノ段友里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 59-59, 2021. |
|---|
|
|
S01-1. Invitation to approach "in consideration of renal function in" cancer medical care 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 60-60, 2021. |
|---|
|
|
S01-2. Knead on; fluoroGee outline 門脇大介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 61-61, 2021. |
|---|
|
|
S01-3. About the oral anticancer agent and renal function evaluation in the health insurance pharmacy 長久保久仁子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 62-62, 2021. |
|---|
|
|
S01-4. It is ... mainly on renal function evaluation - injection drug in the cancer medical therapy 上ノ段友里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 63-63, 2021. |
|---|
|
|
S01-5. From the position of the palliative care pharmacist Total Care - at - decreased renal function 森理保 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 64-64, 2021. |
|---|
|
|
Symposium 2. Term of relation intervention and case - organizer to summary ... rare case of the pharmacist specialized in a cancer 河原昌美, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 65-65, 2021. |
|---|
|
|
S02-1. Expect it about the case examination of the pharmacist specialized in a cancer 河原昌美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 66-66, 2021. |
|---|
|
|
S02-2. Interaction evasion case with herb and grapefruit juice and the paclitaxel 大辻貴司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 67-67, 2021. |
|---|
|
|
S02-3. Case of the DPD slow-up symptom that caused Serious ADR of the capecitabine 下川福子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 68-68, 2021. |
|---|
|
|
S02-4. The case that judged the bendamustine administration to patients with renal disease from pharmacokinetic grounds 宮島律子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 69-69, 2021. |
|---|
|
|
S02-5. Pharmaceutical intervention to the patients that chemotherapy falls on a menstrual cycle 小倉真由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 70-70, 2021. |
|---|
|
|
S02-6. The case that adrenal hypofunction was suspected in nivolumab following dermatopathy 中野泰寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 71-71, 2021. |
|---|
|
|
S02-7. Relation licensee to the case through the extensive viewpoint 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 72-72, 2021. |
|---|
|
|
Symposium 3. It is the term of the organizer for the cancer medical therapy support - cooperation full addition and calculation promotion of specific drug management instruction addition 2 to work on in an area 辻井聡容, 小玉博一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 73-73, 2021. |
|---|
|
|
S03-1. About the cooperation full addition calculation in the university hospital and the problem 丹田雅明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 74-74, 2021. |
|---|
|
|
S03-2. About the cooperation full addition calculation in the local core hospital and the problem 廣畑秀記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 75-75, 2021. |
|---|
|
|
S03-3. About the cooperation full addition calculation in the small hospital and the problem 岡本勇二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 76-76, 2021. |
|---|
|
|
S03-4. Calculation of specified drug management guidance premium 2 at insurance pharmacies and its issues, and introduction of the Takarazuka-drug collaboration "Takara-tu-ka Association" 畑世剛1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 77-77, 2021. |
|---|
|
|
S03-5. Setting and activity report ... of efforts ... advanced drug duties special committee of the foreign cancer chemotherapy support by the Hyogo hospital pharmacist society, Hyogo pharmacist society 辻井聡容 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 78-78, 2021. |
|---|
|
|
Symposium 4. Examine pharmacist upbringing and illness corresponding to the cancer medical therapy; the term of the construction organizer of the medicine cooperation 近藤元三, 山室蕗子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 79-79, 2021. |
|---|
|
|
S04-1. We examine pharmacist upbringing and illness corresponding to the cancer medical therapy and are built the medicine cooperation 近藤元三 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 80-80, 2021. |
|---|
|
|
S04-2. Efforts and problem of the local prefecture-designated cancer practice cooperation base hospital 西千春 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 81-81, 2021. |
|---|
|
|
S04-3. Efforts in the area cancer practice cooperation base Hospital 合澤啓二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 82-82, 2021. |
|---|
|
|
S04-4. Efforts in the metropolis and districts cancer practice cooperation base Hospital 大山高廣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 83-83, 2021. |
|---|
|
|
S04-5. Efforts in the pharmacist training institution (basic institution) specialized in local pharmacy care 山室蕗子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 84-84, 2021. |
|---|
|
|
S04-6. Efforts in the pharmacist training institution (cooperation institution) specialized in local pharmacy care 稲葉一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 85-85, 2021. |
|---|
|
|
Symposium 5. Term of real - organizer of the cancer reproductive medicine practice to want to know one step in - now to step 日置三紀, 米村雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 86-86, 2021. |
|---|
|
|
S05-1. Cancer treatment and generative function, hypogonadism - basics-like way of thinking and recent topic - 日置三紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 87-87, 2021. |
|---|
|
|
S05-2. As a medical person, how do you face each other in the nature of patients with cancer and a generative problem? 安宅大輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 88-88, 2021. |
|---|
|
|
S05-3. From cancer treatment and position of generative function - hospital pharmacist that a story complies with before treatment 小室雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 89-89, 2021. |
|---|
|
|
S05-4. From a cancer and the position of support - family pharmacist to living women that a story complies with in life 宮原富士子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 90-90, 2021. |
|---|
|
|
Symposium 6. It is the term of the organizer from a viewpoint of the environmental change regional alliances hospitalization and release support remote instruction to think about the strategic intervention by the medication adherence maintenance difficulty case 田上直美, 尾崎淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 91-91, 2021. |
|---|
|
|
S06-1. What is made for the explanation medication adherence maintenance difficulty case of the plan purpose? 尾崎淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 92-92, 2021. |
|---|
|
|
S06-2. Efforts of our hospital for HIV-positive patients 野田綾香1,2, 野村直幸1,2, 河野泰弘1,2, 倉本成一郎1, 田村浩二1, 山崎由佳2, 飯塚暁子2, 木梨貴博2, 藤原千尋2, 門田悦子2, 齊藤誠司2, 坂田達朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 93-93, 2021. |
|---|
|
|
S06-3. Utilization and drug control support of the online medication counseling 宮崎美世 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 94-94, 2021. |
|---|
|
|
S06-4. It is ... from the situation of hospitalization and release support, regional alliances - MSW for medication support of patients 岡本学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 95-95, 2021. |
|---|
|
|
S06-5. About strategic intervention of the medication adherence in patients with mental disorder 竹林実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 96-96, 2021. |
|---|
|
|
Symposium 7. Term of new possibility - organizer of the pharmacist sought by challenge - extensive pharmacy management to "HIV infection X cancer chemotherapy X relaxation medical care" 平野淳, 石原千春 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 97-97, 2021. |
|---|
|
|
S07-1. The current situation of "the HIV infection X cancer chemotherapy X relaxation medical care" 平野淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 98-98, 2021. |
|---|
|
|
S07-2. It is ... from the situation of pharmacist cancer (temporarily) specialized in problems - area pharmacy care of "the HIV infection X cancer chemotherapy X relaxation medical care" in regional alliances 石原千春 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 99-99, 2021. |
|---|
|
|
S07-3. A ratio and interhospital cooperation of patients with HIV infection in the cancer special hospital 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 100-100, 2021. |
|---|
|
|
S07-4. The current situation and problem of patients with HIV infection and "the antiHIV therapy X cancer chemotherapy X relaxation medical care" 矢倉裕輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 101-101, 2021. |
|---|
|
|
S07-5. The drug interaction management of "the antiHIV medicine X antitumor agents X opioid" 石原正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 102-102, 2021. |
|---|
|
|
S07-6. Expectation to the pharmacist from the viewpoint of "HIV infection X cancer chemotherapy X relaxation medical care" medical care policy 横幕能行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 103-103, 2021. |
|---|
|
|
Symposium 8. Term of the upbringing organizer of next-generation leader (pharmacist-scientists) intending better cancer medical care 河添仁, 横川貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 104-104, 2021. |
|---|
|
|
S08-1. To you to be a pharmacist, a cancer instruction pharmacist specialized in a cancer: The beginning is an abecedarian in anyone 河添仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 105-105, 2021. |
|---|
|
|
S08-2. It is ... from the position of own omen case - abecedarian of clinical studies by the hospital pharmacist 島貫裕実子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 106-106, 2021. |
|---|
|
|
S08-3. Significance of a study and the graduation to solve a clinical problem in the cancer chemotherapy 横川貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 107-107, 2021. |
|---|
|
|
S08-4. The present and the future prospects that moved from the healthcare setting to academia 林稔展, 中野貴文, 江川孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 108-108, 2021. |
|---|
|
|
S08-5. Gut flora and tumor im-munity 金倫基 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 109-109, 2021. |
|---|
|
|
Symposium 9. Term of clinical studies - organizer performing it in intention in challenge and evolution - future to the side effect management in cancer treatment 川田敬, 林稔展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 110-110, 2021. |
|---|
|
|
S09-1. We search optimal antiemesis therapy 林稔展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 111-111, 2021. |
|---|
|
|
S09-2. Development of the quick and safe cancer supportive care that assumed medical big data a base 相澤風花1, 梶本春奈2, 森山大嗣2, 新村貴博1, 合田光寛2,3, 新田綾香1, 高橋志門1, 濱野裕章2, 八木健太3, 石澤有紀4, 座間味義人1,2,5, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 112-112, 2021. |
|---|
|
|
S09-3. We think about the appropriate bowel movement management in patients with blood cancer 川田敬 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 113-113, 2021. |
|---|
|
|
S09-4. Pharmacist-led clinical research aimed at improving therapeutic efficacy in cancer chemotherapy - Adverse events as a prognostic predictor - 藤井宏典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 114-114, 2021. |
|---|
|
|
S09-5. Effect on hemodynamics with the oral medication (5-aminolevulinic acid) for the cancer diagnosis and the pharmacologic action 森沢惇平1,2, 石田智滉1, 川田敬1,2, 常風興平1, 福田仁3, 川西裕3, 中山沢4, 山本新九郎5, 政平訓貴6, 上羽哲也3, 井上啓司4,5, 宮村充彦1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 115-115, 2021. |
|---|
|
|
Symposium 10. Term of the case report organizer whom a clinical pharmacist receives 百賢二, 安武夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 116-116, 2021. |
|---|
|
|
S10-1. The case that was able to deal with drug interaction by medicine - medicine cooperation using the tracing report 渡邊亜矢子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 117-117, 2021. |
|---|
|
|
S10-2. An example of patients with breast cancer that presented cancer cachexia in the treatment at home 大野朋子1,2, 百賢二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 118-118, 2021. |
|---|
|
|
S10-3. Example that naldemedine was useful for the bowel control in patients with COVID-19 serious case pneumonia under the artificial respiration management 疋田絵梨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 119-119, 2021. |
|---|
|
|
S10-4. Making of the case report which a college of pharmacy supports 安武夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 120-120, 2021. |
|---|
|
|
S10-5. A point of the case report and study ethic 百賢二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 121-121, 2021. |
|---|
|
|
Symposium 11. Term of knowledge and the skill organizer of the infection domain demanded from all pharmacists after a corona evil 村木優一, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 122-122, 2021. |
|---|
|
|
S11-1. Skill to practice Antimicrobial stewardship activity and a study 浜田幸宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 123-123, 2021. |
|---|
|
|
S11-2. We think about hospital infection measures necessary for a pharmacist now 中川博雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 124-124, 2021. |
|---|
|
|
S11-3. People and connection, career path of the young pharmacist who is cultivated in science if clinical 花井雄貴1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 125-125, 2021. |
|---|
|
|
S11-4. I was able to do it, too; is practice support and team approach in medical care and a clinical pharmacy study 朝岡みなみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 126-126, 2021. |
|---|
|
|
Symposium 12. Make use of the professional ability of operability - pharmacist of the double blind trial targeted for the placebo in the support/palliative treatment regional study; and the term of ... organizer 米村雅人, 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 127-127, 2021. |
|---|
|
|
S12-1. The clinical studies in support/palliative treatment domain and the system maintenance 全田貞幹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 128-128, 2021. |
|---|
|
|
S12-2. About a way of thinking about the setting of the placebo drug 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 129-129, 2021. |
|---|
|
|
S12-3. Example of the choice of the placebo medicine in the researcher-led clinical study 米村雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 130-130, 2021. |
|---|
|
|
S12-4. To conduct a clinical study with high quality using the placebo drug 岡野朋果 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 131-131, 2021. |
|---|
|
|
Symposium 13. Do the sale reporting guidelines inhibit information sharing? Term of the way of the reporting after ... GL and the clinical on-site information needs organizer 吉光寺敏泰, 渡邊伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 132-132, 2021. |
|---|
|
|
S13-1. The current situation of the guidelines about the sale reporting activity on ethical drug and the sale reporting activity surveillance business 山本剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 133-133, 2021. |
|---|
|
|
S13-2. The current situation of the response of the pharmaceutical company to sale reporting activity guidelines 羽田野誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 134-134, 2021. |
|---|
|
|
S13-3. The current situation and problem (from the situation of the physician) of the reporting by the pharmaceutical company after the guidelines enforcement 深田雅之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 135-135, 2021. |
|---|
|
|
S13-4. To make current situation and problem (from the position of the pharmacist) "sale reporting activity GL" of the reporting the healthcare setting on the common ruler of the pharmaceutical company 後藤伸之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 136-136, 2021. |
|---|
|
|
S13-5. Found clinical study information, the clinical study information that is not asked for 漆原尚巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 137-137, 2021. |
|---|
|
|
Symposium 14. Treat the information from the pharmaceutical company for adequacy of the information provided by the pharmaceutical company how in the ... new life era; or the term of ... organizer 若林進, 水八寿裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 138-138, 2021. |
|---|
|
|
S14-1. For adequacy of the information provided by the pharmaceutical company 若林進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 139-139, 2021. |
|---|
|
|
S14-2. It is MR authorization system drastic reform for adequacy of the information provided by MR 近澤洋平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 140-140, 2021. |
|---|
|
|
S14-3. How should the pharmaceutical company deal for the new life era? 水八寿裕1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 141-141, 2021. |
|---|
|
|
S14-4. Efforts ... of the ... Tokyo hospital pharmacist society evaluating the reporting from the pharmaceutical company definitely 佐々木祐樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 142-142, 2021. |
|---|
|
|
Symposium 15. Realize high quality pharmaceutical approach from the large field; is the term of expectation - organizer to ... specialty pharmacist 樋口則英, 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 143-143, 2021. |
|---|
|
|
S15-1. Clinical pharmaceutics 兒玉幸修 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 144-144, 2021. |
|---|
|
|
S15-2. Pharmacogenetics to inflect by pharmacogenetics ... true clinical practice 辻大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 145-145, 2021. |
|---|
|
|
S15-3. Medical therapy of elderly people 木村丈司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 146-146, 2021. |
|---|
|
|
S15-4. The way of thinking of the side effect and the way of correspondence 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 147-147, 2021. |
|---|
|
|
Symposium 16. Term of team approach in medical care and evidence creation - organizer by pharmacist power ... multi-type of job cooperation tried in Onco-Nephrology 堀松高博, 池見泰明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 148-148, 2021. |
|---|
|
|
S16-1. Role of the kidney physician in Onco-Nephrology 桑原孝成, 神吉智子, 水本輝彦, 向山政志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 149-149, 2021. |
|---|
|
|
S16-2. Anticancer medicine proper use in a decreased renal function, patients on dialysis based on the drug information 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 150-150, 2021. |
|---|
|
|
S16-3. up to date of renal failure practice guidelines 2016 at the cancer medical therapy 船越太郎, 堀松高博, 武藤学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 151-151, 2021. |
|---|
|
|
S16-4. Achievement of the pharmacist specialized in cancer in the Onco-Nephrology domain 野田哲史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 152-152, 2021. |
|---|
|
|
Symposium 17. Term of ... latest knowledge and problem - organizer updating the cancer medical therapy of the decreased renal function patients 山本和宏, 藤田行代志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 153-153, 2021. |
|---|
|
|
S17-1. Cancer medical therapy overview of the decreased renal function patients 山本和宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 154-154, 2021. |
|---|
|
|
S17-2. The latest knowledge of the cancer medical therapy for elderly people 藤田行代志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 155-155, 2021. |
|---|
|
|
S17-3. The latest knowledge of the anticancer medicine administration plan for the decreased renal function patients 小泉祐一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 156-156, 2021. |
|---|
|
|
S17-4. The latest knowledge of the anticancer medicine administration plan in patients on dialysis 山本武人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 157-157, 2021. |
|---|
|
|
S17-5. The latest knowledge of the cancer immune therapy in dialysis, renal-transplant recipients 岡田直人1, 座間味義人1,2,3, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 158-158, 2021. |
|---|
|
|
S17-6. The latest knowledge of relaxation, the supportive care in the decreased renal function patients 宮本康敬 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 159-159, 2021. |
|---|
|
|
Symposium 18. Term of the current situation, the further spread of Biosimilar in the clinical practice and the problem organizer 斎藤嘉朗, 米澤淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 160-160, 2021. |
|---|
|
|
S18-1. The current situation, the further spread of Biosimilar in the clinical practice and the problem 米澤淳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 161-161, 2021. |
|---|
|
|
S18-2. About use of the Biosimilar in the intratumoral science 飯田真介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 162-162, 2021. |
|---|
|
|
S18-3. Consideration about the consciousness of the physician based on the questionnaire findings for physicians who related to four kinds of disease domains about Biosimilar 青木良子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 163-163, 2021. |
|---|
|
|
S18-4. Clinical efforts for the Biosimilar spread 百賢二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 164-164, 2021. |
|---|
|
|
S18-5. Efforts to use of Biosimilar to work on by a one team 関屋裕史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 165-165, 2021. |
|---|
|
|
Symposium 19. A medical treatment intervention practice case and term of the evidence organizer to be able to arrive from the young pharmacist of the front line engaging in infection practice 山田智之, 枦秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 166-166, 2021. |
|---|
|
|
S19-1. Activity ... of the Osaka antimicrobial club for education and tradition - young person pharmacist of the antimicrobial proper use support activity in the area 山田智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 167-167, 2021. |
|---|
|
|
S19-2. Yell ... from treatment intervention and the idea culture - young person to a cyst of thyroid infection case to a young person 竹内祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 168-168, 2021. |
|---|
|
|
S19-3. A person from Japan which stood on the shoulder of the giant practiced Antimicrobial Stewardship 枦秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 169-169, 2021. |
|---|
|
|
S19-4. COVID-19 and Antimicrobial Stewardship 村上修太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 170-170, 2021. |
|---|
|
|
S19-5. Pharmacist intervention practice case to infection practice in the ER 齋藤靖弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 171-171, 2021. |
|---|
|
|
S19-6. Optimized Treatment which challenges an infection of a variety of background with every effort 檜山洋子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 172-172, 2021. |
|---|
|
|
Symposium 20. Term of the qualitative improvement and problem organizer of the pharmacist education to take a revision model core curriculum and the next generation on 平田收正, 段林正明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 173-173, 2021. |
|---|
|
|
S20-1. About instruction of the business training utilized the literature evaluation (practice medical treatment) 中田和宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 174-174, 2021. |
|---|
|
|
S20-2. About instruction of the business training in the drug information (DI) 吉田紗理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 175-175, 2021. |
|---|
|
|
S20-3. About instruction of the business training in the infection domain 植竹宣江 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 176-176, 2021. |
|---|
|
|
S20-4. From the position of the ward pharmacist associated with - COVID-19 thinking about the information utilization that a pharmacist can do with a business trainee - 松本乃里子1, 加藤隆寛1, 竹内正幸1, 塩田有史1,2, 築山郁人3, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 177-177, 2021. |
|---|
|
|
S20-5. The current situation and problem of the instruction about the acute phase medical care in the business training 添田博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 178-178, 2021. |
|---|
|
|
S20-6. A problem and the future in the multi-type of job cooperation education 津田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 179-179, 2021. |
|---|
|
|
Symposium 21. Where can the innovation - pharmacist of the blood pressure management contribute to? Term of ... organizer 土岐真路, 芦川直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 180-180, 2021. |
|---|
|
|
S21-1. Here is important! Blood pressure management 岸拓弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 181-181, 2021. |
|---|
|
|
S21-2. The knowledge that you should know when a pharmacist talks about blood pressure 篠原徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 182-182, 2021. |
|---|
|
|
S21-3. Efforts to raise awareness of self-assessment of blood pressure at pharmacies - Nagano Prefecture Pharmacists Association's "Let's Measure Blood Pressure" campaign - 高田弘子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 183-183, 2021. |
|---|
|
|
S21-4. Invisible outcome of management method - depression management that considered over high blood pressure and comorbidities and patients background and visible individualization monitoring ... 土岐真路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 184-184, 2021. |
|---|
|
|
S21-5. We can do it because it is life-style related diseases and blood pressure management - pharmacist of patients with cancer 石井聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 185-185, 2021. |
|---|
|
|
Symposium 22. With the viewpoint that a pharmacist should have in the problems over the heart failure management? Term of the organizer 木下照常, 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 186-186, 2021. |
|---|
|
|
S22-1. Polypharmacy and medication adherence 西村文宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 187-187, 2021. |
|---|
|
|
S22-2. Drug control in the renal failure merger case 木下照常 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 188-188, 2021. |
|---|
|
|
S22-3. End-of-life drug choice 岡本禎晃 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 189-189, 2021. |
|---|
|
|
S22-4. Care ... which patients with multi-type of job cooperation - heart failure to lead to improvement of the community medical care continued 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 190-190, 2021. |
|---|
|
|
S22-5. With the viewpoint that a pharmacist should have in the new heart failure therapeutic drug prescription case? 芦川直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 191-191, 2021. |
|---|
|
|
Symposium 23. Term of the disincentive of role - electronic edition prescription notebook spread of pharmacists who should carry it out in medical DX being what or - organizer 池田和之, 高田敦史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 192-192, 2021. |
|---|
|
|
S23-1. About functions, and the like to expect what the disincentive of the role electronic edition prescription notebook spread of pharmacists who should carry it out in medical DX is from electronic edition prescription notebook as a user 土屋文人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 193-193, 2021. |
|---|
|
|
S23-2. Digitization and electronic medication notebooks in pharmacies - To cross the chasm - 原口亨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 194-194, 2021. |
|---|
|
|
S23-3. Current situation and problem - at electronic edition prescription notebook operation - hospital in the hospital which sounds easy, and is difficult 行本拓史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 195-195, 2021. |
|---|
|
|
S23-4. Disincentive of the electronic edition prescription notebook spread judging from a viewpoint of ICT companies 島崎肇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 196-196, 2021. |
|---|
|
|
Symposium 24. Term of ... organizer for way of thinking, process of study - abecedarians in the healthcare setting 寺田智祐, 石澤啓介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 197-197, 2021. |
|---|
|
|
S24-1. The process of clinical studies: To brighten the healthcare setting more 福間真悟 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 198-198, 2021. |
|---|
|
|
S24-2. Basic knowledge of an ethic guideline and the personal information in clinical studies 八木健太1, 合田光寛1,2, 濱野裕章2, 坂口暁1, 楊河宏章1, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 199-199, 2021. |
|---|
|
|
S24-3. Will not do it; is a presentation at the meeting 鈴木渉太1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 200-200, 2021. |
|---|
|
|
S24-4. The viewpoint that a pharmacist of the general hospital duty should have to raise the operability of clinical studies 土手賢史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 201-201, 2021. |
|---|
|
|
S24-5. Efforts ... of the medicine medicine cooperation that aimed at the standardization of the side effect evaluation by clinical studies - dermatopathy measures flow making in the health insurance pharmacy 圓藤晶子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 202-202, 2021. |
|---|
|
|
Symposium 25. Frailty and nourishment measures, term of the challenge organizer of the pharmacist 篠永浩, 倉田なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 203-203, 2021. |
|---|
|
|
S25-1. Expectation ... to frailty prevention - pharmacist, the family drugstore as the national strategy 飯島勝矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 204-204, 2021. |
|---|
|
|
S25-2. Possibility of the current situation and the pharmacist of potential frailty elderly people 熊木良太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 205-205, 2021. |
|---|
|
|
S25-3. Polypharmacy and frailty measures 樋島学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 206-206, 2021. |
|---|
|
|
S25-4. Rehabilitation nourishment, a rehabilitation drug and frailty measures 中道真理子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 207-207, 2021. |
|---|
|
|
S25-5. Hospitalization, outpatient department, an area and leading frailty measures 篠永浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 208-208, 2021. |
|---|
|
|
Symposium 26. Don't allow an infodemic! The role of pharmacists under COVID-19 - Words from the organizers 岡田浩, 鈴木渉太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 209-209, 2021. |
|---|
|
|
S26-1. How do you make use of the experience of "the drugstore COVID-19 measures project" in the next crisis? 岡田浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 210-210, 2021. |
|---|
|
|
S26-2. It supports geography information and the foreign patients 鈴木渉太1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 211-211, 2021. |
|---|
|
|
S26-3. Handling of the medical information at disaster 西川佳孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 212-212, 2021. |
|---|
|
|
S26-4. Publicity work and access analysis of the COVID-19 measures site 森和明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 213-213, 2021. |
|---|
|
|
Symposium 27. Term of the insatiate challenge organizer for creation, the evolution of the TDM evidence 尾田一貴, 三浦昌朋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 214-214, 2021. |
|---|
|
|
S27-1. Practice of the TDM which assumed AUC of vancomycin an index 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 215-215, 2021. |
|---|
|
|
S27-2. Construction of the TDM evidence for the psychotropic drug 中村友喜1, 三輪高市2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 216-216, 2021. |
|---|
|
|
S27-3. Importance and practice case of the TDM in the poisoning practice 佐藤智人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 217-217, 2021. |
|---|
|
|
S27-4. Attempt of the individualization administration plan that added therapeutic drug monitoring promotion expansion and a metabolism change factor of voriconazole 新岡丈典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 218-218, 2021. |
|---|
|
|
S27-5. For the expansion of the drug targeted for the new TDM in the cancer domain 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 219-219, 2021. |
|---|
|
|
Symposium 28. Pharmacokinetic clinical practice utilized in the personalized medicine and speech of the fundamental researches organizer 工藤敏之, 嶋田努 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 220-220, 2021. |
|---|
|
|
S28-1. Evidence - of drug interactions - short interaction in patients with the heredity seasonal polymorphism 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 221-221, 2021. |
|---|
|
|
S28-2. Clinical implementation of the examination for pharmacogenomics 寺田智祐1,2, 森田真也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 222-222, 2021. |
|---|
|
|
S28-3. Application to personalized medicine of the physiologic pharmacokinetics model analysis 土岐浩介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 223-223, 2021. |
|---|
|
|
S28-4. The impact that the genetic polymorphism of a metabolism enzyme, the transporter gives in clinical pharmacokinetics 前田和哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 224-224, 2021. |
|---|
|
|
Symposium 29. Do not seem to come using a large-scale medical database; the term of effectiveness of the pharmaceutical products using ... receipt information database and safe evaluation - organizer 頭金正博, 飯原なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 225-225, 2021. |
|---|
|
|
S29-1. The usage of the database (NDB) such as anonymity receipt information, and the like and future development 加藤源太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 226-226, 2021. |
|---|
|
|
S29-2. Studies using the database such as the anonymity receipt information, and the like that a pharmacist receives 飯原なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 227-227, 2021. |
|---|
|
|
S29-3. Fact-finding about the examination of blood culture of patients with community-acquired pneumonia 室高広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 228-228, 2021. |
|---|
|
|
S29-4. Study of the racial difference of the severe drug eruption using the receipt data of the East Asia each country 佐井君江1, 佐藤嗣道2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 229-229, 2021. |
|---|
|
|
Symposium 30. Term of the tracing report utilization organizer for medication follow-up practice to work on for future intention 西原昌幸, 新井克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 230-230, 2021. |
|---|
|
|
S30-1. Approach of the Hiroshima hospital pharmacist society for the tracing report spread 大東敏和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 231-231, 2021. |
|---|
|
|
S30-2. Role of the health insurance pharmacy that we saw from the efforts to a tracing report 佐島進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 232-232, 2021. |
|---|
|
|
S30-3. Inflection of the tracing report for continuous medication follow-ups for the purpose of the ambulatory practice support 稲葉健二郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 233-233, 2021. |
|---|
|
|
S30-4. A problem and expectation to utilize a tracing report 池見泰明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 234-234, 2021. |
|---|
|
|
S30-5. Cooperation with the health insurance pharmacy with the tracing report communalization system and the basic hospital in Fukuoka 山口信也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 235-235, 2021. |
|---|
|
|
S30-6. About community medical care cooperation by the tracing report utilization in the Kurume University Hospital 井上光鋭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 236-236, 2021. |
|---|
|
|
Symposium 31. Term of - organizer who relates skill - efficacy, a side effect necessary for patients follow-up of the medical treatment to laboratory tests and image views, and evaluates it 岩本卓也, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 237-237, 2021. |
|---|
|
|
S31-1. Skill of the pharmacist necessary for patients follow-up of the medical treatment 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 238-238, 2021. |
|---|
|
|
S31-2. Examination for image which a pharmacist should know in understanding the condition of a patient 永田幹紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 239-239, 2021. |
|---|
|
|
S31-3. Internal secretion metabolism-related examination, one step of the beginning to make use of in a medical treatment evaluation 日置三紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 240-240, 2021. |
|---|
|
|
S31-4. Skill necessary for the medical treatment evaluation of the cardiovascular disease domain 種田靖久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 241-241, 2021. |
|---|
|
|
S31-5. Skill necessary for the medical treatment evaluation of the autoimmune inflammatory disorder domain 五十嵐敏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 242-242, 2021. |
|---|
|
|
Symposium 32. Aiming to build a regional formulary that supports patients and medical care in a regional comprehensive care system with evidence Organizer's words 岸本真, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 243-243, 2021. |
|---|
|
|
S32-1. Discussion and basic thinking surrounding formulary 川上純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 244-244, 2021. |
|---|
|
|
S32-2. Regional in-hospital formulary formulation and future development 小枝伸行1, 小川充恵2, 西岡達也2, 豊口雅子3, 中野道雄3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 245-245, 2021. |
|---|
|
|
S32-3. Current status and issues of regional formulary in the Awa Medical Area, Chiba Prefecture 舟越亮寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 246-246, 2021. |
|---|
|
|
S32-4. The role of pharmacists in formulary and future prospects 磯部総一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 247-247, 2021. |
|---|
|
|
Symposium 33. Term of a fact and the record organizer of the pharmacy management in the drugstore 出石啓治, 宮崎長一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 248-248, 2021. |
|---|
|
|
S33-1. A viewpoint and record of the pharmacy management in the drugstore 鹿村恵明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 249-249, 2021. |
|---|
|
|
S33-2. Fact and record - life-style related diseases of the pharmacy management as a case - 山本雄一郎1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 250-250, 2021. |
|---|
|
|
S33-3. Fact and record - cancer of the pharmacy management as a case - 村田稔弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 251-251, 2021. |
|---|
|
|
S33-4. Fact and record - depression of the pharmacy management as a case - 青木裕明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 252-252, 2021. |
|---|
|
|
S33-5. Fact and record - asthma of the pharmacy management as a case - 堀越博一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 253-253, 2021. |
|---|
|
|
S33-6. A fact and record of the pharmacy management in the drugstore 赤星顕正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 254-254, 2021. |
|---|
|
|
Symposium 34. Term of the latest knowledge organizer who is useful for a strategy of the risk assessment of the pregnant woman nursing mother medical therapy 中島研, 山根律子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-255, 2021. |
|---|
|
|
S34-1. Non-clinical gametogenesis toxicity evaluation according to new guidelines 下村和裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 256-256, 2021. |
|---|
|
|
S34-2. Placental permeability and drug choice 登美斉俊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 257-257, 2021. |
|---|
|
|
S34-3. Efforts to transitivity and the evidence creation of the drug to mother's milk 齊藤順平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 258-258, 2021. |
|---|
|
|
S34-4. Epidemiologic studies and our country first domperidone cohort study 菱沼加代子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 259-259, 2021. |
|---|
|
|
Symposium 35. Term of the organizer to do it how to convey charm of the clinical pharmacy widely, or to regard as a pharmacy student 村木優一, 原田紘行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 260-260, 2021. |
|---|
|
|
S35-1. Efforts of the federation of Japanese pharmacy student 原田紘行1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-261, 2021. |
|---|
|
|
S35-2. Experience holding of the Asian Pacific pharmacy student symposium (APPS) 2018 中川翼 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 262-262, 2021. |
|---|
|
|
S35-3. Clinical pharmacy study aiming at the conquest of the multidrug-resistant bacteria infection 田代渉, 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 263-263, 2021. |
|---|
|
|
S35-4. Encounter with a pharmacy education and the super pharmacist 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 264-264, 2021. |
|---|
|
|
S35-5. To spend student life to be ... crop towards Pharmacist-Scientist; ... 池村健治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 265-265, 2021. |
|---|
|
|
S35-6. For the further participation in planning to this academic conference activity of the pharmacy student 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 266-266, 2021. |
|---|
|
|
Symposium 36. Work style reform and task shifting in emergency intensive care - Words from an organizer 吉川博, 今井徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 267-267, 2021. |
|---|
|
|
S36-1. Management ... of the prescription support based on task shift share - protocol for the adequacy of the medical therapy in the intensive care unit and the IV line 篠崎浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 268-268, 2021. |
|---|
|
|
S36-2. Mainly on cooperation in construction pneumonia treatment of the drug information cooperation from hospitalization to start from the emergency care to the area 高橋佐和, 宮崎俊明, 筒井由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-269, 2021. |
|---|
|
|
S36-3. Intervention by the multi-type of job using the sedative sedative protocol 安部敏生1, 才穂亮介2, 鹿島秀明3, 田中太郎4, 川手美穂5, 有元秀樹6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 270-270, 2021. |
|---|
|
|
S36-4. Intervention effect of the pharmacist in the ER type first aid system 宮田祐一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2021. |
|---|
|
|
S36-5. A pharmacist and the emergency intensive care that we raise in physicians 太田浩平1, 檜山洋子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-272, 2021. |
|---|
|
|
Symposium 37. There having been relation - pharmacist to cancer treatment in the new corona infection season, term of aiming thing - organizer 上ノ段友里, 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 273-273, 2021. |
|---|
|
|
S37-1. Practice of cancer treatment and the infection measures in the corona evil 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-274, 2021. |
|---|
|
|
S37-2. New coronavirus infection correspondence in Osaka and the problem 小枝伸行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-275, 2021. |
|---|
|
|
S37-3. Experience two times of effect on cancer treatment - clusters at in-hospital cluster infection; and ... 下村真代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 276-276, 2021. |
|---|
|
|
S37-4. BCP at new coronavirus infection development in the cancer practice cooperation base Hospital 上ノ段友里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-277, 2021. |
|---|
|
|
S37-5. Follow-up to infection measures and the patients in the health insurance pharmacy with cancer 村田勇人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 278-278, 2021. |
|---|
|
|
Symposium 38. Term of the cooperation system organizer of a drugstore and the medical institution by the cancer domain demanded now 松井礼子, 安原眞人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-279, 2021. |
|---|
|
|
S38-1. The cooperation system (administration expecting it) of a drugstore and the medical institution on the basis of law revision 安川孝志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-280, 2021. |
|---|
|
|
S38-2. A role and the problem that are demanded from the scientific organization (academic conference) specialized in a cancer 近藤直樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 281-281, 2021. |
|---|
|
|
S38-3. Change of the cooperation with a health insurance pharmacy and the medical institution 松井礼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2021. |
|---|
|
|
S38-4. The current situation and problem of the specialized medical institution cooperation drugstore 村田勇人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 283-283, 2021. |
|---|
|
|
Symposium 39. Term of thing - organizer to see in bottom line - future of the irAE management to realize long-term follow 渡邊裕之, 南晴奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-284, 2021. |
|---|
|
|
S39-1. Bottom line of the irAE management to become complicated 吉野真樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2021. |
|---|
|
|
S39-2. Bottom line of the management tool making for early detection to support in irAE 武井大輔1, 鈴木栄2, 新井隆広3, 国吉央城4, 鈴木貴之5, 中山季昭1, 佐野元彦6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 286-286, 2021. |
|---|
|
|
S39-3. Bottom line of the registry utilization to discover irAE early 松金良祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-287, 2021. |
|---|
|
|
S39-4. Bottom line of the illness disease cooperation for the irAE management 與田賢作 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 288-288, 2021. |
|---|
|
|
S39-5. Bottom line of the irAE monitoring in the health insurance pharmacy 田中智枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-289, 2021. |
|---|
|
|
Symposium 40. Term of data science - organizer of the field of practice - clinical pharmacy of the clinical studies utilizing real world data 堀井剛史, 細見光一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 290-290, 2021. |
|---|
|
|
S40-1. Clinical studies in the infection domain utilizing real world data 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 291-291, 2021. |
|---|
|
|
S40-2. Study on polypharmacy utilizing a variety of medical big data 馬渕賢幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 292-292, 2021. |
|---|
|
|
S40-3. Drug repositioning study utilizing real world data 座間味義人1,2,3, 新村貴博3, 濱野裕章2, 合田光寛2,3, 相澤風花3, 八木健太4, 石澤有紀5, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 293-293, 2021. |
|---|
|
|
S40-4. Seamless evidence creation from the basics utilizing the database study to clinical practice 安藤航1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 294-294, 2021. |
|---|
|
|
S40-5. Inspection of the diabetes guidelines utilizing large-scale medical data 堀井剛史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 295-295, 2021. |
|---|
|
|
Symposium 41. Is usable from tomorrow; is the term of the medical care big data analysis organizer for pharmacists 石澤啓介, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 296-296, 2021. |
|---|
|
|
S41-1. Fusion of data science and the fundamental researches technique 濱野裕章1, 座間味義人1,2,3, 合田光寛4, 相澤風花2, 八木健太4, 石澤啓介1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 297-297, 2021. |
|---|
|
|
S41-2. Beginning to the clinical question solution that big data begin to spin 三星知 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-298, 2021. |
|---|
|
|
S41-3. Creation of a meta-analysis and the high impact evidence by the fusion of the database analysis 中馬真幸1, 中本亜樹2, 坂東貴司2, 新村貴博2, 岡田直人2, 相澤風花2, 濱野裕章3, 八木健太4, 合田光寛4, 座間味義人2,3, 石澤啓介2,3, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-299, 2021. |
|---|
|
|
S41-4. Medical big data turn the tomorrow's normal business routine 武智研志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 300-300, 2021. |
|---|
|
|
S41-5. The big data era resulting in a benefit for epidemiologic studies 小山敏広1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-301, 2021. |
|---|
|
|
Symposium 42. Term of beginning and process - organizer from polypharmacy measures guideline - tomorrow of elderly people 篠永浩, 溝神文博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-302, 2021. |
|---|
|
|
S42-1. Beginning and process - background and purpose ... of the polypharmacy measures of the elderly people in the hospital 道家由行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 303-303, 2021. |
|---|
|
|
S42-2. Utilization method of beginning and process - manual of the polypharmacy measures of the elderly people in the hospital and real efforts example ... 末松文博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-304, 2021. |
|---|
|
|
S42-3. About the development of polypharmacy measures in the Tohoku University Hospital 松浦正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-305, 2021. |
|---|
|
|
S42-4. A role and the process that area base Hospital takes 篠永浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 306-306, 2021. |
|---|
|
|
S42-5. A role and the process that a small and medium size hospital takes 濱浦睦雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 307-307, 2021. |
|---|
|
|
Symposium 43. It is the term of - organizer for the settings of - hospital, drugstore, university thinking about the role of the pharmacist in the COVID-19 correspondence 塩田有史, 三鴨廣繁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-308, 2021. |
|---|
|
|
S43-1. From the side of COVID-19-adaptive - medical treatment in the hospital - 塩田有史1,2,3, 平井潤1,3, 浅井信博1,3, 松本乃里子2, 竹内正幸2, 大西正文2, 三鴨廣繁1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-309, 2021. |
|---|
|
|
S43-2. From the side of efforts - infection measures of the hospital pharmacist in the COVID-19 correspondence - 片山歳也, 鈴木朋克 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 310-310, 2021. |
|---|
|
|
S43-3. COVID19 correspondence in the drugstore 瀧藤重道1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-311, 2021. |
|---|
|
|
S43-4. Correspondence of COVID-19 in the university pharmacy school 藤村茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-312, 2021. |
|---|
|
|
S43-5. Condition of a patient, diagnosis, treatment, infection measures of COVID-19 三鴨廣繁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 313-313, 2021. |
|---|
|
|
Symposium 44. Term of relation ... organizer for the medical treatment life of continuous pharmacy management - Personal Oriented which a hospital, a drugstore pharmacist aims at in a diabetes domain 武藤達也, 朝倉俊成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 314-314, 2021. |
|---|
|
|
S44-1. Proper use of the diabetes therapeutic drug based on the clinical test value 堀井剛史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 315-315, 2021. |
|---|
|
|
S44-2. Continuous pharmacy management of the use of appropriate insulin injection preparation 朝倉俊成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 316-316, 2021. |
|---|
|
|
S44-3. Hypoglycemia measures support for appropriate diabetes medical therapy and chic day rule instruction 佐竹正子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2021. |
|---|
|
|
S44-4. Follow-up of patients with diabetes in the treatment at home 篠原久仁子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 318-318, 2021. |
|---|
|
|
S44-5. Disaster response for continuous pharmacy management of the patients with diabetes 西村博之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 319-319, 2021. |
|---|
|
|
Symposium 45. It is the term of ... organizer with the competency in collaboration - healthcare worker upbringing business of the multi-type of job about patients with at-home cancer 串田一樹, 塩川満 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2021. |
|---|
|
|
S45-1. About cancer disease treatment at home personnel training 蘆野吉和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-321, 2021. |
|---|
|
|
S45-2. Information ... which we want to introduce from a hospital into the area from ... hospital 伊東俊雅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 322-322, 2021. |
|---|
|
|
S45-3. Information ... which information sharing - drugstore which we pointed from hospitalization to being at home from hospitalization requires 坂本岳志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 323-323, 2021. |
|---|
|
|
S45-4. Collaboration ... such as multi-type of job cooperation ... physician, the nurse in the area, care imitation, a dietician, the pharmacist, and the like 白石丈也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-324, 2021. |
|---|
|
|
S45-5. We think about the collaboration of the multi-type of job about patients with at-home cancer from the function of regional alliances drugstore, the specialized medical institution cooperation drugstore 串田一樹1, 谷川大夢1,2, 廣原正宜1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 325-325, 2021. |
|---|
|
|
Symposium 46. (annual convention plan) the term of ... organizer thinking about the pharmaceutical products supply system in the areas from role - disaster cycle acute phase of the pharmacist at disaster to a chronic phase 稲葉一郎, 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2021. |
|---|
|
|
S46-1. ... which thinks about the pharmaceutical products supply system in the areas from role - disaster cycle acute phase of the pharmacist at disaster to a chronic phase 西名武士 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-327, 2021. |
|---|
|
|
S46-2. It is ... about dispatch of the summary of the disaster agreement and the mobile pharmacy from the situation of the ... pharmacist society 金子雅好 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 328-328, 2021. |
|---|
|
|
S46-3. It is ... from experience of the ... Kumamoto earthquake about the pharmaceutical products supply method in the disaster area and the way of the support activity by the pharmacist 稲葉一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-329, 2021. |
|---|
|
|
S46-4. The pharmaceutical products supply system in the disaster area and problems and task of the support activity 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 330-330, 2021. |
|---|
|
|
Symposium 47. (annual convention plan) the term of the strategy organizer to offer collection, joint ownership and inflection - optimal medical therapy of the information at disaster 小林政彦, 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 331-331, 2021. |
|---|
|
|
S47-1. Intelligence and utilization for duties continuation in the 2016 Kumamoto earthquake 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-332, 2021. |
|---|
|
|
S47-2. Development of the application to apply in the distribution information of pharmaceutical products and future application 石渡俊二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-333, 2021. |
|---|
|
|
S47-3. About the information at disaster around J-SPEED 江川孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 334-334, 2021. |
|---|
|
|
S47-4. An introduction and inflection of information utilization disaster health medical care caring support system D24H at disaster 市川学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 335-335, 2021. |
|---|
|
|
S47-5. Problem for intelligence, the joint ownership at disaster and the utilization 片山潤 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-336, 2021. |
|---|
|
|
Symposium 48. Term of evolution, deepening, true value - organizer of the ... area pharmacist society activity that the post Nakagyo pharmacist society of the cooperation reinforcement does not stop 黄前尚樹, 寸田靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-337, 2021. |
|---|
|
|
S48-1. ... that the way - Nakagyo pharmacist society of the local pharmacist society for better cooperation walked it in this way 黄前尚樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-338, 2021. |
|---|
|
|
S48-2. It is ... from position of ... hospital pharmacist connecting from a hospital to the area 中村美樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 339-339, 2021. |
|---|
|
|
S48-3. Thing ... which was seen from the making of relations that only patients-centered medicine medicine cooperation ... face obtained 竹家広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2021. |
|---|
|
|
S48-4. "What you can do from a pharmacy in a small town, not in front of a large hospital - Participating in multidisciplinary collaboration" 片岡礼奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-341, 2021. |
|---|
|
|
S48-5. It is ... mainly on efforts - outpatient department chemotherapy for the cooperation reinforcement with a hospital and the drugstore 大野恵一, 本多伸二, 目黒裕史, 三松史野, 佐分利美帆子, 寸田靖, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 342-342, 2021. |
|---|
|
|
Symposium 49. It is the term of the organizer from upbringing - basics, the education of the pharmacist contributing to psychiatry clinical practice to clinical practice 加藤剛, 阿部裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2021. |
|---|
|
|
S49-1. Molecular pharmacology and the therapeutic drug front line of mood disorders 武田泰生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-344, 2021. |
|---|
|
|
S49-2. It is ... from the position of upbringing ... university teacher of the pharmacist contributing to psychiatry clinical practice 山崎啓之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 345-345, 2021. |
|---|
|
|
S49-3. Significance to do the knowledge in English with one one case one carefully to the idea culture 村田司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2021. |
|---|
|
|
S49-4. And "we are concerned with the national prescription investigation of - antipsychotics keeping statistics person alive on the site -" 加藤剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2021. |
|---|
|
|
S49-5. A pharmacist is ... from cooperation - hospitalization for psychiatry medical therapy adequacy to connect to the outpatient department 井上裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2021. |
|---|
|
|
Symposium 50. Term of psychiatric approach - organizer making use in the general course X psychiatry - public family 坪内清貴, 祖川倫太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2021. |
|---|
|
|
S50-1. Psychiatry medical treatment and role of the pharmacist that are demanded in a general course 坪内清貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-350, 2021. |
|---|
|
|
S50-2. Pharmacokinetics and individualization therapy of the psychotropic drug 猿渡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-351, 2021. |
|---|
|
|
S50-3. Proper use of the psychotropic drug under the internal disease coexistence 吉川明良 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 352-352, 2021. |
|---|
|
|
S50-4. We consult for a liaison team by the first aid 祖川倫太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2021. |
|---|
|
|
S50-5. From a viewpoint of the consultation liaison by the psychology job 厚坊浩史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 354-354, 2021. |
|---|
|
|
Symposium 51. Term of the organizer thinking about the career path of gender equality - pharmacist in the field of pharmacist, clinical pharmacy 三宅健文, 塚本有子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 355-355, 2021. |
|---|
|
|
S51-1. The reason why I remain an administrator in the small and medium size hospital 井上潤子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2021. |
|---|
|
|
S51-2. Expect it for the career path construction of the pharmacist in pharmacy education in the future 西村亜佐子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2021. |
|---|
|
|
S51-3. In a cancer domain for carrier hope from - this and uneasy - 西上依里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 358-358, 2021. |
|---|
|
|
S51-4. The workplace and expectation and anxiety that are easy to act that the pharmacist of the child care generation thinks of in the future 辻芙美, 大竹優樹, 安田早織, 植村有加, 谷崎泰広, 三宅健文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-359, 2021. |
|---|
|
|
S51-5. From the 6-year pharmacy school to a doctor (pharmacy): As university teacher the career path of the working woman researcher 高橋未来 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-360, 2021. |
|---|
|
|
S51-6. We explore the workplace environment that can support the career path of the pharmacist 三宅健文, 楠斐未, 瀬良郁実, 辻芙美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 361-361, 2021. |
|---|
|
|
Symposium 52. Term of the organizer thinking about career path, a way of working, the future image of the women in the course of a variety of pharmacists 土屋雅美, 河添仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 362-362, 2021. |
|---|
|
|
S52-1. Does God of the chance have only a forelock? Carrier formation strategy of the pharmacist specialized in a local cancer 土屋雅美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-363, 2021. |
|---|
|
|
S52-2. The career path which we learned from an encounter 文靖子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 364-364, 2021. |
|---|
|
|
S52-3. Career path as the researcher of the pharmaceutical products information science 堀里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2021. |
|---|
|
|
S52-4. Is decision of the carrier accidental accumulation? 島田美樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-366, 2021. |
|---|
|
|
S52-5. The medical secret to act on Sus Tina bulldog throughout the trade is work life balance 大西友美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 367-367, 2021. |
|---|
|
|
Symposium 53. Is the readiness of the pharmacist called into question? Term of the urgent contraceptive sale organizer at the drugstore 岡田浩, 鈴木渉太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2021. |
|---|
|
|
S53-1. Kyoto University SPH drugstore information group "drugstore emergency contraceptive sale support project" 岡田浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 369-369, 2021. |
|---|
|
|
S53-2. It is urgently all drugstores with a contraceptive: Efforts of the canola flower drugstore 鈴木達彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2021. |
|---|
|
|
S53-3. Point to be urgently careful about at the grant of the contraceptive that we saw from the obstetrics and gynecology department specialist 池田裕美枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2021. |
|---|
|
|
S53-4. It is "Sexsual reproductive health and rights (SRHR) in a pharmacy school How do you tell "? 西村亜佐子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-372, 2021. |
|---|
|
|
Symposium 54. I think the most difficult aspect of prescription audits right now is the dosage of direct-acting oral anticoagulants (DOACs), so let's think about that Words from an organizer 鈴木大介, 古久保拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 373-373, 2021. |
|---|
|
|
S54-1. A viewpoint of underdose from the pharmacist of the circulatory organ domain 木下照常 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 374-374, 2021. |
|---|
|
|
S54-2. A viewpoint of overdose from the pharmacist of the kidney domain 新海大智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2021. |
|---|
|
|
S54-3. A viewpoint of the drug interaction from a DI charge pharmacist 冨田猛, 木村丈司, 矢野育子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 376-376, 2021. |
|---|
|
|
S54-4. From the viewpoint of the health insurance pharmacy 児島悠史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 377-377, 2021. |
|---|
|
|
Symposium 55. It is the term of - organizer from the analysis of the hospitalization and release support task according to - hospital function to think about the hospitalization and release support corresponding to medical needs and an advanced example 室井延之, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-378, 2021. |
|---|
|
|
S55-1. Analysis of hospitalization and release support task and the example collection about the pharmacist cooperation 室井延之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 379-379, 2021. |
|---|
|
|
S55-2. Community collaboration efforts to address medication notebook issues - Introducing the Yasadaru Man Card and unified format for providing information at the time of discharge - 今井圭介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2021. |
|---|
|
|
S55-3. Example ... of the counseling before evaluation before hospitalization and release support task - discharge that fixed its eyes on after discharge, ERAS surgery 國永智昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-381, 2021. |
|---|
|
|
S55-4. Practice - of the seamless medical therapy using the information contact book between hospital pharmacist and - institutions which share beneficial information in offering medical therapy between local pharmacists 鈴木亮平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-382, 2021. |
|---|
|
|
S55-5. Patients follow, drugstore cooperation after the patients information sharing and discharge before hospitalization utilizing the medical cooperation 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 383-383, 2021. |
|---|
|
|
Symposium 56. Term of a task shift organizer who should have the original pharmacist in perioperative care 柴田ゆうか, 舟越亮寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 384-384, 2021. |
|---|
|
|
S56-1. Task sharing in the perioperative period / Promoting team medical care for task shifting 齋藤繁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 385-385, 2021. |
|---|
|
|
S56-2. Preoperative outpatient workload survey and task shifting issues 千葉陽月, 野口雅美, 井上真由美, 佐藤邦義, 荒川隆太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 386-386, 2021. |
|---|
|
|
S56-3. Pharmaceutical intervention and evaluation in by practice support - surgery front and by endoscopy front by the outpatient department pharmacist 久岡清子, 増田博也, 佐々木健志, 大荒政志, 川村大輔, 間千晴, 木原俊文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-387, 2021. |
|---|
|
|
S56-4. Cooperation with hospital pharmacy and the neighborhood ethical pharmacy using prescription notebook about the cancellation medicine before examination, surgery 藤井達郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-388, 2021. |
|---|
|
|
S56-5. A task shift who should have the original pharmacist in perioperative care 猪田宏美, 鍛治園誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-389, 2021. |
|---|
|
|
Symposium 57. It is the term of the organizer for research activities and improvement of the clinical competence 中村任, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 390-390, 2021. |
|---|
|
|
S57-1. It is ... for education, research activities based on pharmacist system - clinical experience specialized in clinical pharmacy 百瀬泰行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-391, 2021. |
|---|
|
|
S57-2. It is ... from the position of creation - clinical pharmacist of the clinical studies mind 郷真貴子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2021. |
|---|
|
|
S57-3. It is ... from the position of creation - clinical system teacher of the clinical studies mind 松下良 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-393, 2021. |
|---|
|
|
S57-4. Efforts of pharmacy school and Keio University about the cooperation with the university hospital 青森達1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-394, 2021. |
|---|
|
|
Symposium 58. (annual convention plan) is the term of ... organizer for the study development that is like clinical pharmacy different field study - creation that a young researcher joins together 五十嵐裕貴, 三宅俊介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 395-395, 2021. |
|---|
|
|
S58-1. Inspection of the usefulness as the pre-back prediction, the effect predictor of the tumor-suppressor gene CYLD expression disappearance in ovarian cancer 三宅俊介1,2, 齋藤秀之1,2, 城野博史1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-396, 2021. |
|---|
|
|
S58-2. Pharmacokinetic model analysis of the sunitinib in patients with renal carcinoma 伊藤雄大1,2, 山本和宏1,2, 大村友博1,2, 矢野育子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-397, 2021. |
|---|
|
|
S58-3. Participation of the derived albumin receptor having an influence on the internal change of Abraxane 濱眞壱 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 398-398, 2021. |
|---|
|
|
S58-4. Reverse translational research utilizing the large-scale medical information database analysis for the anticancer agent side effect prevention 神田将哉1,2, 合田光寛3,4, 吉岡俊彦1,2, 吉田愛美3, 新村貴博2, 櫻田巧2, 小川敦2, 岡田直人2, 相澤風花2, 座間味義人2,3,5, 八木健太4, 濱野裕章3, 石澤有紀6, 石澤啓介2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2021. |
|---|
|
|
S58-5. New suggestion of the condition of a patient analysis using in vivo antigen-antibody reaction 森石麻梨乃 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 400-400, 2021. |
|---|
|
|
S58-6. Effective evaluation for multidrug-resistant bacteria of new β-lactamase inhibitor Nacubactam 五十嵐裕貴, 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-401, 2021. |
|---|
|
|
Symposium 59. Pharmacist duties to meet expectation practice immediately, term of the new development organizer of young person upbringing 尾上雅英, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-402, 2021. |
|---|
|
|
S59-1. The training acceptance and the prospects of the health insurance pharmacy pharmacist who assumed the acquisition of the cancer medical therapy a base 萱野勇一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 403-403, 2021. |
|---|
|
|
S59-2. Skill up through the innovative duties development in the infection domain 小林和博, 高橋有, 上田覚, 尾上雅英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2021. |
|---|
|
|
S59-3. For a pharmacist contributing to local medical treatment the dispatch by the pharmacist 吉良俊彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2021. |
|---|
|
|
S59-4. Upbringing and the tissue management of the pharmacist taking medical care in the future 高橋一栄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 406-406, 2021. |
|---|
|
|
Symposium 60. Let's have it now, and how do ride out a wave of the digitization to pharmacist digital transformation - medical care industry; or the term of ... organizer 小枝伸行, 岡橋孝侍 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 407-407, 2021. |
|---|
|
|
S60-1. Is connected because connect it; pass; ... electron package insert and bar code ... 岡橋孝侍 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 408-408, 2021. |
|---|
|
|
S60-2. Inflection of ePath project and the drug information 山下貴範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 409-409, 2021. |
|---|
|
|
S60-3. Introduction of the online qualification confirmation and the development 佐藤弘康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-410, 2021. |
|---|
|
|
S60-4. It is ... for use and application of the health information gathered with securing of drug safety - digital by an electronic prescription and the electronic drug history 宮村信輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-411, 2021. |
|---|
|
|
S60-5. Settings correspondence of the digital transformation 山中理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 412-412, 2021. |
|---|
|
|
Symposium 61. Term of one or ... organizer that medical therapy - pharmacist is associated with childhood palliative care how 冨家俊弥, 石川洋一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2021. |
|---|
|
|
S61-1. Multiverse of the role of the pharmacist in the childhood palliative care 笹月桃子1,2, 若杉陽子3, 古賀友紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 414-414, 2021. |
|---|
|
|
S61-2. Empowering pharmacists to help children who need medical care at homeist 松丸実奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 415-415, 2021. |
|---|
|
|
S61-3. Childhood palliative care by the pharmacist in daily relations 笠原庸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-416, 2021. |
|---|
|
|
S61-4. The current situation, role, problem of the pharmacist in the pediatric palliative care team of the pediatric hospital 歌野智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 417-417, 2021. |
|---|
|
|
Symposium 62. Term of the intervention organizer of the pharmacist for understanding of eating dysphagia and the appropriate medication support 倉田なおみ, 賀勢泰子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2021. |
|---|
|
|
S62-1. Eating dysphagia and dosage form choice, topic to surround the simple suspension method 倉田なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-419, 2021. |
|---|
|
|
S62-2. The medication situation that a dentist examines 石井良昌 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2021. |
|---|
|
|
S62-3. Calculation ... of cooperation ... transluminal medication support charges of a hospital and the health insurance pharmacy in the simple suspension method 古澤洋子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 421-421, 2021. |
|---|
|
|
S62-4. The simple suspension method introduction example in the health insurance pharmacy 鈴木邦彦1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2021. |
|---|
|
|
S62-5. The simple suspension method judging from dosage form design 原田努 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 423-423, 2021. |
|---|
|
|
S62-6. Incompatibility in the crush and simple suspension method 石田志朗1, 倉田なおみ2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-424, 2021. |
|---|
|
|
Symposium 63. Delivering well-being to patients - Robust cardiac rehabilitation and renal medicine, exercise, nutrition, and cardiorenal connections - Words from the organizer 吉国健司, 柴田啓智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-425, 2021. |
|---|
|
|
S63-1. The heart rehabilitation in the super-aged society: It is also a malignant tumor heart, kidney 福本義弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-426, 2021. |
|---|
|
|
S63-2. Skill mixture to want a pharmacist to know it from the position of the physical therapist 齊藤正和, 作山晃裕, 森沢知之, 高橋哲也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 427-427, 2021. |
|---|
|
|
S63-3. Skill mixture to want a pharmacist to know it from the position of the dietician 宮島功 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2021. |
|---|
|
|
S63-4. Deep - honeymoon and cross-purposes ... with the heart which kidney talks about concerned 古久保拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 429-429, 2021. |
|---|
|
|
S63-5. The heart kidney linkage that a specialist of the heart talks about 櫻下弘志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 430-430, 2021. |
|---|
|
|
Symposium 64. Term of - organizer learning a way of the display of the ability as the pharmacist from the example of quality improvement - others institution of the patients management to push forward by the power of the pharmacist 榎本貴一, 小坂鎮太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-431, 2021. |
|---|
|
|
S64-1. Expectation and the prospects to the pharmacist in the domain of the medical quality, patients security 小坂鎮太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-432, 2021. |
|---|
|
|
S64-2. That maintain Quality Improvement - quality improvement activity to begin with the hospitalization complications measures such as the delirium, and the like; learn; - 榎本貴一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 433-433, 2021. |
|---|
|
|
S64-3. Team Building ... with other types of job through ... polypharmacy measures to do drug rearranging by the multi-type of job, and to promote patients collaboration 中込哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2021. |
|---|
|
|
S64-4. Importance ... of the pharmacist in the efforts for relation ... quality improvement of the pharmacist in in-hospital overall QI 川名賢一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-435, 2021. |
|---|
|
|
Symposium 65. Term of process of pharmacist upbringing - organizer to receive the enforcement of the Basic Law for stroke, cardiovascular disease measures, and to examine ... patients 徳永仁, 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 436-436, 2021. |
|---|
|
|
S65-1. Upbringing ... of the pharmacist who they receive the enforcement of the Basic Law for stroke, cardiovascular disease measures, and examines ... patients 高井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-437, 2021. |
|---|
|
|
S65-2. Consideration to pharmacist education in the circulatory organ intensive care and the durability 土岐真路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-438, 2021. |
|---|
|
|
S65-3. Upbringing of the pharmacist who can do comprehensive medical treatment instruction in the heart failure team 櫻下弘志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 439-439, 2021. |
|---|
|
|
S65-4. In the circulatory organ domain, what is necessary to bring up a pharmacist looking after patients? 梶原洋文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-440, 2021. |
|---|
|
|
S65-5. Simulation education to examine patients 徳永仁1, 園田純一郎1, 緒方賢次2, 興梠靖幸2, 高村徳人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 441-441, 2021. |
|---|
|
|
Symposium 66. Term of challenge - organizer of the pharmacist showing specialty from ... scientific viewpoint that an academic D tailing turns the future of the clinical pharmacy 小茂田昌代, 宮崎美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 442-442, 2021. |
|---|
|
|
S66-1. A drug discovery scientist and the academic D tailing which builds the information infrastructure 小茂田昌代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-443, 2021. |
|---|
|
|
S66-2. Practice of PBPM utilizing the constipation therapeutic drug academic D tailing material of patients with cancer 河本怜史1, 青柳友彦1, 都築竜太1, 木村敦1, 香取哲哉1, 出雲貴文1, 小茂田昌代1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-444, 2021. |
|---|
|
|
S66-3. Chemical viewpoint in the academic D tailing material development 清水忠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 445-445, 2021. |
|---|
|
|
S66-4. Practice of the academic D tailing in the circulatory organ domain 古野喬志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2021. |
|---|
|
|
S66-5. Academic D tailing after the business training 伊藤俊将1, 土肥弘久1, 廣澤伊織1, 水谷顕洋1, 宮崎美子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 447-447, 2021. |
|---|
|
|
S66-6. Education of the academic D tailing in the pharmacy school 青山隆夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-448, 2021. |
|---|
|
|
Symposium 67. Term of thing - organizer who should succeed it to a young generation in professionalism - now of the pharmacist whom we felt to be a corona evil 細谷治, 安野伸浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 449-449, 2021. |
|---|
|
|
S67-1. Through a pharmacist experience in professionalism foreign countries of the pharmacist whom we felt to be a corona evil 若子直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 450-450, 2021. |
|---|
|
|
S67-2. As a visit pharmacist associated with patients with professionalism - cancer of the pharmacist who felt to be a corona evil ... 川名三知代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2021. |
|---|
|
|
S67-3. Expect it to become the pharmacist who can cope with a change 安川孝志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 452-452, 2021. |
|---|
|
|
S67-4. As the professionalism University teacher of the pharmacist whom we felt to be a corona evil 荒田洋一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 453-453, 2021. |
|---|
|
|
S67-5. As professionalism hospital pharmacist of the pharmacist whom we felt to be a corona evil 細谷治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 454-454, 2021. |
|---|
|
|
Symposium 68. Term of construction and the use and application organizer of the unified management technique for standardization of the large-scale medical information 折井孝男, 高田敦史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-455, 2021. |
|---|
|
|
S68-1. The present of the standard cord governance center in the MID-NET cooperation medical institution 康東天1, 高田淳史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 456-456, 2021. |
|---|
|
|
S68-2. The present of MID-NET and standard cord governance in the future 陰山卓哉, 岸塲真理, 大田有佳里, 宇山佳明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-457, 2021. |
|---|
|
|
S68-3. For problem solution to data standardization of the field of pharmaceutical products in clinical settings 横山威一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 458-458, 2021. |
|---|
|
|
S68-4. Of the education about the medical information utilization and coding in pharmacy education settings, actually 室高広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-459, 2021. |
|---|
|
|
Symposium 69. Examining and preparing for the future - What pharmacists have been able to do and what they have not been able to do regarding the new coronavirus infection - Words from the organizers 高田勝利, 高山和郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 460-460, 2021. |
|---|
|
|
S69-1. It is measures and the correspondence in the corona evil utilizing the infection measures area network by a pinch in a chance 崎本裕治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-461, 2021. |
|---|
|
|
S69-2. Upbringing - of the pharmacist who is strong in - infection from With corona to Post corona 中南秀将 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 462-462, 2021. |
|---|
|
|
S69-3. Through the "Namara Simple Project", public health and information dissemination required of pharmacists as seen from the experience of large-scale cluster disasters 長塚健太1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 463-463, 2021. |
|---|
|
|
S69-4. The fact of the pharmacist duties in the COVID-19 ward and the task which we saw 茂野絢子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 464-464, 2021. |
|---|
|
|
S69-5. Expectation to the response to new coronavirus infection and a problem and a pharmacist 緒方剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-465, 2021. |
|---|
|
|
Symposium 70. Want to show - to reconsider an index and a method to visualize ward duties now; is the term of presence - organizer of the pharmacist in the ward 長谷川裕矢, 矢野良一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 466-466, 2021. |
|---|
|
|
S70-1. For the visualization of the clinical index of ward drug duties and the qualitative index 舟越亮寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 467-467, 2021. |
|---|
|
|
S70-2. Outcome evaluation of the pharmacist in the intensive care unit 前田幹広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-468, 2021. |
|---|
|
|
S70-3. We regard an on-the-job problem as the significance of various indexes from the actual situation that it seemed that we visualize the ward duties of the pharmacist 長谷川裕矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 469-469, 2021. |
|---|
|
|
S70-4. What we can do to increase the value of ward pharmacy services - Starting a new business is the best chance to visualize results - 古俵孝明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 470-470, 2021. |
|---|
|
|
S70-5. Advice of a relation and the information cooperation to the multi-type of job that a small and medium size hospital practices 上ノ段友里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 471-471, 2021. |
|---|
|
|
WS. Pharmacist application case form specialized in medical therapy 石井伊都子, 渡邊裕之, 山崎美保, 細野智美, 樋口則英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-472, 2021. |
|---|
|
|
IO-01. The exploratory and early-stage initiative of emergency medicine pharmacist at limited pharmacist service in Japan. Miku Tamura, Mitsuhiro Ohtake Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 474-474, 2021. |
|---|
|
|
IO-02. Nonsteroidal anti-inflammatory drugs utilization in patients with Parkinson's Disease : a Japanese retrospective claims database study Sachiko Kasamo1, Yoshikazu Tasaki2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2021. |
|---|
|
|
IO-03. Clinical significance of therapeutic drug monitoring of sunitinib in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule Takahiro Ito1, Kazuhiro Yamamoto1, Junya Furukawa2, Kenichi Harada2, Masato Fujisawa2, Tomohiro Omura1, Ikuko Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 476-476, 2021. |
|---|
|
|
IO-04. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Yuko Kanbayash1,2, Koichi Sakaguchi3, Fumiya Hongo4, Takeshi Ishikawa2,5, Osamu Ukimura4, Tetsuya Taguchi3, Koichi Takayama2,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 477-477, 2021. |
|---|
|
|
IO-05. Effect of Underlying Disease on Efficacy of Drugs for Delirium : A Comparison of Cancerous and Non-Cancerous Diseases Tomonori Ohya1,2, Momoka Suda2, Ayumi Ozawa2, Suzuka Umeda1, Mayumi Tsukagoshi3, Yu Yamada4, Junya Sato1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 478-478, 2021. |
|---|
|
|
IO-06. Survey on the Amount of Fugitive Dust when Dispensing Drugs with Formulation Processing for Children with Medical Complexity Takenori Tamaki1, Yuji Yoshiyama2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-479, 2021. |
|---|
|
|
IO-07. Development and validation of a new LC-MS / MS assay for simultaneous determination of parent compounds and active metabolites of second- / third-generation EGFR-TKIs in human serum, and its clinical application for cancer patients Emi Ishikawa1, Yuta Yokoyama1,2, Haruna Chishima2, Ouki Kuniyoshi3, Itaru Satou4, Naoki Nakaya4, Hideo Nakajima4, Motonori Kimura5, Jun Hakamata5, Naoya Suehiro5, Hideo Nakada5, Shinnosuke Ikemura6,7, Aya Jibiki2, Hitoshi Kawazoe1,2, Hiroshi Muramatsu5, Sayo Suzuki1,2, Tomonori Nakamura1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 480-480, 2021. |
|---|
|
|
YIA1-01. Using existing clinical study data is examined the effectiveness of the oral anticoagulant drug and the racial difference about the safety directly 秋田彩佑1,2, 魏捷2, 安部賀央里1,2, 頭金正博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 482-482, 2021. |
|---|
|
|
YIA1-02. Liposome about association with the serum electrolyte concentration before the amphotericin B-induced impaired renal function and administration 山城海渡1,2, 平田敦士2, 太田涼介2, 緒方文彦1, 中村武浩1, 川崎直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 483-483, 2021. |
|---|
|
|
YIA1-03. Manufacture of brain capillary endothelial cells derived from the human iPS cells which are applicable for the condition of a patient elucidation study 山下美紗季1, 青木啓将2, 青山峰芳2, 坡下真大1, 松永民秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-484, 2021. |
|---|
|
|
YIA1-04. Examination of the dose design utilizing the metabolic capacity evaluation by voriconazole in children and the metabolite concentrations 加藤美和1, 横山雄太1, 松山佳奈苗1, 齊藤順平2, 文靖子2, 歌野智之2, 千葉杏子2, 長谷川彩薫2, 地引綾1, 河添仁1, 山谷明正2, 松元一明3, 鈴木小夜1, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-485, 2021. |
|---|
|
|
YIA1-05. Risk analysis of radiation-induced retching, vomiting in patients with uterine cervix cancer and effective evaluation of the antiemesis therapy 海野茜1, 山本扇里2, 飯原大稔1,2, 藤井宏典1,2, 上田祐稀乃1, 加藤寛子2, 安江萌夏2, 森重健一郎3, 松尾政之3, 鈴木昭夫1,2, 林秀樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 486-486, 2021. |
|---|
|
|
YIA1-06. Integration analysis of the genetic factor influencing expression of chemotherapy-induced retching, vomiting 小玉千佳1, 辻大樹1, 山本圭祐2, 米澤樹1, 宮城壮裕1, 中道秀徳3, 矢部勝茂2, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2021. |
|---|
|
|
YIA1-07. Look at adverse event spontaneous report database analysis and the rear; protective efficacy of palonosetron for the cisplatin-induced renal failure based on the mark study 竹村美穂1, 池村健治2, 山根章寛1, 仁木一順1, 上田幹子1, 奥田真弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 488-488, 2021. |
|---|
|
|
YIA1-08. Participation of the exosome derived from a skeletal muscle in the septicemic condition of a patient exacerbation due to the disuse muscle atrophy 長邑花, 榎木裕紀, 田口和明, 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 489-489, 2021. |
|---|
|
|
YIA1-09. Antioxidant ability evaluation of the active metabolite of benzbromarone 住吉琴桃1, 前田侑里1, 松本挙典1, 寒水壽朗1, 平田憲史郎1, 岡崎祥子1, 竹下啓蔵1, 佐藤圭創2, 瀬尾量1, 門脇大介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 490-490, 2021. |
|---|
|
|
YIA2-01. The elucidation of the usefulness of the family pharmacist system and the modifying factor: Retrospective cohort study using receipt data 池谷怜, 此村恵子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 492-492, 2021. |
|---|
|
|
YIA2-02. Comparison between levetiracetam and mental disorder expression of Lacosamide or Perampanel by the combination 松沼悟1, 須永茂樹2, 西岡菜々子1, 輿石徹1, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2021. |
|---|
|
|
YIA2-03. Effect (the second report) that hypertriglyceridemia gives to serum amiodarone levels 橋本直明1, 土岐浩介1,2, 河野了2, 青沼和隆2, 家田真樹2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 494-494, 2021. |
|---|
|
|
YIA2-04. The discovery of drug interactions at warfarin and tolvaptan combination and elucidation of the mechanism 齊藤将之1,2, 岩尾岳洋2, 前田徹3, 市原利彦4, 味岡正純5, 山田哲也1, 鈴木匡2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 495-495, 2021. |
|---|
|
|
YIA2-05. The effect that mTOR-HIF pathway gives for efficacy of Roxadustat and a side effect 中西正範1,2, 水野智博3, 長野文彦4, 伊藤辰将2, 高橋和男5, 山田成樹1,3, 坪井直毅2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-496, 2021. |
|---|
|
|
YIA2-06. Search of the rise in blood vancomycin levels predictor which does not depend on the renal function change 磯田和也1, 中出順也1, 藤田有美1, 菅幸生2, 嶋田努1, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 497-497, 2021. |
|---|
|
|
YIA2-07. Pharmacologic approach - of the effect of the DPP-4 inhibitor using search - rat of the new therapy on male sexual dysfunction with the vincristine administration 片岡智哉1, 真川明将2, 堀田祐志2, 日比陽子2, 木村和哲1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 498-498, 2021. |
|---|
|
|
YIA2-08. Fact-finding of the Carboplatin desensitization in the gynecologic cancer domain 寺田公介1,2, 宇田川涼子1, 齋藤義正1, 石川光信1, 赤木徹1, 橋本浩伸1, 山口正和2, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2021. |
|---|
|
|
YIA2-09. Examination of the toxicity and the effect of treatment for patients with endometrial cancer in the Carboplatin doses setting using the revision creatinine clearance 片山健太郎1,3, 今村牧夫2, 上原孝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 500-500, 2021. |
|---|
|
|
YIA3-01. Study on neutrophilic/lymphocytes ratio and effect of treatment in the Palbociclib therapy 鈴木かおり1, 宇田川涼子1, 大塚亮1, 渡部大介1, 石川光信1, 赤木徹1, 橋本浩伸1, 山口正和2, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-502, 2021. |
|---|
|
|
YIA3-02. It is a relative dose intensity of the adjuvant chemotherapy and the association of the no recurrence survival period after the non-small cell lung cancer technique: Look at the single institution rear; a mark cohort study 冨士原あゆみ, 塩飽英二, 松原菜美, 土手賢史, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 503-503, 2021. |
|---|
|
|
YIA3-03. It is examined the paclitaxel + Carboplatin therapy as the adjuvant chemotherapy after the operation for the early carcino-sarcoma uterus 後藤千尋1, 片山健太郎1, 仁井寛彦1, 今村牧夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 504-504, 2021. |
|---|
|
|
YIA3-04. Correlation analysis with the blood level of the drug which we used for new coronavirus infection (COVID-19) treatment in Tohoku University Hospital and the clinical index 佐藤稔之1, 高崎新也1, 森下啓1, 千葉僚1, 小林大典1, 鈴木博也1, 佐藤裕1, 佐藤紀宏1, 菊地正史1, 早川禎宏2, 杉浦久敏3, 青柳哲史4, 前川正充1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2021. |
|---|
|
|
YIA3-05. The use actual situation of the daptomycin and safe examination 山口莉穂, 勝又瑛梨奈, 松本勝城, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-506, 2021. |
|---|
|
|
YIA3-06. Use of the proton pump inhibitor and potassium ion competition type acid blocker and risk review of the Clostridioides difficile infection 渡邉愛悠1, 佐藤智香1, 高取士剛1, 岩堀真弓1, 久保淳一1, 和泉秀明1, 田畑裕和1, 小原郁司1, 樋浦一哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 507-507, 2021. |
|---|
|
|
YIA3-07. Effect on discharge dose and drug costs investigation by the TDM of the Clozapine 阿部裕也1, 渡辺研弥1, 野崎啓子2, 陣野大輔1, 平田祥一朗2,3, 鈴木二妙香2,4, 後藤將之2,3, 一瀬瑞絵2, 山本慎之助2,5, 堀越翔2,6, 金子春香2,7, 須藤孝浩1, 黒田純子1, 三浦至2, 矢部博興2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2021. |
|---|
|
|
YIA3-08. Efforts of the discharge drug information cooperation addition in our hospital and evaluation of the health insurance pharmacy 和仁昇1, 大澤琢郎1, 山本和哉1, 洞口拓也1, 小林和正1, 田中知代1, 嶋俊弥1, 政井恵1, 元田美佳1, 近藤佑香1, 長柄智美1, 上田秀親1, 阪口直樹1, 若田達朗1, 和仁寿彦2, 竹中勝信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-509, 2021. |
|---|
|
|
O01-01. The acetaminophen-induced low blood pressure in the septicemic patients: Single institution retrospective cohort study 稲毛俊介, 矢島領, 長原新太郎, 風間彩, 高村萌, 庄司知紘, 門井美香, 田代友紀子, 伊勢雄也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2021. |
|---|
|
|
O01-02. Usefulness evaluation of the drug confirmation before operation of the perioperative care team pharmacist for the surgery rate of discontinuation 白倉由基1,2, 石田茂1,2, 田川慎二1,2, 辛島裕士1,3, 藤吉哲宏1,4, 梅原薫3, 淀川千穂1,5, 渡邊裕之2, 辻敏和2, 江頭伸昭2, 中川尚志1,6, 家入一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-512, 2021. |
|---|
|
|
O01-03. Examination of the eye manifestation onset factor with voriconazole 岡冨大輔1, 宮庄杏奈1, 上野千奈美1, 樫本考司1, 片山雄太2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 513-513, 2021. |
|---|
|
|
O01-04. Risk factor analysis of the nonionic iodine adverse reaction to contrast medium onset 上村忠聖1, 茶谷良一2, 鈴木信也3, 小松原江里子1, 林誠一1, 橋口正行2, 木崎速人2, 堀里子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2021. |
|---|
|
|
O01-05. The current situation of the application support system of the Relief System for Sufferers from Adverse Drug Reactions 中川義浩1, 坂田光平2, 藤田強記2, 浮池香奈子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-515, 2021. |
|---|
|
|
O02-01. Development of the in vivo intracerebral multiple receptor share simultaneous measurement method that aimed at the effectiveness, the safety assessment of antipsychotics 赤下学, 中谷絵理子, 佐々木渉, 宮下映里果, 黄倉崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-517, 2021. |
|---|
|
|
O02-02. Factor analysis of the OATP1B activity individual differences that assumed the plasma Coproporphyrin-I concentrations in patients with rheumatoid arthritis an index 小野寛之1, 田中遼大1, 鈴木陽介2, 小田絢子2, 尾崎貴士3, 龍田涼佑1, 大野恵子2, 柴田洋孝3, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-518, 2021. |
|---|
|
|
O02-03. PK-PD-PGx analysis of the factor Xa inhibitor edoxaban and its active metabolite M-4 in patients with atrial fibrillation 中川潤一1, 金城貴彦2, 相内尚也1, 上野桂代1, 富田泰史2, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 519-519, 2021. |
|---|
|
|
O02-04. The proton pump inhibitor reduces the effectiveness of the capecitabine therapy in patients with early colon cancer: Look at the multicenter rear; a mark observational study 高橋克之1, 北爪賀子2, 河添仁3, 魚住龍史4, 吉澤朝枝5, 飯原大稔6, 藤井宏典6, 新井隆広7, 村地康8,9, 佐藤由美子10, 三上貴弘11, 橋口宏司12, 山崎朋子5, 高橋正也1, 藤田行代志7, 細川祐岐8, 諸角一成10, 土屋雅美11, 横山敦12, 橋本浩伸2, 山口正和13 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2021. |
|---|
|
|
O02-05. Development of human serum Pembrolizumab densitometry by the column switching LC-MS/MS method using the online solid-phase extraction column 清水穂香1, 阿部一樹1, 内藤隆文1, 大塚篤史2, 前川真人3, 三宅秀明2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-521, 2021. |
|---|
|
|
O03-01. Construction of the predictive model of the onset of serious neutropenia in patients with AC therapy enforcement breast cancer 宮城壮裕1, 辻大樹1, 仕子優樹2, 山本圭祐3, 中道秀徳3, 矢部勝茂3, 川崎洋平4, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2021. |
|---|
|
|
O03-02. It is investigated the adhesion situation of the ingredient in the PTP sheet after taking lenalidomide capsule 小室雅人1, 古屋貴人1, 大橋養賢2, 渡部大介3, 野村久祥4, 小室亜由美4, 田部井彰5, 澤村星吾6, 百武宏志7, 宮澤淑子8, 楠浩子9, 寺門浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-524, 2021. |
|---|
|
|
O03-03. Relations analysis with blood aprepitant based on the cachectic progress degree in patients with head and neck cancer and the active metabolite levels and antiemesis effect 鈴木祐介1,2, 内藤隆文1, 柴田海斗1, 細川誠二2, 峯田周幸2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 525-525, 2021. |
|---|
|
|
O03-04. Look at the rear about the clinical significance of the appropriate blood pressure management for the proteinuria onset of patients receiving VEGF inhibitor; a mark cohort study 二瓶哲1,2, 朝賀純一1,2, 高橋宏彰1,2, 氏家悠貴3, 青木朋彦1, 大坂紗也佳1, 村里風太1, 佐藤文彦1, 旭浩一4, 前門戸任5, 工藤賢三1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2021. |
|---|
|
|
O03-05. First/II phase study (DGA-study) of the Amitose-DGA-containing cream for the prevention of the hands and feet skin test for patients with renal cell carcinoma taking sunitinib 山本和宏1, 西山智司2, 国定充2, 五百蔵武士1, 飯田真之1, 伊藤雄大1, 槇本博雄1, 大村友博1, 原田健一3, 藤澤正人3, 錦織千佳子2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-527, 2021. |
|---|
|
|
O04-01. We look at the effectiveness in the change and the safe rear in an administration schedule of trifluridine/Tipiracil and are examined a mark 原伸輔1, 坂井大介2, 新谷拓也1, 山本智也1, 佐藤太郎2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2021. |
|---|
|
|
O04-02. The blood favipiravir levels are associated with the rise in uric acid level depending on a ferritin level 森川剛1, 久保田健1, 近藤大地2, 高梨靖久2, 南聡3, 金城恒道4, 守岩友紀子5, 柳田顕郎5, 岡澤香津子1, 千秋智重2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-530, 2021. |
|---|
|
|
O04-03. Examination of the clinical outcome with the dexamethasone administration for the new coronavirus infection 伊部裕太1, 石郷友之1, 北川学1, 木明智子1, 藤谷好弘2, 黒沼幸治3, 藤居賢1, 高橋聡2, 福土将秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 531-531, 2021. |
|---|
|
|
O04-04. Association between rehospitalization and polypharmacy in patients with heart failure 竹村有美, 樋口裕己, 山田健一, 幸邦憲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2021. |
|---|
|
|
O04-05. Application to extraction and the liver metabolism type drug proper use of patients with potential cirrhosis using the ALBI score 吉井圭佑1, 田坂祐一1, 吉田昭昌2, 田頭尚士3, 星島祐美子4, 田坂友紀4, 杉山哲大5, 山本宏6, 名和秀起1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-533, 2021. |
|---|
|
|
MS01. New developments in cancer cachexia treatment - based on experience with Adlumiz - 濱内諭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-536, 2021. |
|---|
|
|
MS03. 2021 appearance - of age - antiCGRP antibody of the change of migraine headache treatment 橋本洋一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2021. |
|---|
|
|
MS04. Benefit and problem of the irAE management and the ePRO utilization in the cancer medical therapy 太良哲彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-540, 2021. |
|---|
|
|
MS05. It is ... from the medication support of patients with thing - HIV infection to want you to know it being a role of the hospital pharmacist in the ambulatory practice of the chronic disease for "the day" 矢倉裕輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2021. |
|---|
|
|
MS06. New hematology 柴田啓智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 544-544, 2021. |
|---|
|
|
MS07-1. Current situation/MS07-2. of the migraine headache therapeutic drug which we looked at from a pharmacist New migraine headache treatment to want all pharmacists to know it 杉上香織, 今井昇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-546, 2021. |
|---|
|
|
MS08-1. Usefulness and safety ... of the JAK inhibitor which we looked at from the glance of rheumatoid arthritis practice ... physician that JAK inhibitor became the main force 三崎健太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-548, 2021. |
|---|
|
|
MS08-2. Role of the pharmacist in rheumatoid arthritis treatment 曽根本恵美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-549, 2021. |
|---|
|
|
MS09. From adult T cell leukemia, lymphoma (ATL) - viral infections to malignant transformation, how do also cure; ... 野坂生郷 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-551, 2021. |
|---|
|
|
MS10. What is the strongest supportive care to develop every day? Efforts ... of the pharmacist specialized in a cancer about retching, vomiting of ... our hospital 石川寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 553-553, 2021. |
|---|
|
|
MS11. Understanding and introduction case to Biosimilar 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 555-555, 2021. |
|---|
|
|
MS12-1. Basics of breast cancer treatment and importance/MS12-2. of the team approach in medical care Role of the pharmacist in the team approach in medical care 西村令喜, 森岡淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2021. |
|---|
|
|
MS13. About the efforts of the pharmacist for hepatitis B to occur by immunodepression, chemotherapy 水谷栄梨, 宮崎俊明, 谷口潤 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 559-559, 2021. |
|---|
|
|
MS14-1. Basic knowledge of the equol and clinical evidence 内山成人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-561, 2021. |
|---|
|
|
MS14-2. Pharmaceutical viewpoint and approach in the breast cancer endocrine therapy 今村知世 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2021. |
|---|
|
|
MS15. Implementation of regional formularies in Japan - Role of hospital pharmacists - 今井博久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2021. |
|---|
|
|
MS16. To realize cooperation of role - truth of the pharmacist sought by community medical care cooperation; ... 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2021. |
|---|
|
|
MS17. Evidence ... which is usable from resistant bacteria infection treatment - today based on scientific grounds 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 568-568, 2021. |
|---|
|
|
MS18. Should the medical person (physician) think about medical expenses? Significance ... of the generic introduction in ... cancer domain 後藤悌 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-570, 2021. |
|---|
|
|
MS19. Role of the pharmacist for a fact of misuse, the abuse of the opioid analgesic and the prevention 細川豊史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2021. |
|---|
|
|
MS20-1. Let's evaluate a pharmacokinetic profile as a pharmacist definitely 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2021. |
|---|
|
|
MS20-2. How are you associated with medical therapy as a pharmacist? 鈴木貴明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-575, 2021. |
|---|
|
|
MS21-1. Supporting "Living with Cancer" - Encounter with Appearance Care - 吉野真樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 577-577, 2021. |
|---|
|
|
MS21-2. Importance ... of symptom management - moisture retention and the skin care for the dermatopathy to be caused by cancer medical therapy 山崎直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2021. |
|---|
|
|
MS22. Because a pharmacist is concerned with patients lifesaving, read ... clinical practice guidelines to think about the way on drug intervention, and untie it; and ... 吉廣尚大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2021. |
|---|
|
|
MS23. How to use Chinese medicine in acute phase, the ward 加島雅之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2021. |
|---|
|
|
MS24. About neuromyelitis optica spectrum disorder (NMOSD) 岡本智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-584, 2021. |
|---|
|
|
MS25. Need - of the evaluation from a viewpoint of the medical security at pharmaceutical products adoption and the design evaluation at risk management - pharmaceutical products adoption 菅野浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2021. |
|---|
|
|
MS26. With the information sharing tool which form - all can utilize of the proper use of the oral anticancer agent "thinking about from a gastric cancer case" and the future medical cooperation? 藤堂真紀, 下川友香理, 藤田あゆみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2021. |
|---|
|
|
MS27. Multi-type of job collaboration approach ... to work-style reform - sleeplessness, the delirium of the ward pharmacist by the specialist in hospital synthesis 園田幸生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-590, 2021. |
|---|
|
|
MS28. The tide that the medical therapy is new after in front of art of the breast cancer, the operation 山本豊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2021. |
|---|
|
|
MS29. Reach the ... HIF-PH inhibitor era with the appropriate diagnosis and treatment of the anemia in renal disease; and ... 桑原孝成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-594, 2021. |
|---|
|
|
P01-01. Case of patients during Afatinib remedy given information feedback from the family drugstore to a medical institution 辻真利1, 笹野寿基2, 安川徹2, 竹原美穂2, 吉田貴大3, 山田裕介3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-597, 2021. |
|---|
|
|
P01-02. Consideration of problems in the storage of the pharmaceutical products with the bag with the light blocking effect 井上智咲, 田崎眞生, 辻本勉, 桑原晶子, 濱宏仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2021. |
|---|
|
|
P01-03. Inspection of the system for the purpose of the efficiency of the drug dose confirmation depending on renal function 住吉恵1,2, 山中紗弥花1, 安森奈緒子1, 大石裕樹2, 川俣洋生1, 花田聖典1, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 599-599, 2021. |
|---|
|
|
P01-04. About the venous thrombosis prevention in the edoxaban administration after the orthopedics lower limbs surgery 吉山昂佑, 松元大地, 永見康男, 山本和宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-600, 2021. |
|---|
|
|
P01-05. Examination of the change of the number of doubt inquiries by the default use setting 上松祐貴, 三村享, 関夏望, 中澤佑香, 村井健太郎, 土屋広行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2021. |
|---|
|
|
P01-06. Setting - of the dosage interval every efforts - drug to evade drug interaction by the remedy at the same time 成瀬圭, 升田万祐子, 多留木崇志, 楠川侑吾, 村田龍宣, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2021. |
|---|
|
|
P01-07. Comparison of the medication counseling time between the antiinfluenza medicine in the health insurance pharmacy 高橋渉1, 伊藤元太2, 藤原正和2, 本郷良泳2, 長沼未加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2021. |
|---|
|
|
P01-08. Comparison in the sex test to pass a transluminal tube of the loxoprofen sodium infinitesimal grain preparation 高野克彦1, 毎田千恵子1, 秋山滋男2, 石田志朗3, 宮本悦子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2021. |
|---|
|
|
P01-09. Efforts for the checking prescription by the electronic medium of oral anticancer agent lenalidomide 山中葵1, 有馬崇充1, 住吉愛1, 渡部大介1, 石川光信1, 赤木徹1, 橋本浩伸1, 山口正和2, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2021. |
|---|
|
|
P01-10. Change of the doubt inquiry contents from the health insurance pharmacy before and after the electronic medical chart system change 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2021. |
|---|
|
|
P01-11. Analysis of doubt inquiry in injection drug formulations 小谷咲, 大澤勇貴, 佐竹美咲, 酒井正博, 木村麗砂, 日浦寿美子, 小林秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2021. |
|---|
|
|
P02-01. It is the change of color of telmisartan tablets accompanied with the use of tablet assortment device (TABSORT) and the factor one package 岡崎裕太朗1, 竹下治範2, 藤澤諒子1, 山下和彦1, 山本和宏1, 槇本博雄1, 大村友博1, 國正淳一2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-609, 2021. |
|---|
|
|
P02-02. Investigation about the pharmaceutical products traceability system in temperature-controling it after the drug withdrawal to need cool place preservation 渡邊裕之1,2, 山本大介3, 先崎公祐3, 小島真弥4, 桜沢雅洋5, 石原聖也5, 宅和真由美1, 平田敦宏2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2021. |
|---|
|
|
P02-03. Establishment and implementation of grading management standard for antineoplastic drugs Zhou Muzi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 611-611, 2021. |
|---|
|
|
P02-04. Survey on the reuse of discontinued medicines in one package - With an eye to task shifting in pharmacist work - 阪元孝志, 鳥山純司, 松島静香, 梅本啓史, 吉井景祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2021. |
|---|
|
|
P02-05. Making of the pharmaceutical products ordering system using Excel VBA 牧原明秀, 吉田弘樹, 葛谷真理, 今高多佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2021. |
|---|
|
|
P02-06. Regarding the usage status of proton pump inhibitors after in-hospital formulary operation 高田恵司, 千葉さくら Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2021. |
|---|
|
|
P02-07. Procedure construction and evaluation of the pharmaceutical products proper use using optimal use promotion guidelines 赤阪未来, 濱口直美, 向原里佳, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-615, 2021. |
|---|
|
|
P02-08. Improvement effect by the general anesthesia set review in the operating room 直井一久, 近藤崇泰, 植竹龍一, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2021. |
|---|
|
|
P02-09. Establishment of a common formulary for co-adopted drugs and economic effects - Focusing on biopharmaceuticals - 武田怜1,2,3, 寺川央一1, 木立康太2, 山本譲1, 安達知輝1, 大滝康一3, 小野尚志1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-617, 2021. |
|---|
|
|
P02-10. Clinical application analysis of human albumin during perioperative period of liver transplantation patients Zhang Wei Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 618-618, 2021. |
|---|
|
|
P02-11. Efforts of the pharmaceutical products expiration date for use management 佐藤綾香1, 武藤芳和1, 滝口理菜2, 渡部寿康1, 菊地洋平1, 黒田彩佳1, 矢葺優佳1, 安齋英里1, 大竹麻衣子1, 古賀彩織1, 寺内優紀恵1, 酒井亮1, 井上可奈子1, 二瓶瑶子1, 佐藤南1, 川村早苗1, 緑上淳一1, 我妻禎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-619, 2021. |
|---|
|
|
P02-12. Fact-finding about the voluntary recall of the ethical drug 西順也, 小國正和, 南智香子, 緒方健二, 内田任仁弘, 合原嘉伸, 江本晶子, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2021. |
|---|
|
|
P02-13. Economic effect by the participation of the pharmacist for the pharmaceutical products management in the operating room 小牧誉典1, 井黒俊2, 中野公1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2021. |
|---|
|
|
P03-01. Development and evaluation of "pregel" granule for the purpose of the adherence improvement of children 加藤里菜, 宮嵜靖則, 内野智信, 賀川義之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2021. |
|---|
|
|
P03-02. Quality evaluation of three-drug mixed eye drops to use for cataract surgery pre-treatment 山内理恵1, 大野修司1, 竹場和代2, 川崎智子2, 北岡晃2, 井上信宏1, 久保元1, 浅井和範1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 624-624, 2021. |
|---|
|
|
P03-03. Quality evaluation of the hospital preparation diclofenac gargle by the fixed-quantity NMR 明樂一己1, 野原彩香1, 宇都宮悠花1, 見留英路1, 渡邉真一3, 田中守2, 田中亮裕4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2021. |
|---|
|
|
P03-04. Bitterness masking of the preparation for the children using the seamlessness method 田中咲妃, 草村把奈, 深水啓朗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-626, 2021. |
|---|
|
|
P04-01. Examination of the mode of transportation of the cool place preservative to the patients's house 石原優1, 丹勝弘2, 工藤亘2, 浅子恵利3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2021. |
|---|
|
|
P04-02. Evaluation of the dissolution in starting pharmaceutical products of the pH-dependent type mesalazine Enteric tablet and the generic medicine 石田志朗1, 田畑寛明2, 秋山滋男3, 毎田千恵子4, 地野幹子2, 増永高晴5, 宮本悦子6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-629, 2021. |
|---|
|
|
P04-03. Preservation stability - of the metoclopramide hydrochloride which we mixed to stability evaluation - Elneopa infusion of the parenteral injection mixture hyperalimentation stored in patients's house 松川美佐子1, 小山紗矢1, 谷田佳香1, 白木孝2, 黒田英津子3, 竹内敦子4, 都出千里4, 中山優子1, 寺岡麗子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 630-630, 2021. |
|---|
|
|
P04-04. Duties efficiency by the Excel macro of the periodical prescription 佐澤卓哉, 黒田絋生, 小迫晶寛, 上村豪, 植村隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2021. |
|---|
|
|
P05-01. About pharmacist duties in the respiratory medical service in the corona evil 三屋良太, 佐々弥栄子, 高木裕介, 笠井翼, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2021. |
|---|
|
|
P05-02. Efforts of a regime and the proper use of the Nusinersen by the other types of job cooperation in our hospital 齊藤綾子1, 宮本晋治1, 小篠史郎2, 政賢悟1, 田中順子1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 636-636, 2021. |
|---|
|
|
P05-03. Effect of the bringing medicine instructions representation duties based on the protocol for the cardiovascular surgery patients 森田祐基1, 中島のぞみ1, 内田佳菜子1, 竹原眞人2, 津丸真一2, 島本健2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-637, 2021. |
|---|
|
|
P05-04. Questionary survey to the healthcare worker about the evaluation for the ward resident duties of the pharmacist 新田茜1, 本多秀俊1, 木下淳2, 麻丘真葵2, 稲村澄子1, 林由紀子1, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2021. |
|---|
|
|
P05-05. Effect by the sleeplessness use drug change in the urologic clinical path 平野史, 馬場亮一, 成末まさみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 639-639, 2021. |
|---|
|
|
P05-06. The current situation investigation for the polypharmacy measures in the convalescent rehabilitation hospital 木村早希, 鬼澤ひかり, 渡邉幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2021. |
|---|
|
|
P05-07. The receptive current situation investigation of the use situation and the tablet internal use of the oral prednisolone to non-school children in our hospital 久保拓己, 栗原陽介, 赤沢翼, 増田純一, 寺門浩之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2021. |
|---|
|
|
P05-08. Efforts for the polypharmacy in our hospital general medicine ward 戎浦規文1, 雪矢良輔1, 奥田佳子1, 清水悠弥1, 松岡里枝1, 抱恵子1, 梶田貴司1, 奥野智之1, 明保洋之2, 田川竣介2, 真辺諄2, 柏原英里子2, 三宅啓史2, 佐田竜一2, 石丸裕康2, 八田和大2, 熊木郁子3, 中島壽惠3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2021. |
|---|
|
|
P05-09. Efforts to reduce medication for polypharmacy at our hospital 佐藤実由, 古谷智裕, 武井秀樹, 北本真一, 宮森伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2021. |
|---|
|
|
P05-10. Examination of the intervention by the pharmacist for the local inclusion care ward inpatient 元木孝, 田口諒, 澁谷基宏, 渡邊清人, 高柳昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2021. |
|---|
|
|
P05-11. Efforts of the drug global assessment adjustment addition in the orthopedics ward 松木克仁, 前田玲於奈, 山梨領太, 平野淳, 薄雅人, 林誠, 中井正彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2021. |
|---|
|
|
P05-12. The case report which reached the improvement by a change to vonoprazan for a diarrhea symptom speculated that it was caused by lansoprazole which we combined with low-dose aspirin 岩下裕美, 薗田晃弘, 中尾承司, 兒玉麻代, 高田侑那, 浜園龍, 久永あゆみ, 森永知沙, 上堀正博, 柴田奨, 長島菜子, 岩下佳敬, 石田和久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2021. |
|---|
|
|
P05-13. Examination of a PONV generating factor and measures using the predictive simple score in the surgery 大野凌也1, 佐々木理絵1, 本郷文教1, 木ノ下義宏2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2021. |
|---|
|
|
P05-14. Efforts of the clinical reasoning utilizing the symptom monitoring sheet at the bringing medicine's confirmation 山下諒祐, 遠原大地, 弟子丸恵実, 齊藤綾子, 高林学, 政賢悟, 田中順子, 齋藤秀之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 648-648, 2021. |
|---|
|
|
P05-15. About the intervention situation of the local highly-concentrated antimicrobial perfusion therapy (iSAP, iMAP) TDM facing each other in our hospital 山中俊哉, 小寺聖, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2021. |
|---|
|
|
P05-16. Evaluation of the antiemesis effect on cisplatin regimen by having made Fosaprepitant and pre-medication prescription using magnesium adequate 尾崎正和, 幸田恭治, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2021. |
|---|
|
|
P05-17. Pilot study - in study on distance - clinical practice between optimal patients - pharmacists at medication counseling 牛膓沙織1,2,4, 水口日南野2, 中山千佳3, 宮城雪菜2, 宮地佑佳2, 大嶋耐之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 651-651, 2021. |
|---|
|
|
P05-18. Investigation of the use of constipation therapeutic drug situation in our hospital palliative care unit 後藤義之, 角紀一郎, 岡田久美, 古本真由美, 松岡未紗, 茶野下貴恵, 島崎沙織, 青木理恵, 清水翔子, 西川達也, 梅下翔, 室田恵里, 橋本夏恵, 山下陽夏, 森戸敏志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2021. |
|---|
|
|
P05-19. Making of the "drug needing particularly careful administration" in the drug global assessment adjustment addition extraction system 渡辺智康, 山崎恵, 難波良平, 高取孝一, 安藤哲信 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2021. |
|---|
|
|
P05-20. The effect that the anticholinergic load in patients with elderly people stroke during convalescent rehabilitation ward hospitalization gives to medication self-care 田中絵里子1,2, 藤原久登1,2,3, 鈴木奈緒1,2,3, 中村彰子1,2,3, 高木桂子1,2, 川手信行4, 佐々木忠徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2021. |
|---|
|
|
P05-21. Analysis, evaluation ... of role - pharmaceutical intervention example of the pharmacist in the convalescent rehabilitation ward 建部宏子, 藤田裕子, 徳冨江里, 塩川満 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2021. |
|---|
|
|
P05-22. Drug section polypharmacy measures of our hospital which we worked on altogether 山田瑠依, 横田美有, 鬼塚智行, 藤村裕美, 中川伊久美, 井上香奈子, 高田恵司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-656, 2021. |
|---|
|
|
P05-23. Efforts for practice and the drug global assessment adjustment addition calculation of the rehabilitation drug in the local inclusion care ward 横田美有, 高田恵司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2021. |
|---|
|
|
P05-24. Challenge ... of the cottage-hospital out of efforts ... of the drug adjustment in the local inclusion care ward using the flowchart 道坂瑳恵, 細木慈子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2021. |
|---|
|
|
P05-25. Investigation about the change of the quality of efforts and pharmacist duties for drug global assessment adjustment addition calculation in our hospital 淺井俊平, 松山陽香, 丸山あずさ, 高取裕司, 池上信昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2021. |
|---|
|
|
P05-26. Study on immunoglobulin refractoriness case prediction in childhood Kawasaki's disease treatment 丹代恭太, 工藤晋, 米内和暉, 冨山育朗, 鈴木弘文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 660-660, 2021. |
|---|
|
|
P05-27. Role of efforts and the pharmacist to the polypharmacy cancellation in the circulatory organ ward 高橋直博, 野澤直史, 中里健志, 新井亘, 増田裕一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2021. |
|---|
|
|
P05-28. Comparison between evaluation - In-Check and In-Check DIAL - before and after the inspiratory flow rate measuring instrument change to use for inhalational instruction 菅原拓也, 鈴木麻友, 志田幸平, 荒井潤, 後藤純一, 関口徳志, 齋藤順, 延川正雄, 松田圭一郎, 荒井浩一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2021. |
|---|
|
|
P05-29. The efforts situation to polypharmacy in our hospital 原田若奈, 長戸優也, 升田万祐子, 三松史野, 小野勝, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2021. |
|---|
|
|
P05-30. About the activity of the polypharmacy measures team of our hospital and the result 小倉弥生, 生沼仁美, 下田麻祐子, 江原可成子, 大木孝夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2021. |
|---|
|
|
P05-31. The urination care team which intervenes in the viewpoint of the pharmacist 林剛史, 古川大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 665-665, 2021. |
|---|
|
|
P05-32. Effect of the situation and the drug adjustment of the polypharmacy in the stroke care unit 福田裕子1, 井岡瑞樹子1, 伊東里紗1, 森あやか1, 早崎浩司2, 高橋務3, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2021. |
|---|
|
|
P05-33. Practice of the practice flow about the osteoporosis therapeutic drug 親富祖翔太郎, 東千夏, 平田やよい, 川上博瀬, 宮里弥篤, 村田利恵子, 浜元善仁, 翁長真一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2021. |
|---|
|
|
P05-34. Efforts of the proper use promotion by the voriconazole side effect + blood level confirmation tabulation 宮庄杏奈, 岡冨大輔, 上野千奈美, 樫本考司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2021. |
|---|
|
|
P05-35. Examination of the protective efficacy of analysis of the risk factor of nausea, vomiting after the catheter ablation and diphenhydramine/diprophylline combination tablets 有馬智裕, 西村文宏, 牛島智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 669-669, 2021. |
|---|
|
|
P05-36. Efforts to discharge drug reporting management instruction reinforcement 堀内賢一, 菊池環, 須田裕之, 氣仙早希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2021. |
|---|
|
|
P05-37. Report of the enforcement situation and the attitude survey of the discharge drug instruction cooperation addition in the Shinshu Ueda medical center 平山武宏, 鈴木春子, 渡辺章功, 荒義昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-671, 2021. |
|---|
|
|
P05-38. Changes in ward drug operations and pre-avoid reporting due to the introduction of electronic medical records and medical economic effects 數本直規, 若林雅人, 牛山利昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2021. |
|---|
|
|
P05-39. Making of new efforts - medication situation confirmation flow sheet for the false medicine prevention by the ward pharmacist and evaluation ... 池田隆, 後藤明人, 多田隼起, 佐藤千比呂, 中原慎平, 金田美咲緒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2021. |
|---|
|
|
P05-40. A change and effect of the duties system aiming at improvement in quality of the pharmacist duties in the ward 越塚宏美1,2, 百賢二1, 喜田昌記1,2, 阿部久瑠美1,2, 柏原由佳1,2, 田中克巳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2021. |
|---|
|
|
P05-41. Efforts of the video production of the medicine for patients to support a planned inpatient and the usefulness 森あやか1, 北澤文章1, 大橋浩子2, 木立泰子3, 乙名さおり4, 山田真一5, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2021. |
|---|
|
|
P05-42. Examination 2 of the communication analytical procedure using the feelings recognition AI from the viewpoint of feelings level: 宮城雪菜1,3, 河野明莉1, 仲山千佳2, 牛膓沙織1,3,4, 宮地佑佳1, 大嶋耐之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2021. |
|---|
|
|
P05-43. The efforts which aimed at the utilization of the metrics of ward duties aiming at the improvement of the patients contribution degree and the consciousness reform of the pharmacist 岸本真1, 中村杏果1, 森永崇史1, 池沢若菜1, 田中恭人1, 豊留麻衣1, 北園幸大1, 中野一馬1, 山本梢1, 屋敷大輔1, 淵脇ゆかり1, 徳丸章佳1, 長ヶ原琢磨1, 荻尾夕起子1, 児玉友和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2021. |
|---|
|
|
P05-44. Change to calculation by the template making for the record of discharge drug information management instruction charges 淺香圭寛1, 中村俊貴1, 小林彦登1, 南有里1, 幅麻衣子1, 貝沼潤1, 左右田和枝1, 松原肇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2021. |
|---|
|
|
P05-45. About a characteristic and the discharge outcome of the heart failure conference enforcement patients in our hospital 中島一1, 吉国健司1, 角田菜緒1, 椛島寛子2, 櫻井栄子3, 小倉秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-679, 2021. |
|---|
|
|
P05-46. In-hospital formula remaking by the working together of a pharmacist, the physician who is a beginning of the drug costs reduction 前万紀子, 山崎彬史, 中浴伸二, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-680, 2021. |
|---|
|
|
P05-47. Examination about the personal evaluation method of the number of drug control guideposts in the ward duties enforcement addition calculation institution 高橋史織, 柏瀬しのぶ, 深谷寛, 長谷川由希, 浜田幸宏, 木村利美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-681, 2021. |
|---|
|
|
P06-01. Evaluation of the administration situation and the effectiveness of the naldemedine for the constipation during use of fentanyl in the intensive care 中里健志, 赤池沙織, 高橋直博, 新井亘, 増田裕一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 683-683, 2021. |
|---|
|
|
P06-02. The adverse event 2 case that occurred by an injection drug in first aid, an intensive care unit 濱名哲大1, 梅原聡子1, 大瀧あかね1, 寺田椋1, 橋本佑香1, 奥村直生1, 井上聡子2, 坂上嘉浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 684-684, 2021. |
|---|
|
|
P06-03. An evaluation of the pharmaceutical intervention by the pharmacist duties in the ICU and the multi-type of job rounds and future problem 藤戸靖久1, 土井延平1, 橋本宜享1, 福井道彦2, 橋本昌幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-685, 2021. |
|---|
|
|
P06-04. The drug information offer by the ICU exclusive duty pharmacist and effect to medical treatment 市原麻友子, 有銘千賀子, 長濱藍, 府川祥子, 坂口結斗, 白木萌, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 686-686, 2021. |
|---|
|
|
P06-05. The case that was able to evade rebleeding by PT-INR reascension and vitamin K2 supplementation after the Kay Saint lah (R) use 柳岡祥太, 松原浩司, 前田直大, 伊佐治麻里子, 木藤貴弘, 白井博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 687-687, 2021. |
|---|
|
|
P06-06. The change of the drug information offer contents accompanied with the exclusive duty pharmacist increase of the staff in the emergency ward and the evaluation 黒岩亮平, 梅森蓉子, 井口恵美子, 猪股克彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 688-688, 2021. |
|---|
|
|
P06-07. The current situation of the drug intoxication with the commercial drug of young people 広瀬正幸1,2, 平川昭彦3, 田島康介4, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2021. |
|---|
|
|
P06-08. Examination of the adsorption behavior of the antiMRSA medicine for various dialyzer used for sustained hemofiltration dialysis 熊野諒太1, 稲野祥宗1, 土屋香代子1, 仲佐啓詳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 690-690, 2021. |
|---|
|
|
P06-09. One case that blood vancomycin levels presented false high level by the reflux drawing blood from a central intravenous line 鈴木英二1, 小林恵子1, 伊藤陽一1, 大森教雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-691, 2021. |
|---|
|
|
P06-10. Intervention to time to administration of wide area antimicrobial start shortening for sepsis or the septic shock patients and the effect 上田実穂1, 田村亮1, 鎌田里紗1, 入江慶1,2, 池末裕明1, 橋田亨1,2, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2021. |
|---|
|
|
P06-11. Examination about the crystal separation of the anticoagulant which occurred in an expression membrane type heart-lung machine circuit out of the body 小林恵子, 鈴木英二, 伊藤陽一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2021. |
|---|
|
|
P06-12. The development of in-hospital operation procedures of the highly-concentrated potassium preparation and the safety 上野希望, 山村亮太, 龍田涼佑, 中原良介, 田中遼大, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2021. |
|---|
|
|
P06-13. Role of the operating room charge pharmacist for safe epidural anaesthesia enforcement 風間彩, 矢島領, 平井瑞希, 三浦義彦, 伊勢雄也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2021. |
|---|
|
|
P07-01. Effect (the first report) of a physician and the pharmacist cooperation in the ambulatory practice of the rheumatoid arthritis 平田一耕1,2, 六反田諒3, 舟越亮寛4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2021. |
|---|
|
|
P07-02. The current situation investigation of the effect of the pharmacist intervention in the hospitalization and release support center 松尾美怜, 寺沢匡史, 福島綾, 島本沙代, 久保あかね Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2021. |
|---|
|
|
P07-03. Examination about the usefulness of the pharmacist interview before hospitalization by the pharmacist 岸本亜矢子, 山崎彬史, 松尾種代, 中浴伸二, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2021. |
|---|
|
|
P07-04. Introduction of the pharmacist outpatient department for oral anticancer agents and questionary survey for the physician 小澤有輝, 草野淳一, 山本龍世, 矢吹優, 林誠一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2021. |
|---|
|
|
P07-05. Examination of the usefulness of the intervention by the pharmacist in the outpatient department for Lenvatinib treated patients 桂川みき1, 大下瑚姫1, 山田順子1, 大久保凛香1, 松木有莉1, 石塚仁保1, 山下友輝1, 鈴木千波1, 小原秀治1, 柴波明男1, 樋浦一哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2021. |
|---|
|
|
P07-06. Investigation, examination about the drug instruction in the going to hospital treatment center 後藤総太郎, 吉田茜, 松尾拓馬, 殿村直也, 清美奈, 石原溶子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2021. |
|---|
|
|
P07-07. Efforts of the effective and effective cooperation full addition in the area cancer practice cooperation base Hospital 金原千明, 村地康, 近藤裕志, 成瀬祐奈, 由田飛馬, 相馬沙希, 高垣佳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-703, 2021. |
|---|
|
|
P07-08. Usefulness of a pharmacist attending it in the palliative care outpatient department 大野凜太郎1,4, 粕田晴之2,4, 伊澤紀子3,4, 斎藤和悦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2021. |
|---|
|
|
P07-09. About the calculation situation of the cooperation full addition in our hospital and a future problem 小笠裕斗, 上津沙織, 柿原圭佑, 吉国健司, 小倉秀美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2021. |
|---|
|
|
P07-10. It is ... in investigation and outcome - harmful effect hemophilia patients of the patients with COVID-19 infection change associated with the medical therapy that occurred under the effect 田上直美1, 高林学1, 高木雅敏2, 中田浩智3, 内場光浩3, 松下修三4, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2021. |
|---|
|
|
P07-11. Evaluation of the usefulness by the early intervention of the pharmacist in the patients support center 江島怜那, 小原直紘, 丸山直岳, 別府博仁, 土井敏行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-707, 2021. |
|---|
|
|
P07-12. The pharmacist permanent residence to the hospitalization support center about an effect of becoming it 中山潤美, 石原祥子, 鈴木加奈子, 加藤まゆ, 水谷彩伽, 水野淑子, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2021. |
|---|
|
|
P07-13. We respond after the medication in the childhood medical therapy 大木潤一, 石田洋介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-709, 2021. |
|---|
|
|
P08-01. Enforcement and inspection of the acting pharmacist input protocol in the prescription correction after doubt inquiry 森本芙未1, 坂倉彩香1, 佐伯真澄1, 山吉康子1, 村松博1, 青森達1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-711, 2021. |
|---|
|
|
P08-02. Evaluation of the internal use, medicine for external application picking duties by the person except the pharmacist using the bar code collation system 杉野友紀, 濱口直美, 平井利典, 岡本明大, 石橋美紀, 堀内桂子, 向原里佳, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2021. |
|---|
|
|
P08-03. Effect ... by introduction and usefulness - injection drug management of hospital pharmaceutical products management system "McHIL" 関根祐介, 鈴木篤, 藤本涼子, 宮里明芽, 東加奈子, 金子亜希子, 長尾達哉, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2021. |
|---|
|
|
P08-04. Effect ... by introduction and usefulness - compounding of medicines duties of hospital pharmaceutical products management system "McHIL" 金子亜希子, 関根祐介, 鈴木篤, 東加奈子, 海野由香子, 鮎原秀明, 北野安紀, 宮城聖子, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2021. |
|---|
|
|
P08-05. Practice - of medical treatment management (PBPM) based on representation order - protocol of blood, the urinalysis associated with the pharmaceutical products by the pharmacist 宮津大輔, 立石裕樹, 與田賢作, 松浦徹, 山下大貴, 安部由起子, 後藤貴央, 秋吉正貴, 田中博和, 渡邊裕之, 平川雅章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2021. |
|---|
|
|
P08-06. Flat enforcement ... on efforts ... hospital scale to the prescription support task by the pharmacist 瀬名波暢子, 森田直, 有江宏樹, 上野沙恵子, 数井沙織, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2021. |
|---|
|
|
P08-07. Efforts about the drug appropriateness by the polypharmacy team using a specific drug, the test value screening system 陶山泰治郎1, 香川瞭子1, 今滝泉1, 佐藤拓洋1, 篠永浩1, 原田典和1, 加地努1, 藤川達也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-717, 2021. |
|---|
|
|
P08-08. Task shifting using PBPM by an inpatient support room pharmacist 安田愛実1, 吉川依里1, 丸山あずさ1, 新井孝文1, 牛膓沙織1, 高橋典男2, 池上信昭1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2021. |
|---|
|
|
P08-09. Antibiotic Appropriate Use Support Team (AST) task-shifting efforts by managing vancomycin (VCM) concentration in injected blood 古川早矢香1, 高橋希1, 佐藤浩太郎1, 梶野哲1, 丸山伸樹1, 河野綾香1, 渋江寧2, 井口恵美子1, 猪股克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-719, 2021. |
|---|
|
|
P08-10. Examination - Kure-shi osteoporosis aggravation prevention project - of the intervention based on the multi-theory integration model of the pharmacist 覚前美希1, 羽山順子2, 松村智子3, 濱崎匡史4, 要田弥生5, 金子富美6, 津田彰7, 大塚幸三8, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2021. |
|---|
|
|
P08-11. The operation of the simplification protocol of the formulations act inquiry in the outside Parliament prescription and the evaluation 久保愛美, 深谷寛, 外賀裕次郎, 八田部良子, 吉田まり絵, 浜田幸宏, 木村利美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2021. |
|---|
|
|
P08-12. Effect of the physician duties burden reduction by the prescription support task of the pharmacist and the safe prescription management 喜多洋嗣1, 駒井勇太1, 人見百合子1, 田仲祐子1, 喜多幸子1, 小山淳2, 小畑慎也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-722, 2021. |
|---|
|
|
P08-13. Efforts for the duties reduction of the physician by the prescription deletion of the pharmacist 長友隆雄, 関屋裕史, 吉田桃花, 江藤結花, 江原幸菜, 平田梨沙, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-723, 2021. |
|---|
|
|
P09-01. Introduction results of infusion rate of application check system (IAAS-WEB) and examination about effectively utilizing it of the future 伊藤幸男, 堀田栄治, 五十嵐弘幸, 水野賀夫, 佐野正毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2021. |
|---|
|
|
P09-02. The input system construction of the doubt inquiry duties utilizing the eXChart function of the electronic medical chart and the effect 高村誠, 種村瞭, 仁谷美希, 関口陽子, 岩田真子, 山岸宏和, 鈴木さくら, 今成拓, 矢吹剛, 寺口敦, 南場信人, 五十嵐詠美, 中島楓, 貝瀬眞由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-726, 2021. |
|---|
|
|
P09-03. The current situation investigation for the new mobile health-related application development aiming at effective medical treatment and improvement in health science 福井一玄, 鈴木小夜, 菊山史博, 横山雄太, 地引綾, 河添仁, 中村智徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 727-727, 2021. |
|---|
|
|
P09-04. Examination of the standardization of the electronic medical chart use master in the Gifu comprehensive medical care center 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-728, 2021. |
|---|
|
|
P09-05. A comparison between medication counseling support software making and number of drug control instruction before and after the introduction and usefulness evaluation 橋本奈々1, 室宮智彦1, 小野誠志2, 梅田友子1, 堀井雄之介1, 望月友美1, 新田真緒1, 池島健広1, 浜田信太郎1, 藤田昌雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2021. |
|---|
|
|
P09-06. Construction of the antithrombotic drug cancellation patients search system which we connected to electronic medical chart DB and ODBC 岩尾恭寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2021. |
|---|
|
|
P09-07. A comparison between drug information confirmation software making and number of doubt introductions before and after the introduction and usefulness evaluation 北岡華奈, 室宮智彦, 望月友美, 池島健広, 岡田茉鈴, 橋本奈々, 藤田昌雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2021. |
|---|
|
|
P09-08. Inspection of the system for the purpose of the improvement in rate of use of the HBV screening test to be carried out at chemotherapy 峰山恵理子1, 安森奈緒子1, 大石裕樹2, 川俣洋生1, 花田聖典1, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2021. |
|---|
|
|
P09-09. Development of the medical treatment place choice support tool using the Analytic Hierarchy Processes visualizing the intention in the choice of the medical treatment place of the patients with end-stage cancer family 永井隼多1, 田辺公一1, 村上望2, 杉浦伸3, 酒井隆全1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-733, 2021. |
|---|
|
|
P09-10. About the review of the drug-related system at electronic medical chart replacement in our hospital 倉田徹, 森由香利, 長能優子, 浜屋正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-734, 2021. |
|---|
|
|
P09-11. Efforts about the pharmaceutical products master management standardization 冨岡謙二, 小林愛弓, 松浦奈保子, 原康晃, 長谷川千絵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2021. |
|---|
|
|
P10-01. Fact-finding about formulations support information mention in the interview form 佐藤弘康, 荒井理乃, 久保萌美, 島津智行, 三本松泰孝, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2021. |
|---|
|
|
P10-02. Investigation about the available maximal dose of the nonsteroidal antiinflammatory drug percutaneous absorption type preparation 吉村光弘1, 清家幸土2, 木村圭輔3, 二村直行4, 北谷和之5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2021. |
|---|
|
|
P10-03. Formulary "Primary Insomnia" Construction Procedure - Efforts of Toda Chuo Medical Group - 安藤正純1, 金井紀仁1, 宮本拓也2, 佐藤光3, 吾妻隼人4, 永瀬真理子5, 奈良部修弘6, 澤田雄太7, 中新田朋未8, 下館桃子9, 宮崎美子2, 齋藤俊夫10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2021. |
|---|
|
|
P10-04. Use and application ... of current situation and problem - smartphone application "recommendation navigator" of pharmacist duties by the package insert computerization 鈴木高弘1,2, 横山佳代子1, 國重勝也1, 小林杏里1, 坂田志保1, 四條めぐみ1, 河野奏1, 橋爪敦弘1, 加茂薫1, 深井克彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2021. |
|---|
|
|
P10-05. Evaluation about the usefulness of the pharmaceutical products master input duties automation using Robotic Process Automation 景山修介, 陶山裕平, 石原裕介, 尾崎俊幸, 頼光翔, 安食健一, 園山智宏, 横手克樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2021. |
|---|
|
|
P10-06. Examination about the onset of lymphocytopenia with bendamustine using JADER 坂本竜平, 向井淳治, 小竹優希, 竹原涼子, 濱崎淳哉, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2021. |
|---|
|
|
P10-07. What kind of effect did the outbreak of COVID-19 result in for a reporting, collection of MR activity? 田中秀和1, 若林進2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2021. |
|---|
|
|
P10-08. Attitude survey about the effect on "usability" that the style revision of the package insert gives it to 十佐近歩実1, 渡邉享平1,2, 今野彩1, 櫻川さほり1, 東高士1, 渡瀬友貴1, 北出結伽1, 奥村直也1, 森下真明1, 寺澤優子1, 佐藤友美3, 鈴木大吾4, 矢野良一5, 古俵孝明1, 塚本仁1, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 745-745, 2021. |
|---|
|
|
P10-09. About hypertensive development between the fibrate: Analysis using receipt data 関口佳純1, 鈴木奈緒1, 瀬野遥1, 福島栄2, 栃倉尚広2, 大塚進2, 福岡憲泰1, 大場延浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2021. |
|---|
|
|
P10-10. Evaluation of the Clostridioides difficile-related enterocolitis using the adverse event spontaneous report database 升田万祐子1,2, 中尾智史1,3, 長谷川栞1,4, 島田和代1, 向井梨々香1, 田中瑞希1, 松本清香1, 浦西洋彰1,5, 池末裕明4, 橋田亨4, 井口和弘6, 中村光浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2021. |
|---|
|
|
P10-11. Analysis of the factor influencing onset of interstitial lung disease of the methotrexate using adverse drug reaction database JADER 櫻井周斗1, 大久保伸哉1, 大磯茂1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2021. |
|---|
|
|
P10-12. About the possibility that rebamipide results in protective efficacy for NSAIDs origin-related lower digestive tract injury analysis - using the database of - FAERS and JADER two 間勝之, 今井徹, 鈴木慎一郎, 大塚進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2021. |
|---|
|
|
P10-13. Search of the risk factor of the diarrhea with the drug using adverse drug reaction database (JADER) 小宮実直1, 細谷龍一郎1,2, 宗山真梨奈1, 柴崎功1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2021. |
|---|
|
|
P10-14. Analysis about the delirium risk of the antiulcer agent using adverse drug reaction database (JADER) 橘川奈生, 祖川倫太郎, 角真太郎, 久保利樹, 江口祐子, 江越正芳, 宮本由貴, 飛田修康, 加茂真宏, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2021. |
|---|
|
|
P10-15. Analysis of ward suspicion inquiries, side effect reports, and pre-avoidance case studies with the main purpose of pharmacist education: Focusing on drug-drug interactions 臼井拓也, 佐藤紀宏, 佐藤裕, 前川麻央, 佐藤祐司, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2021. |
|---|
|
|
P10-16. Exploratory study on sex differences of the hiccups using side effect database FEARS 細谷龍一郎1,3, 野澤(石井)玲子2, 黒崎宏太3, 植沢芳広3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2021. |
|---|
|
|
P10-17. Proper use of the antiinfluenza medicine judging from a prescription trend of the Baloxavir 藤原奈緒美1, 藤原崇志2, 伊勢雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2021. |
|---|
|
|
P10-18. Evaluation of the taste of various hyperkalemic therapeutic agents by the sensory evaluation 竹下絵梨香, 田杭直哉, 黒田香織, 佐藤淳子, 徳丸翔大, 菅谷量俊, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2021. |
|---|
|
|
P10-19. Construction of mineralocorticoid receptor antagonist formulary for heart failure 宮本拓也1, 金井紀仁2, 宮崎美子1, 福田稔1, 齋藤俊夫3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2021. |
|---|
|
|
P10-20. Cooperation - with the new style package insert information made study on inflection - electron of the drug information in the electronic prescription notebook 折井孝男1, 田代朋子2, 下村百合子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2021. |
|---|
|
|
P10-21. Evaluation of the DI offer Web site aiming at the efficiency of the drug information (DI) duties of the drugstore pharmacist 村阪敏規1, 加藤秀雄1,3, 須藤宏文2, 岩本卓也1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2021. |
|---|
|
|
P10-22. The effect that "the guidelines about the sale reporting activity on ethical drug" give for a business activity of the wholesaler of drug 崎野健一1, 鈴木三尚1, 山口聡一1, 古澤陽一1, 諏江裕2, 一條宏2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2021. |
|---|
|
|
P11-01. Possibility observational study of the potential inappropriate prescription in the decreased renal function patients in outpatient department, the inpatient 小林正太郎1,2, 須釜規夫1, 永野浩之2,3, 高橋雅弘2, 櫛山暁史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2021. |
|---|
|
|
P11-02. The situation investigation of the one increase one decrease rule to affect the dosage form adoption for new children 春岡美姫1, 山谷明正1, 中村秀文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2021. |
|---|
|
|
P11-03. Examination about the inhalational device choice depending on age in the childhood bronchial asthma 木澤翠, 水野彩, 石原祥子, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 764-764, 2021. |
|---|
|
|
P11-04. It is investigated the antithrombotic therapy in the chronic phase from cerebral infarction acute phase 福島将友, 木原慶子, 小林慶子, 村井悠紀, 福地光栄, 前田朱香, 富田敏章, 入江利行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-765, 2021. |
|---|
|
|
P11-05. Use fact-finding of the sleeping drug in the inpatient 土元研史, 安田礼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2021. |
|---|
|
|
P11-06. Formulation of in-hospital formulary for proton pump inhibitors, promotion of generic drug use at our hospital, and effect of reducing drug costs 大澤史宜, 赤坂寛子, 岡崎彰仁, 山根真也, 岩城晃一, 石坂忠博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2021. |
|---|
|
|
P11-08. Creation of an in-hospital formulary and changes in drug usage at Saiseikai Yokohama Nanbu Hospital 上原美佐, 海野明子, 勝又瑛梨奈, 田辺真里, 平間盛吾, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2021. |
|---|
|
|
P11-09. Investigation about the demand for support by the use of supplement situation and the pharmacist of patients with cancer 西川隆一1, 中島直彦1, 小笠原章記1, 荒木寛也2, 澤柳直樹2, 藤井友和2, 辻博幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2021. |
|---|
|
|
P11-10. Characteristic of patients with Parkinson's disease associated diseases to take a constipation therapeutic drug regularly 安高勇気1,2, 藤岡伸助3, 三嶋崇靖3, 今給黎修1, 坪井義夫3, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2021. |
|---|
|
|
P11-11. The TDM enforcement situation investigation of gentamicin and examination of the renal failure risk factor 唐川聖司, 酒井義朗, 樋口恭子, 三輪涼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2021. |
|---|
|
|
P11-12. Cases in which ARNI was introduced due to the usage status of angiotensin receptor neprilysin inhibitor (ARNI) at our hospital and prior administration of ivabradine 眞野裕1,2, 長井紀章2, 石田茂伸1, 多胡友絵1, 星育子1, 小泉祐一1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-772, 2021. |
|---|
|
|
P11-13. The actual situation and characteristic of the medical therapy for the steroidal osteoporosis prophylaxis 清木静乃1, 鏑木美帆2, 山下修司1,3, 玉木啓文3,4, 野口義紘3,5, 長内理大3,4, 伊野陽子3,4, 井口和弘3,4, 寺町ひとみ2,3,5, 林秀樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2021. |
|---|
|
|
P11-14. Efforts to the serum magnesium measurement promotion for the magnesium oxide tablets prescription patients 山本将司1,2, 小谷智美1, 升味紀子1, 濱岡照隆1, 相良義弘1, 藤本剛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2021. |
|---|
|
|
P11-15. Investigation about the possibility of the drug interaction through prescription situation and CYP of antipsychotics and the concomitant drug 横田真希1, 前川正充1,2, 鈴木直人2, 小林大典2, 鈴鹿雅人2, 佐藤祐司2, 公文代將希2, 佐藤裕2, 佐藤紀宏2, 菊地正史1,2, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2021. |
|---|
|
|
P11-16. Proper use investigation of metformin depending on renal function 松本貴行, 立石裕樹, 古川桂子, 秋吉正貴, 宮津大輔, 田中博和, 平川雅章, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2021. |
|---|
|
|
P11-17. Use of antimicrobial fact-finding as the initial treatment for febrile neutropenia derived from chemotherapy in the Kasugai Municipal Hospital 中川圭司1, 浅野嘉之1, 水草博希1, 鈴木大吾1, 田中伸明1, 中村敏史1, 坂田洋1, 服部芳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2021. |
|---|
|
|
P11-18. The use of blonanserin percutaneous absorption type preparation situation, side effect expression situation investigation 藤田強記1, 中川義浩2, 湊本康則1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2021. |
|---|
|
|
P11-19. Participation in planning of the pharmacist for the delirium high risk patients care addition 遠山泰崇, 福島祐子, 赤星一恵, 平山沙和, 末延裕海, 新宮裕美, 小野友香理, 福田智哉, 柴田麻美, 野村一馬, 後藤友里絵, 村上里穂, 矢野由起, 井上真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2021. |
|---|
|
|
P11-20. Search of the factor to have an influence on the medication adherence of the Kremezin preparation in patients with chronic kidney disease 坪井絵乃1, 柏倉康治1, 茂木麻里奈1, 田中紫茉子1, 内田信也1, 並木徳之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2021. |
|---|
|
|
P11-21. The polypharmacy fact-finding of elderly people with the chronic kidney disease and a drug inappropriate potentially and examination about the stage 町田加純, 稲艸優生子, 間所萌, 遠竹偲乃, 鈴木智美, 土江学, 藤田啓子, 西原昌幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2021. |
|---|
|
|
P11-22. Improvement of the making of the "instillation method" explanation video and the instillation behavior after the video seeing and hearing 池田博昭1,2,4, 谷本知美1, 池田純子2, 中妻章1, 芳地一1, 森久美子1, 飯原なおみ1, 二宮昌樹1, 河野清尊3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 782-782, 2021. |
|---|
|
|
P11-23. About the use situation of the liquid for the status epilepticus therapeutic drug midazolam oral cavity in our hospital 小迫晶寛, 浦更紗, 佐澤卓哉, 上村豪, 山下典子, 植村隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2021. |
|---|
|
|
P11-24. Hit the number of the remedy drugs and the relations with the age group that ketogenic diet therapy results in 矢嶋隆宏, 山本吉章, 福島悠太郎, 古屋裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-784, 2021. |
|---|
|
|
P11-25. Inspection about the duties improvement effect by the outside Parliament prescription doubt inquiry window change 中川和成, 満武亜弥, 渡邉幸子, 大津有加, 松永蓉子, 石井智子, 本多志保里, 山橋昌代, 細川由起子, 沖島さくら, 深見徹郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2021. |
|---|
|
|
P11-26. Attitude survey of a hearing person with a disability and the pharmacist about the effect that a hearing loss gives for communication by understanding and the medication counseling of how to use medicine 俵口奈穂美1, 吉田力久2, 小倉秀美3, 山崎博史3, 田中泰三4, 窪田敏夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2021. |
|---|
|
|
P11-27. It is ... from a viewpoint of investigation analysis - management of the factor to influence quitting a job intention of the hospital pharmacist 土屋博子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2021. |
|---|
|
|
P12-01. Attempt of the medical economical evaluation of the pharmaceutical intervention in the cancer domain 南谷奈々, 疋田絵梨, 城田幹生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2021. |
|---|
|
|
P12-02. About the incidence of glaucoma in the statin user: Analysis using receipt data 川口優里子, 春藤里海, 冨永光咲, 岸英輝, 福岡憲泰, 大場延浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2021. |
|---|
|
|
P12-03. An association between use and hypertensive development of the fibrate: Retrospective cohort study using receipt data 鈴木奈緒1, 瀬野遥1, 関口佳純1, 中山敏光2, 福岡憲泰1, 大場延浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2021. |
|---|
|
|
P12-04. Use fact-finding and adherence about the imatinib 川邊一寛1,2, 大場延浩2, 中山敏光3, 福岡憲泰2, 坂本靖宜1, 後藤洋仁1, 鈴木太一1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 792-792, 2021. |
|---|
|
|
P12-05. Effect of reducing drug costs through PPI formulary creation and pharmacist prescription suggestions 寺口敦1, 関口陽子1, 高村誠1, 山田宜和2, 岩田真子1, 山岸宏和1, 鈴木さくら1, 今成拓1, 矢吹剛1, 小森裕3, 五十嵐詠美1, 南場信人1, 種村瞭1, 仁谷美希1, 中島楓1, 貝瀬眞由美1, 須田剛士4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-793, 2021. |
|---|
|
|
P12-06. Evaluation after introduction of formulary at Tokyo Women's Medical University Hospital 守矢昌弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-794, 2021. |
|---|
|
|
P12-07. Cost effect analysis about the agent-shaped difference of the migraine headache therapeutic drug sumatriptan preparation 菊池朋美1, 柏原正美2, 高畑篤2, 中川直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-795, 2021. |
|---|
|
|
P12-08. Cost effect analysis of the Shoseiryuto to use for allergic rhinitis 佐々木彩花1, 柏原正美2, 高畑篤2, 中川直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2021. |
|---|
|
|
P12-09. Cost-effectiveness analysis of baloxavir marboxil and oseltamivir in influenza virus infection - from a pharmacy perspective - 金澤幸訓1, 中川直人2, 森川昭正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-797, 2021. |
|---|
|
|
P13-01. Examination about the bringing medicine differentiation duties efficiency by the bringing medicine differentiation support equipment introduction 淀川進也1, 橋爪敦弘2, 田口みどり1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2021. |
|---|
|
|
P13-02. Physician for the polypharmacy, attitude survey of the pharmacist 山田充宏, 山田邦夫, 森岡淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-800, 2021. |
|---|
|
|
P13-03. Through after operation day, operation before relation - operation of the pharmacist in the perioperative period - 徳用百合奈, 金原寛子, 加川公恵, 高本美由喜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 801-801, 2021. |
|---|
|
|
P14-01. The thing to see from the fact of the OTC pharmaceutical products online sale in the information-technology age? 泉澤恵1, 古山恵美1, 岸優佑1, 木村直寛1, Guyue Tang2, 小山慎一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2021. |
|---|
|
|
P14-02. Fact-finding about the self-medication taxation system for healthy seminar participants 田口和明1, 榎木裕紀1, 有賀聡美2, 榊原幹夫2, 堀里子1, 山浦克典1, 松元一明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-804, 2021. |
|---|
|
|
P14-03. Effect of basic knowledge and the medicine education about the proper use of the medicine of the primary schoolchild 寺本里那, 末廣真理恵, 室高広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-805, 2021. |
|---|
|
|
P15-01. Preparation properties change of the ketoprofen tape by the opening preservation 宮崎玉樹, 菅野仁美, 臼井明子, 阿部康弘, 安藤大介, 山本栄一, 吉田寛幸, 伊豆津健一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2021. |
|---|
|
|
P15-02. Change of the quality check results by the public testing institution performed in securing of generic medicine quality measures business 阿部康弘, 吉田寛幸, 栗田麻里, 伊豆津健一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2021. |
|---|
|
|
P15-03. Comparison between innovator drug and side effect frequency of the generic drug in the sulfamethoxazole trimethoprim medical mixture 根上朋子1, 吉岡睦展1, 杉生雅和1, 高子優子1, 今戸健人2, 清水義文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2021. |
|---|
|
|
P15-04. Pharmaceutical evaluation of Duotrav combination ophthalmic solution and its successor drugs, and study on visibility considering the usability of the ophthalmic container and the color of the ophthalmic nozzle 秋山滋男1, 土井信幸2, 田沼和紀3, 川上彩乃1, 堀祐輔1, 宮本悦子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2021. |
|---|
|
|
P16-01. Intervention of the pharmacist for changes from a precedent article of the etanercept preparation to Biosimilar 草場さやか, 尾濱直子, 三浦誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2021. |
|---|
|
|
P16-02. Comparison between rituximab innovator drug and infusion reaction of the biofollowing article in patients with B-cell lymphoma 上田哲也1,2, 中島寿久1, 福司弥生1, 橋本浩伸1, 伊豆津宏二2, 山口正和1, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-813, 2021. |
|---|
|
|
P16-03. Efforts to improvement in Biosimilar rate of use by the pharmacist 奥山裕子, 田村健悦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-814, 2021. |
|---|
|
|
P16-04. About the usefulness in the rituximab follower product change in our hospital blood internal medicine and safe examination 山本美智子, 荒瀬弘幸, 大庭理寛, 庭木宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2021. |
|---|
|
|
P16-05. Safety assessment of the CT-P6 initial administration at change from standard drug trastuzumab of 30 minutes: Multicenter observational study 長谷川遥1, 齋藤佳敬2, 玉木慎也3, 高橋健太4, 徳留章5, 高田慎也1, 美濃興三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2021. |
|---|
|
|
P16-06. It is the attitude survey of the patients at change from an insulin analog squirrel pro note to insulin lispro BS note 鎌田敬志, 松田千佳, 荒井真智子, 田中大輔, 清野由利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2021. |
|---|
|
|
P17-01. One case of acute myocardial infarction with suspected hoarseness by the enalapril 長澤欣弘, 近藤和宏, 瀧内瑛輔, 尾形美絵, 中村槙一郎, 羽生智宏, 新関みどり, 田村和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2021. |
|---|
|
|
P17-02. One case that a liver damage was complicated with thrombocytopenia by the minocycline 冨田詩織1, 藤井良平1, 今井雄介1, 西山徳人1, 田中雅幸1,2, 打谷和記1, 村中達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-822, 2021. |
|---|
|
|
P17-03. One case that induced paroxysmal atrial fibrillation by a change of β stimulation inhalant for patients with bronchial asthma 船越晴喜1,2, 百賢二2, 大田進3, 岡崎敬之介1,2, 江波戸貴哉3, 山本成則3, 宇野知輝3, 相良博典3, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2021. |
|---|
|
|
P17-04. A case in which a drug reduction approach by a pharmacist for 34 types of hyperpolypharmacy led to improvements in clinical test values and ADL 山元孝俊1, 小瀬英司1, 渡部多真紀1,2, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2021. |
|---|
|
|
P17-05. One case with suspected pancytopenia by the retention of the methotrexate accompanied with the heart failure exacerbation 甲元大樹1, 花房伸幸1, 新城唯1, 砂場亜希1, 福島由貴1, 石橋友樹1, 黒田和宏2, 福家聡一郎2, 竹内誠3, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2021. |
|---|
|
|
P17-06. Example that caused PT-INR rise and GI bleeding with antimicrobial administration in the diet intake defectiveness patients 竹田享平, 井上晃汰, 簑島弓未子, 牧瀬英知, 橋本光生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2021. |
|---|
|
|
P17-07. One patient whom we collaborated with the chief physician, and a cause of the fever was able to give a diagnosis of drug fever 佐々木有彩1, 原弘士1, 澤村公志1, 高橋素彦2, 山本郁生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-827, 2021. |
|---|
|
|
P17-08. One case that metabolic alkalosis developed by the combination of loop diuretic, thiazide system diuretics, and hypokalemia was prolonged 森田有香, 門口直仁, 濱本真歩, 濱田恵輔, 段松雅弘, 田中聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2021. |
|---|
|
|
P17-09. Renal function change after the use of iodine contrast media in the renin-angiotensin inhibitor remedy patients undergoing percutaneous transluminal coronary angioplasty 山本恭平1, 二宮直紀1, 鵜飼茜1, 新海大智1, 粟田浩文1, 澤田和久1, 久保田敏行2, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2021. |
|---|
|
|
P17-10. One case that reached the enforcement of the temporary pacing by severe sinus bradycardia after two days of the administration of carteolol hydrochloride durability eye drops resumption after the self-interruption 佐古守人, 吉田道治, 大西美香, 美甘早紀, 山本侑弥, 黒沢秀夫, 野村剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-830, 2021. |
|---|
|
|
P17-11. The type of the side effect for the antirheumatic drug remedy patients and the frequency 大崎俊啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2021. |
|---|
|
|
P17-12. About the effect by the years of experience of the current situation and the reporter of the side effect report of pharmaceutical products in the Gifu comprehensive medical care center 小寺聖, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2021. |
|---|
|
|
P17-13. 1 case of the folic acid deficiency anemia with suspected nephrogenic diabetes due to the lithium poisoning 田村和彦, 近藤和宏, 中村槙一郎, 瀧内瑛輔, 長澤欣弘, 尾形美絵, 羽生智宏, 新関みどり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2021. |
|---|
|
|
P17-14. Look at the rear about the blood toxicity with vancomycin; mark investigation 猪股羽矢人1, 前川正充1, 小林智徳1, 石田優理香1, 岩崎瑞生1, 郷内琢也1, 松本侑子1, 小倉次郎2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2021. |
|---|
|
|
P17-15. CYP3A5 and effect of the genetic polymorphism of CYP2C19 to give to blood change of cilostazol in patients with cerebral infarction and a cardiovascular side effect 横山匡1,2, 山内滋3, 山形桂司3, 金城雄太3, 浦野裕美子3, 村田敬二3, 前田利男2, 浅原慶徳1, 賀川義之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2021. |
|---|
|
|
P17-16. One patient whom myositis merger myasthenia gravis developed in after the nivolumab administration as gastric cancer third treatment 小林俊博1, 坪谷綾子1, 小宮詠子1, 松本浩1, 小倉孝氏2, 篠原健介3, 伊藤由香1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2021. |
|---|
|
|
P17-17. Effect of the oral cooling for the accumulation on tongue tissue inducing a sweetness-sensitive drop in PEG ornamentation liposome formulation oxaliplatin dosage rat 茂木啓佑1, 平尾彩香1, 阿部礼奈1, 森戸克弥1, 高山健太郎1, 土井祐輔2, 安藤英紀2, 石田竜弘2, 長澤一樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-837, 2021. |
|---|
|
|
P17-18. A case of malignant syndrome developed due to abrupt discontinuation of drugs at the terminal stage of cancer 殿垣聖子1, 今井裕子1, 細川舞2, 高寺章代1, 相原直彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2021. |
|---|
|
|
P17-19. Examination of the risk factor about the onset of diarrhea by the naldemedine 工藤範子, 島田泉, 新木貴大, 鈴木直人, 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2021. |
|---|
|
|
P17-20. 1 case of treatment with oxaliplatin rectal cancer that it resulted in cardiopulmonary arrest by the hypersensitivity reaction at the second cycle after reintroducing it into 杉原弘記1, 岡田昌浩1, 岡本伸也1, 村上史承1, 岡崎和子1, 江木美峰2, 渡辺陽子2, 田代操1, 竹井英介1, 村田年弘3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2021. |
|---|
|
|
P17-21. 1 case of the coma type acute hepatic failure that it was thought that it was caused by regorafenib 桑田奈穂子1, 石原泰子1, 松本浩明1, 平大地2, 仁科慎一3, 西村健二1, 亀井健人1, 赤木晋介1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2021. |
|---|
|
|
P17-22. A case of drug-induced pneumonia caused by bortezomib administered as previous treatment (bortezomib + pomalidomide + dexamethasone therapy) 荻野健吾, 増渕幸二, 西村栄一, 近藤智幸, 美馬禎俊, 設楽愛美, 橋本光生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2021. |
|---|
|
|
P17-23. 4 cases that resulted in neutropenia by vancomycin in the orthopedics domain 高橋諒多, 小林正拓, 辻本高志, 大谷薫, 大下直宏, 上田晃, 川本由加里, 後藤仁和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 843-843, 2021. |
|---|
|
|
P17-24. One case that drug-related syndrome of inapp ADH secretion was suspected in a pharmacist in patients during antipsychotics remedy and adjusted a drug to 櫻塲絵梨香1, 原弘士1, 澤村公志1, 奈良典子2, 尾久守侑3, 山本郁生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2021. |
|---|
|
|
P17-25. One case that repeated a hallucination, visual hallucination, and suffered from the sleeplessness treatment of patients with Alzheimer's dementia 岩本圭太1, 坂中清香2, 飯征士3, 藤田あゆみ3, 杉浦伸哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2021. |
|---|
|
|
P17-26. One case that presented a blood sugar rise during nontuberculous acid-fast bacterium disease treatment 穴見俊祐, 藤井信大郎, 君羅加奈恵, 開発利江, 奥野護 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2021. |
|---|
|
|
P17-27. One patient who conducted a telephone follow-up aiming at sleepiness, the evasion of the quality of life drop by the drift 水野剛1, 八木澤恭子2, 藤田あゆみ3, 杉浦伸哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2021. |
|---|
|
|
P17-28. It is fact-finding of hepatic dysfunction after the operation for the gastric cancer excision patients 辻将成1, 小林一男2, 名和亜利沙2, 坂本啓3, 青山剛2, 横川貴志2, 舘合慶一2, 渡部秀一2, 清水久範2, 井田智3, 布部創也3, 山口正和2, 濱敏弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2021. |
|---|
|
|
P17-29. One patient whom vein of lower extremity thrombosis developed in for protein S drop by the low dose pill internal use 武田真央1, 山本諭2, 櫻井雄太1, 佐藤裕和1, 中村裕義1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2021. |
|---|
|
|
P17-30. The effect that aspartame included in the preparation gives to the phenylketonuric patients 高田裕奈1, 石川洋一2, 安武夫2, 深水啓朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2021. |
|---|
|
|
P17-31. The effect that sulfamethoxazole - trimethoprim combination drug gives to serum creatinine, sodium and a potassium level 横山智士1,2, 中川潤一2, 相内尚也2, 清藤達矢1, 新岡丈典2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-851, 2021. |
|---|
|
|
P17-32. Case report avoiding the side effect becoming severe of the patients who presented with aciclovir encephalopathy by a pharmacist doubt inquiry 田井達也1, 山口佳津騎1, 新村航1, 松原亜季1, 渡邊政博2, 鈴木聖1, 元木貴大1, 田中裕章1, 芳地一3, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-852, 2021. |
|---|
|
|
P17-33. Examination about the effect on lipid abnormality with the lipid microsphere administration in postgastrectomy patients 名和亜利沙1, 小林一男1, 辻将成2, 坂本啓3, 青山剛1, 横川貴志1, 舘合慶一1, 渡部秀一1, 清水久範1, 井田智3, 布部創也3, 山口正和1, 濱敏弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2021. |
|---|
|
|
P17-34. One case of the right lung abscess with suspected drug-related thrombocytopenia with the meropenem 下山雄一朗1, 安東大智1, 牛嶋量一2, 宗広樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2021. |
|---|
|
|
P17-35. Effect of prochlorperazine on retching, vomiting prevention of tramadol in the orthopedics postoperative pain 石井菜紬子, 槙原克也, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 855-855, 2021. |
|---|
|
|
P17-36. Examination about the use situation and the side effect expression situation of the nintedanib 石田早絵1, 前山隆茂2, 柳原豊史2, 野中敏治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2021. |
|---|
|
|
P17-37. Summary of the specialist in citizen of Osaka consecutive side effect Committee 2019 report 新文1, 坂田勝美2, 清水順子3, 平方まり子5, 松本ミユキ6, 山本京4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2021. |
|---|
|
|
P18-01. Establishment of the podocyte differentiation derivative method of human iPS cells for the glomerulus imitation model construction 岩崎萌実, 坡下真大, 岩尾岳洋, 松永民秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2021. |
|---|
|
|
P18-02. Examination of the sex differences in the oxidative metabolism response of the regorafenib 小島綾華1, 加藤美紀2, 曽我部鮎果2, 灘井雅行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2021. |
|---|
|
|
P18-03. Regular Tolly science study on functional additive varying in a point of action with the tight junction control activity 杉村早耶香1, 橘敬祐2, 近藤昌夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-861, 2021. |
|---|
|
|
P18-04. The current situation and problem of the pharmaceutical regulation that paid its attention to drug metabolism by the gut flora 庄真喜子1,2, 橘敬祐1,2, 原田和生1, 平田收正3, 堤康央1, 國澤純1,2,4,5,6,7, 近藤昌夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2021. |
|---|
|
|
P18-05. Immunohistochemical pharmacokinetic study of the alogliptin in the type 2 diabetes model rat 浦叶恵, 齋田哲也, 進正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2021. |
|---|
|
|
P18-06. Localized analysis study of the Afatinib using the immunohistochemical examination 岡明日輝, 齋田哲也, 進正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2021. |
|---|
|
|
P18-07. Gene expression analysis in the human skin tissue of drug metabolizing enzyme Cytochrome P450 (CYP) participating in transdermal absorbing form preparation 槇原弘子, 赤瀬智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-865, 2021. |
|---|
|
|
P18-08. Study on rat intestinal tract system of cancer molecular target drug Dacomitinib and localization in the skin and accumulation characteristics 松川拓磨, 進正志, 齋田哲也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2021. |
|---|
|
|
P18-09. Develop-ment research of the enzyme immunity method of measurement (ELISA) of tyrosine kinase inhibitor Sunitinib 片岡裕登, 齋田哲也, 進正志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-867, 2021. |
|---|
|
|
P18-10. Examination of circadian fluctuations in plasma xanthine oxidoreductase protein expression 田邉建志1, 田山剛崇1, 前田志津子1, 西村さとみ1, 喜多智生1, 岡本友理香2, 杉原数美1, 三宅勝志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-868, 2021. |
|---|
|
|
P18-11. The establishment of the endodermal differentiation method derived from the human iPS cells under the Feeder-free condition and differentiation instruction to small intestine epithelium cells and hepatocytes 白井晃太郎, 邱施萌, 岩尾岳洋, 松永民秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2021. |
|---|
|
|
P19-01. Examination of the bone fracture risk for patients with refractory epilepsy 福島悠太郎, 山本吉章, 矢嶋隆宏, 古屋裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2021. |
|---|
|
|
P19-02. Search of the factor having an influence on the intraindividual variability of blood voriconazole levels for patients with blood malignant disorder 前田悠, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2021. |
|---|
|
|
P19-03. Population pharmacokinetics analysis of sildenafil in patients with Japanese pulmonary artery-related pulmonary hypertension and bosentan 粟飯原りりか1, 田中紫茉子1, 神谷千明2, 小田切圭一2, 龍口万里子2, 柏倉康治1, 乾直輝2, 並木徳之1,3, 渡邉裕司2, 内田信也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2021. |
|---|
|
|
P19-04. Population pharmacokinetics analysis of the Lacosamide in patients with Japanese adult epilepsy 上地まお1, 小林大介1, 村木翔太2, 豊瀬裕人1, 末次王卓3, 川尻雄大1, 廣田豪3, 江頭伸昭3, 家入一郎3, 島添隆雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2021. |
|---|
|
|
P19-05. One case that an effect was found in IsaPd therapy in RRMM (recurrent intractable multiple myeloma) where DLd therapy became PD 岡崎将也1, 新谷貴洋2, 吉川明良1, 山内健1, 三村奈美子1, 脇本友絵1, 渡辺美和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2021. |
|---|
|
|
P19-06. Population pharmacokinetics analysis of vancomycin in patients who underwent operation on the heart using the heart-lung machine 朝田瑞穂1, 永田将司1,2, 水野友裕3, 荒井裕国3, 高橋弘充1, 安原眞人2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2021. |
|---|
|
|
P19-07. Comparison between bisoprolol oral medicine and effect of the patch in elderly people 犬飼友梨, 木下照常, 山岸千恵, 滝本典夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-877, 2021. |
|---|
|
|
P19-08. Effect examination of the genetically-modified humans in the impaired renal function merger DIC-soluble thrombomodulin 阿部一仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2021. |
|---|
|
|
P20-01. 1 case that PTINR increased by combination of warfarin K and multiple antimicrobial including the ST medical mixture conspicuously 関戸匡恵1,2, 玉造竜郎1,2, 杉田栄樹1,2, 岡田菜津美1,2, 阿部和正1,2, 縄田修一1,2, 楠本壮二郎3, 佐々木忠徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2021. |
|---|
|
|
P20-02. Investigation of the potential drug interactions in the rehabilitation ward 立石裕樹, 宮津大輔, 田中博和, 渡邊裕之, 平川雅章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2021. |
|---|
|
|
P20-03. Drug interactions with azathioprine and allopurinol in the decreased renal function patients: Case accumulation study 平井利典1, 白石ちひろ1, 村田智博2, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2021. |
|---|
|
|
P20-04. We look at methotrexate and the rear about drug interactions between the proton pump inhibitor and are analyzed a mark evaluation and the interaction mechanism 鳴海克哉1, 上田一奈太1, 佐藤優1, 古堅彩子1, 井関健2, 小林正紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-883, 2021. |
|---|
|
|
P20-05. The effect that doxorubicin administration gives to the metabolism activity of the CYP2C substrate drug and the internal change 福野修平, 長井克仁, 谷村岳洋, 山本弘平, 小西廣己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-884, 2021. |
|---|
|
|
P20-06. Physiologic pharmacokinetics model analysis and comparison of the drug interactions prediction by the CR-IR method 小林萌南1, 大久保健二郎1, 加藤基浩1,2, 山岸喜彰1, 工藤敏之1, 伊藤清美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 885-885, 2021. |
|---|
|
|
P20-07. Functional decline of the organic cationic transportation bearer by the sorafenib in human gastrointestinal epithelium Caco-2 cells 松本優花 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-886, 2021. |
|---|
|
|
P20-08. It is one case of children after the hematopoietic stem cell transplantation that accepted a rise in blood level of tacrolimus by voriconazole and a CYP3A4 irreversible inhibitor 高橋勇人, 歌野智之, 高藤由紀子, 山谷明正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2021. |
|---|
|
|
P20-09. A case of lung transplantation in which tacrolimus blood concentration decreased due to combination use of Enoras(R) enteral solution. 青山あづさ1, 小園友明2, 倉橋宏和3, 斉藤佑治2, 竹内正幸2, 大西正文2, 脇田康志1,4, 奥村彰久3, 築山郁人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-888, 2021. |
|---|
|
|
P20-10. The effect that Enzalutamide gives to a depression effect of the calcium-channel blocker 守田和憲, 市川洋一, 山下愛子, 北岡朋子, 田上治美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2021. |
|---|
|
|
P20-11. Effect of the concomitant drug giving it to the effectiveness of the nivolumab in patients with stomach cancer 畠山智明1, 高崎修一2, 梅原健吾3, 佐藤友昭4, 鈴木直哉5, 宇野健一6, 井上靖隆7, 渡邉大毅8, 畠中仁大9, 伊佐治麻里子10, 太田明秀11, 元茂拓法12, 徳留章13, 藤井達郎14, 神垣輝美15 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-890, 2021. |
|---|
|
|
P20-12. One case of patients with central nerve origin malignant lymphoma which produced a methotrexate excretion delay 浦田修平1, 吉川直樹1, 齋藤清貴2, 田崎智也1, 大野梨絵1, 竹島秀雄2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-891, 2021. |
|---|
|
|
P20-13. Efforts of the AST person in charge of use of rifampicin case pharmacist for the medical treatment adequacy 森田眞由, 村田龍宣, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2021. |
|---|
|
|
P20-14. Effect (the second report) of the methylprednisolone giving it to the blood clotting ability of the warfarin remedy patients 大西由莉1, 土岐浩介1,2, 安部沙織2, 臼井丈一2, 齋藤知栄2, 辻浩史2, 森島祐子2, 山崎浩2, 松本功2, 家田真樹2, 玉岡晃2, 檜澤伸之2, 山縣邦弘2, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2021. |
|---|
|
|
P21-01. Levetiracetam blood concentration changes and administration design during pregnancy and after childbirth 平松亜依1,2, 高塚博一1, 山崎伸吾1, 鈴木貴明1, 山口正和2, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2021. |
|---|
|
|
P21-02. Examination of the VCM adsorption rate due to the AN69ST membrane 入江知美1,2,3, 山科卓也1, 山崎貴史1, 古海和博1, 鶴山萌子2, 平木洋一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2021. |
|---|
|
|
P21-03. Blood level survey of the TDM recommendation medicine in the outpatient 村瀬正, 畑本慶太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2021. |
|---|
|
|
P21-04. It is effect on initial blood level after the loading by the Teicoplanin late departure preparation brand change 松永典子1, 山口直夏2, 太田千代枝1, 森塚暁裕1, 塩尻恭平1, 里加代子1, 兒玉幸修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2021. |
|---|
|
|
P21-05. Attempt of the early period of vancomycin doses weight loss in a piperacillin tazobactam combination drug and the vancomycin combination patients 渡邊瑛理, 古庄弘和, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2021. |
|---|
|
|
P21-06. The effect that Everolimus in the therapeutic range area gives to cells derived from kidney 白橋佳樹, 平田憲史郎, 門脇大介, 石黒貴子, 宮村重幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2021. |
|---|
|
|
P21-07. Search of the thiamylal therapeutic range area in children 杉田有輝1, 石本まり1, 平田憲史郎1, 小原隆史2, 陣上祥子3, 渡邊博志4, 丸山徹4, 平井克樹5, 石黒貴子1, 宮村重幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-903, 2021. |
|---|
|
|
P21-08. Establishment of the simple and easy simultaneous assay of hydromorphone out of the human plasma and the glucuronic acid conjugated compound 鈴木利昌1,2, 内藤隆文1, 柴田海斗1,2, 北嶋諒2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2021. |
|---|
|
|
P21-09. It is ... based on relationship - part specific PK-PD analysis with blood level and the intestinal tract fat concentration of the cefmetazole in the lower digestive tract surgery 小松敏彰1, 森田妃南子2, 高山陽子3, 夏目祐衣4, 友田吉則2, 中村隆俊5, 花木秀明6, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2021. |
|---|
|
|
P21-10. Precautions for TDM in pediatric patients receiving tacrolimus and voriconazole concomitantly - Lessons learned from cases - 楠川侑吾, 田村優衣, 村田龍宣, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2021. |
|---|
|
|
P21-11. The current situation of the blood vancomycin levels precision management in subnutrition, the decreased renal function patients 川上智也, 広田瑞季, 飯田有貴, 伊藤玲奈, 宮川春香, 引地華子, 辻桃子, 福田光司, 圓崎信也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-907, 2021. |
|---|
|
|
P21-12. Construction of the simple and easy method for measurement of the highly-concentrated cefmetazole using the HPLC for PK/PD evaluation in patients with impaired renal function 並木孝哉1,2, 横山雄太1,3, 枦秀樹2, 地引綾3, 河添仁1,3, 鈴木小夜1,3, 中村智徳1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-908, 2021. |
|---|
|
|
P21-13. Establishment of the plasma concentration assay of chronic thrombo embolic pulmonary hypertension therapeutic drug riociguat 砂川由香理1, 田中紫茉子1, 若松しのぶ1, 龍口万里子2, 柏倉康治1, 秋田敬太郎3, 前川裕一郎3, 並木徳之1,4, 渡邉裕司2, 乾直輝2, 内田信也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2021. |
|---|
|
|
P21-14. Development of the assay using the LC-MS/MS of human serum ramucirumab 坂口健太1, 柴田海斗1, 内藤隆文1, 菊池寛利2, 前川真人3, 竹内裕也2, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2021. |
|---|
|
|
P21-15. Examination of a loading dose and a therapeutic range achievement quotient of the Teicoplanin and the effectiveness 鈴川誠, 佐々英也, 内山耕作, 平尾祐樹, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2021. |
|---|
|
|
P21-16. Establishment of a method for quantifying belimumab in human plasma using UHPLC-MS/MS 吉島千智1, 鈴木陽介1, 田中遼大2, 小野寛之2, 小田絢子1, 尾崎貴士3, 柴田洋孝3, 伊東弘樹2, 大野恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2021. |
|---|
|
|
P21-17. 1 case that it was speculated that antimicrobial-related loose bowels by tazobactam/piperacillin inhibited enterohepatic circulation of mycophenolic acid 田中遼大, 鈴木芳, 松本麻美, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2021. |
|---|
|
|
P21-18. Consideration of the pharmacogenetics of a plasma drug concentration and the drug metabolizing enzyme genetic polymorphism in the metronidazole encephalopathy 上森将吾1, 羽山希2, 山田悠人1,3, 鈴木景子3, 丹羽隆3, 山路文範4, 吉田省造5, 林祐一6, 下畑享良6, 小倉真治5, 鈴木昭夫1,3, 林秀樹1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2021. |
|---|
|
|
P21-19. One case of cancer of maxillary antrum which gave Carboplatin combination chemotherapy under the haemodialysis, and measured the free form platinum concentration 中尾祐貴, 森本隼多, 加藤絢, 樋川珠代, 武居宏樹, 鮎原秀明, 竹内裕紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2021. |
|---|
|
|
P21-20. The case that racked its brains about blood level management using vancomycin for ventilator-associated pneumonia complicated with a new coronavirus infection 喜多岡洋樹1, 中村真希1, 楠本将裕1, 早坂香織1, 吉田愛1, 田中泉1, 田中由起子1, 山室蕗子1, 岩越一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2021. |
|---|
|
|
P21-21. Safe examination with the vancomycin initial loading dose 松本勝城, 奥村梨央, 青木旦未, 鹿島弥生, 小林奈緒, 海野明子, 長澤彩華, 深沢貴志, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2021. |
|---|
|
|
P21-22. Examination of the optimal population average parameter in the VCM initial design for patients with neurologic intractable disease 山科卓也1, 山崎貴史1, 小坂隆介2, 古海和博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2021. |
|---|
|
|
P21-23. Predictive precision evaluation of the Teicoplanin blood level by two kinds of parameters for patients with neurologic intractable disease 山崎貴史1, 山科卓也1, 小坂隆介2, 古海和博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2021. |
|---|
|
|
P21-24. Examination about the usefulness of the therapeutic drug monitoring of voriconazole in the ambulatory practice 横尾卓也1, 花井雄貴1,2, 松尾和廣2, 植草秀介2, 大谷真理子1, 下山航平1, 鈴木美香奈1, 草野歩1, 坂本真紀1, 西澤健司1, 松本高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2021. |
|---|
|
|
P21-25. Examination of the Teicoplanin administration plan for the sustained hemofiltration dialysis enforcement case to achieve 20 μg/mL of initial trough values or more 植田貴史1, 竹末芳生2,3, 中嶋一彦1,3, 一木薫1, 石川かおり1, 山田久美子1, 土田敏恵1, 高橋佳子4, 石原美佳4, 木村健4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-921, 2021. |
|---|
|
|
P21-26. Can the vancomycin-induced renal failure at tazobactam piperacillin combination be avoided by the TDM which assumed area under the curve an index at blood level time? 岡田直人1,2, 中本亜樹1, 泉侑希1, 中馬真幸3, 合田光寛4, 八木健太4, 相澤風花1, 濱野裕章5, 座間味義人1,5, 東桃代2, 石澤啓介1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2021. |
|---|
|
|
P21-27. Comparison between vancomycin and usefulness of the Teicoplanin in the infectible easily state after the hematopoietic stem cell transplantation 大塚恵子1, 中島寿久1, 大塚亮1, 石川光信1, 赤木徹1, 橋本浩伸1, 福田隆浩2, 山口正和1, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2021. |
|---|
|
|
P21-28. Initial administration plan-style construction of vancomycin in consideration of growth and the comorbidities of children and anticipatory evaluation 小野達昌1, 富島喜朗1, 猿渡淳二2, 陣上祥子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2021. |
|---|
|
|
P21-29. Existing prediction-style comparison of blood vancomycin levels in neonates 大橋隼人1, 花井雄貴1,2, 横尾卓也1, 大谷真理子1, 松尾和廣2, 草野歩1, 坂本真紀1, 松本高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-925, 2021. |
|---|
|
|
P21-30. The expansion of the vancomycin TDM duties that took advantage of medical service fees revision in 2020 and the effect 村田翔, 木村美咲, 川崎亮輔, 相原敏彦, 増尾昌則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-926, 2021. |
|---|
|
|
P21-31. Examination about shortening of the medical treatment intervention time to MRSA bacteremia by the MALDI-TOF MS introduction 福井温子, 奥平正美, 澤田和久, 杉浦洋二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-927, 2021. |
|---|
|
|
P21-32. Development of the levofloxacin levels assay by the ELISA method using the peroxidase label monoclonal antibody 園田恵理1, 大久保伸哉1, 大磯茂1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-928, 2021. |
|---|
|
|
P21-33. Examination of the validity of the round up method to serum creatinine level 0.6 mg/dL for the purpose of the correction of the renal function overestimate for the quantity of muscle drop patients 内海紗良1, 前田圭介2, 久保田丈太3, 中谷咲良1, 原田義彦1, 成田勇樹1,4, 猿渡淳二1, 近藤悠希1, 石塚洋一1, 入江徹美1, 門脇大介5, 平田純生1,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 929-929, 2021. |
|---|
|
|
P21-34. The case that was given administration plan support of the law for the cyclosporine micro emulsion preparation (CyA-MEPC) once a day time before a meal for psoriasis vulgaris 小林宇太郎1, 一ノ瀬由衣1, 清原龍士2, 小山田純治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2021. |
|---|
|
|
P22-01. About the examination for NUDT15 genetic polymorphism situation in patients with inflammatory bowel disease of our hospital 屋敷大輔, 中村杏果, 森永崇史, 池沢若菜, 田中恭人, 豊留麻衣, 北園幸大, 中野一馬, 山本梢, 淵脇ゆかり, 徳丸章佳, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2021. |
|---|
|
|
P22-02. Based on the 2019 version for the fact-finding - colon cancer treatment guidelines on medical therapy physician for unresectable progress recurrence colon cancer - 竹野孝慶 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2021. |
|---|
|
|
P23-01. Efforts to regimen inspection system introduction in the cancer medical therapy 藤井元, 神山知也, 米田航佑, 永井道雄, 上田武司, 鶴田洋平, 石坂忠博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2021. |
|---|
|
|
P23-02. Economic effect by the use adequacy of the closed system anesthesia connection appliance using the existing regimen management system 齊藤安昌, 城綾香, 浅川杏子, 清水忠弘, 島田雅彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2021. |
|---|
|
|
P23-03. Importance of the regimen joint ownership in the foreign cancer chemotherapy 大矢幸恵, 岸川紗江子, 小島友絵, 日野洋子, 山田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2021. |
|---|
|
|
P23-04. Inspection of the onset of low Na blood symptom inhibitory effect by the infusion change of the CDDP regimen in head and neck cancer 石原歩実, 木下照常, 鳥居昌太, 江崎秀樹, 榊原隆志, 滝本典夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2021. |
|---|
|
|
P23-05. Evaluation of usefulness in standardizing isatuximab administration method 湯山聡1,2, 伊勢崎竜也1, 舟越亮寛1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2021. |
|---|
|
|
P23-06. Regimen operation and the evaluation that incorporated protein urine qualitative analysis and the examination of the protein urine/creatinine ratio order in the regimen including the neovascularisation inhibitor 前畠一友, 財間富士子, 築地辰典, 中山恵美, 岡崎直樹, 六田湧紀, 鈴木秀平, 最勝寺貴広, 高橋真理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2021. |
|---|
|
|
P23-07. Examination of safety and the effectiveness in the administration day change of the dexamethasone as eruption measures by the pemetrexed 田川優介1, 多胡友絵1, 星育子1, 小泉祐一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2021. |
|---|
|
|
P24-01. One case of patients with unresectable progress gastric cancer which is treated with other types of job intervention in the chemo conference appropriately and shifts, and is ready to carry out ambulant treatment continuation 中村美樹1, 大上寛子1, 尾藤展克2, 内山清3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-944, 2021. |
|---|
|
|
P24-02. Fact-finding of the operational situation of the tracing report in the cancer medical therapy 文英賢1, 吉田徹也2, 山崎直樹1,2, 木村仁美1, 田坂美咲1, 細川忠士1, 中尾將彦1, 森宏幸1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2021. |
|---|
|
|
P24-03. Usefulness of the side effect situation investigation of the Lenvatinib in hepatocytes cancer and the pharmacist intervention 小武和正1,2, 大月ちひろ1,2, 清水久美子1,2, 池田房雄3, 藤岡真一3, 川上恭弘1,2, 大澤俊哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-946, 2021. |
|---|
|
|
P24-04. Occupational exposure screening sheet making for home health care practitioners corresponding to foreign cancer chemotherapy patients 齊藤直裕1, 松本佳子1, 高橋淳一2, 林光世2, 堀信弥3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-947, 2021. |
|---|
|
|
P24-05. Pharmacist duties (the second report) in the treatment with immune checkpoint inhibitor support team 玉井宏一1, 中野友寛1, 西畑友尋1, 渡部早苗1, 奥津武志1, 田房恭子2, 山下広恵2, 武田千津2, 井上考司3, 中西徳彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 948-948, 2021. |
|---|
|
|
P24-06. The current situation investigation of the tracing report of the patients whom cancer medical therapy is given in in outpatient department 河野史子1, 中島亘2, 高田尚子3, 宇都宮あゆみ4, 倉田真子5, 宮原志帆6, 奥村春咲7, 服部亮太8, 重村淳9, 皆谷和弘10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2021. |
|---|
|
|
P24-07. The intervention of the drugstore pharmacist in the consultation interval between the foreign cancer chemotherapy and effect of the medical cooperation 井上祥平1, 渡邉尚也2, 片山珠季3, 永野悠馬4, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 金剛圭佑5, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 950-950, 2021. |
|---|
|
|
P24-08. One patient who conducted anticancer agent telephone follow using a check sheet in the health insurance pharmacy 伊野陽子1,4, 小俣江利果1, 山下修司2,4, 玉木啓文1,4, 野口義紘3,4, 長内理大1,4, 井口和弘1,4, 寺町ひとみ3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2021. |
|---|
|
|
P24-09. It is efforts ... to calculating it the ... cooperation full addition to prescription notebook by an evaluation of the pharmacist outpatient department 合津貴志, 渡部照美, 佐藤真琴, 関根悠, 渡邉紘章, 久保田真生, 田崎政則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2021. |
|---|
|
|
P24-10. Relation with elderly patients with cancer and the local drugstore 佐藤里穂子1, 疇地拓郎1, 河村香奈子1, 篠崎泉1, 長富範子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2021. |
|---|
|
|
P24-11. Two cases that were connected for improvement in quality of the foreign cancer chemotherapy by the hospital utilizing a treatment notebook and the tracing report and the cooperation with the health insurance pharmacy 堀川美帆, 齋藤究, 雨山智, 高橋阿希子, 菊地正史, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2021. |
|---|
|
|
P24-12. Efforts ... for the making of the cancer treatment protocol and medicine medicine cooperation and the side effect early detection through telephone follow-up - tracing report 加藤誠一1, 田中直哉2, 近藤澄子1, 寺戸靖1, 篠原祐樹1, 矢島毅彦3, 田中秀和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-955, 2021. |
|---|
|
|
P24-13. Efforts for a nurse and the cooperation full addition calculation in the foreign chemotherapy room to be carried out by collaboration 今西義紀1, 桐生浩子1, 池口麻由子1, 寺本朋代2, 中山賀奈子1, 西川嘉広1, 大森加奈子1, 小出哲朗1, 中山真由美2, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-956, 2021. |
|---|
|
|
P24-14. The approach that we conduct while illness examining foreign cancer chemotherapy, and conducting medicine cooperation 齊藤達也, 秋篠夏美, 谷口知明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-957, 2021. |
|---|
|
|
P24-15. Efforts to the cooperation full addition by the regimen seal automatic output system utilization for the prescription notebook 目黒裕史, 佐分利美帆子, 三松史野, 大野恵一, 本多伸二, 小野勝, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-958, 2021. |
|---|
|
|
P24-16. It is treatment continuation and the example that it was by illness medicine cooperation on the basis of patients background for medical therapy patients after the breast cancer technique 佐々木操 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2021. |
|---|
|
|
P24-17. Comparison of a foreign cancer chemotherapy reporting book of our hospital and the information that a health insurance pharmacy asks for 北島比香里, 片山聡子, 田中真衣, 橋本沙耶, 池崎友明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2021. |
|---|
|
|
P24-18. Stand on an advantage and the future problem - 1 case of the cancer medicine medicine cooperation drugstore which was obtained by holding a meeting at a hospital and a few drugstores; and ... 細川清史, 河野智子, 長嶌千紘, 伊勢冴江子, 倉富昌子, 古川亜由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2021. |
|---|
|
|
P24-19. Support of the pharmacist for patients balancing working with foreign chemotherapy 篠原義剛1, 横山雄一1, 植木哲也1, 立石清一郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2021. |
|---|
|
|
P24-20. 1 case of the urothelial carcinoma that vitiligo vulgaris develops by Pembrolizumab, and a long-term treatment effect is obtained 杉山弘樹1, 増田容子2, 横山知明2, 臼井幸男3, 原田晴司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2021. |
|---|
|
|
P24-21. One case of medicine medicine cooperation and the area pharmacy care supporting terminal cancer patient discharge refusing a condition notice during the No Visitors ward hospitalization of the corona evil 工藤信孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2021. |
|---|
|
|
P24-22. Example that patients with treated cancer hoped for a discharge, and the at-home staff cooperated with a hospital, and was able to continue early discharge and home care 中村薫, 川崎博行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2021. |
|---|
|
|
P24-23. Attitude survey of patients with cancer affecting the specialized pharmacist placement of the health insurance pharmacy 大東真理子, 竹林由香, 藤田大樹, 湯山ゆきの, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2021. |
|---|
|
|
P24-24. One case that received end-of-life care care by the multi-type of job cooperation to patients with at-home terminal cancer of non-notice 松本真緒, 西倉加余, 沼田美奈, 山田千沙江 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 967-967, 2021. |
|---|
|
|
P24-25. Efforts of the correspondence improvement at temporary consultation of the use of immune checkpoint inhibitor patients using the PDCA cycle 日比聡1, 城川優子2, 南谷健吾3, 加藤裕子4, 伊藤紳人1, 吉田嵩5, 丸茂義晃5, 片岡孝江5, 湯浅周1, 粥川哲5, 伊奈研次6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2021. |
|---|
|
|
P24-26. Effect by the relation of the multi-type of job to hepatitis B screening 稲垣貴彦1, 安藤洋介1, 豊里星来1, 太田秀基1, 岡本昌隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 969-969, 2021. |
|---|
|
|
P25-01. Evaluation about the usefulness of the reservation preparation function with the anticancer agent automatic preparation robot 外海友規1, 近藤勝弘1, 後藤佳奈1, 竹本将士1, 江崎哲夫1, 木村和哲1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2021. |
|---|
|
|
P25-02. Patients satisfaction investigation of the portable disposable infusion pump to use for colon cancer chemotherapy 山田卓1,2,3, 菊池武友1, 松本浩一1, 堤一貴1, 樋口恭子1, 橋本香代子2, 三輪啓介3, 三輪涼子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2021. |
|---|
|
|
P25-03. Anticancer agent pollution status of anticancer agent preparation front chamber ceiling air conditioning of the Aichi cancer center and the worker 前田章光1, 山内拓也1, 長谷川彩子2, 加藤智子2, 富安直弥2, 加藤正孝1, 稲熊一英2, 松崎雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2021. |
|---|
|
|
P25-04. Attitude survey about the personal protector wearing at anticancer herbalist handling in Saga 古野龍也, 木村早希子, 竹内耕治, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2021. |
|---|
|
|
P25-05. Stability after the medicinal solution preparation in the cytarabine + methotrexate + steroid intraspinal injection therapy 畠中仁大1, 下山哲哉2, 岩崎弘晃1, 佐藤梨奈1, 遠藤貴之1, 伊藤邦彦2, 小林道也2, 泉克明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2021. |
|---|
|
|
P25-06. About an evaluation of the anticancer medicine preparation duties time for the purpose of the closed system anesthesia connection appliance full-scale introduction 明石和也, 増尾直亮, 曾我部直美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2021. |
|---|
|
|
P25-07. Effect in the change on "chemosafe lock" from closed system anesthesia drug transportation system "chemosafe" 上原友美, 末永尚輝, 八汐祥恵, 堀内智裕, 鶴永大貴, 中村有莉恵, 赤星真広, 池増鮎美, 佐多照正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2021. |
|---|
|
|
P25-08. Questionary survey about the operability comparison before and after the changes from chemosafe to a chemosafe lock 鈴木健太1, 原幸稔1, 松本大吾1, 三ツ橋千尋1, 下田純子2, 永野奈美子2, 三宮忠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2021. |
|---|
|
|
P25-09. Examination of the removal means for the living environment pollution of patients who received foreign chemotherapy 宮澤憲治1,2, 茅野尚希2, 嵐達哉2, 八木下愛華2, 秋山哲平1, 岡田守弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2021. |
|---|
|
|
P25-10. CSTD damage with the parenteral injection containing the oil-related solvent 治田匡平, 青井博志, 木村錦子, 岡田和也, 三上知佳, 村田政軌, 松田早代, 佐道花菜, 吉川一吾, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2021. |
|---|
|
|
P25-11. Change unsociable drug transportation system (CSTD) 菅野和彦1, 熊谷史由1, 高松謙1, 袰岩靖子1, 片谷憲子2, 濱中直美2, 大友眞菜1, 菊地未由1, 駒林幸太郎1, 中川こはる1, 小笠原綾子1, 横山咲稀1, 伊藤亮太1, 星野祐太1, 渡邊卓嗣1, 中嶋丈晴1, 穂積史朗1, 宮城宣明3, 大月沢雄1, 石本昌裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2021. |
|---|
|
|
P25-12. Comparison of the appropriate glove wearing method at anticancer agent preparation 南島拓矢, 宮崎雅之, 藤野泰孝, 片岡智美, 倉地茜, 前田愛, 松本千代, 松永安未, 濱田雄平, 奥村啓樹, 小栗佐織, 細見周平, 西山貴章, 南川友香, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2021. |
|---|
|
|
P25-13. Economic effect by the full-scale use of the closed system anesthesia appliance at anticancer agent preparation and safe improvement 藤原未都菜1, 逸見結衣1, 伊勢原祐子1, 村田和歌子2, 井上智恵1, 日生下美紀1, 石田達彦3, 西窪奈津子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2021. |
|---|
|
|
P25-14. Study on resolution, inactivating effect of the anticancer agent with the ozone water 加藤銀次郎1, 見留英路2, 重松沙季2, 宇都宮礼2, 島崎美穂2, 佐々木祐太3, 槇恒雄4, 山本宏5, 田邊知孝2, 舟橋達也2, 波多江典之6, 飛鷹範明7, 田中守7, 明樂一己2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2021. |
|---|
|
|
P25-15. Completely integrated infusion set: Exposure countermeasures and evaluation by introducing Antileak 川田亮, 春原龍矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-985, 2021. |
|---|
|
|
P25-16. Liquid leakage test of cyclophosphamide at the bottle needle stick/puncture 矢野琢也, 星加寿子, 松本知樹, 松本大輝, 加藤あゆみ, 福岡竜逸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2021. |
|---|
|
|
P26-01. 1 case that was given Dabrafenib + Trametinib combination therapy by BRAF mutation in the gene-positive lung cancer 竹尾恵理子1, 後藤健志1, 伊藤功治1, 岩本公一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2021. |
|---|
|
|
P26-02. Look at the rear about the intensity of treatment of the Osimertinib in our hospital; mark investigation 冨士野ひより1, 嘉屋道裕2, 中村和代1, 中垣繁1, 南智1, 平野桂子1, 鈴木貴也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2021. |
|---|
|
|
P26-03. The case that became available for the pharmaceutical intervention for patients with cancer starting from Residual medicine confirmation 鶴海宏之1, 中村佳代2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2021. |
|---|
|
|
P26-04. Examination of the duties efficiency with the tracing paper chase system about the cancer chemotherapy 西宮祐輔1, 松原慎2, 山路和彦3, 梅原このみ4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2021. |
|---|
|
|
P26-05. Questionary survey for drugstore pharmacists about the application of anticancer agent regimen situation which a medical institution releases 関谷秀, 世取山哲史, 小林義幸, 田所真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2021. |
|---|
|
|
P26-06. Example that was able to contribute to treatment by cooperation and the medication follow-up with relation ... caregiver of "the family pharmacist" to patients who received cancer chemotherapy 西川育子1, 与那嶺梨香1, 武部若菜1, 早川太朗2, 高井佳江1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2021. |
|---|
|
|
P26-07. Intervention example by the follow-up of the authorities in the rectal cancer postoperative chemotherapy 山田裕介1, 吉田貴大1, 笹野寿基2, 安川徹2, 竹原美穂2, 辻真利3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2021. |
|---|
|
|
P26-08. 1 case that was able to contribute to qualitative improvement of the pharmaceutical management by conducting illness medicine cooperation at patients with cancer hospitalization and release 松本佳子, 齊藤直裕, 北谷豪朗, 川崎友里江 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2021. |
|---|
|
|
P26-09. Evaluation of the telephone follow-up using the oral anticancer agent side effect check seat 福島岳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2021. |
|---|
|
|
P26-10. The current situation investigation for the information sharing method of the side effect in the cooperation full addition and the measures 中村緑, 光家勉, 木津茂, 上田豊実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2021. |
|---|
|
|
P26-11. 1 case of the breast cancer that adherence improved by a follow-up 島田淳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2021. |
|---|
|
|
P26-12. 1 case that prevented the aggravation of the adverse event by the follow-up for adjuvant chemotherapy (DC therapy) patients with endometrial cancer conducting after the foreign cancer technique 中尾紘子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2021. |
|---|
|
|
P26-13. One case that olanzapine was used in for tardive retching during ddEC therapy 渡部誠士1, 末次加代子2, 藤田あゆみ3, 杉浦伸哉3, 杉浦克典3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2021. |
|---|
|
|
P26-14. The combination of oral anticancer agent and gastric acid antagonist actual situation that intragastric pH influences absorption properties 政本康成1, 田村渓2, 蓮井雄3, 綿引定成4, 中村京香5, 児矢野なつ美6, 山口弘7, 常世田京子8, 永野悠馬9, 前田守9, 長谷川佳孝9, 月岡良太9, 森澤あずさ9, 大石美也9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2021. |
|---|
|
|
P26-15. The combination of aromatase inhibitor and selective estrogen receptor modifier situation 中島直幸1, 青木香奈2, 森山京英3, 片山珠季4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2021. |
|---|
|
|
P26-16. Treatment of skin disorders caused by apalutamide tablets and experience of new adverse events 野田佳子1, 金城裕美子1, 井上千絵美1, 濱田美輝1, 野田哲史2, 須藤正朝2, 蓑輪圭一郎1, 臼井孝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2021. |
|---|
|
|
P26-17. Change of the tracing report of the drugstore pharmacist with "a reporting book about the foreign chemotherapy" whom a hospital issues 佐々木賢輔, 山口陽子, 芳沢寛邦, 今井拓弥, 小田島匡, 筒井志帆, 大坂菜摘, 小谷迅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2021. |
|---|
|
|
P26-18. One case that caused hearing loss, ear drum perforation by Axitinib administration 仲野真悟1, 富田雅之2, 岸田充生3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2021. |
|---|
|
|
P26-19. The case that suggested folic acid prophylaxis after the pemetrexed discontinuation in patients with thymoma using Saga practice information regional alliances system atomic bomb atomic bomb link 竹原美穂1, 辻真利2, 山田裕介3, 笹野寿基1, 吉田貴大3, 安川徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2021. |
|---|
|
|
P26-20. One case that tried intervention for the numbness of hands and feet aggravated by FOLFIRI+Bev therapy 菅原大典1, 末次加代子2, 藤田あゆみ3, 田名邊清3, 杉浦伸哉3, 杉浦克典3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2021. |
|---|
|
|
P26-21. The side effect expression of Abemaciclib situation reported through a tracing report 篠崎千尋1, 桑村恒夫1, 柿原圭佑2, 三上忠司1, 野田聖奈子1, 原田智子1, 中川義浩1, 松尾琴美3, 梅崎りさ4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2021. |
|---|
|
|
P26-22. Example that an online follow-up utilizing the electronic prescription notebook (prescription notebook plus) in the treatment with anticancer agent was effective 山田真弘, 米山大輔, 小林加奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2021. |
|---|
|
|
P26-23. One case of the capecitabine-induced high neutral hyperlipemia that led to chemotherapy continuation by pharmaceutical intervention 池口麻由子1, 桐生浩子1, 松田千裕1, 田中裕子1, 水谷日花里1, 窪田知仁1, 大矢知立城1, 西川嘉広1, 大森加奈子1, 橋本陽1, 今西義紀1, 小出哲朗1, 森脇健太郎1,3, 山本あゆみ2, 伊藤久美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2021. |
|---|
|
|
P26-24. An investigation of the effect that a regimen label grant gives to an insurance pharmacist and guess of the behavior modification 浜口将一1, 木村大地2, 清水克次3, 角川幸男3, 高木麻里3, 藤田敬子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2021. |
|---|
|
|
P26-25. The effect that presence or absence of hospital duty experience gives to the viewpoint of the drugstore pharmacist on foreign cancer chemotherapy prescription 大熊祐美1, 金井良記2, 森山京英3, 石黒貴子4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2021. |
|---|
|
|
P26-26. Utilization to visualization and medication counseling by text mining and the network analysis of the word associated with the main complaint about hand-and-foot syndrome at use of anticancer agent 松浦晶子1, 山崎雅恵2, 黒金崇3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1015, 2021. |
|---|
|
|
P26-27. The combination situation of paroxetine in the tamoxifen remedy patients 渡邉尚也1, 中島直幸2, 澤邉陽美3, 山本健士郎4, 森本真貴5, 四百刈敦子6, 片山珠季7, 永野悠馬8, 前田守8, 長谷川佳孝8, 月岡良太8, 森澤あずさ8, 大石美也8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1016, 2021. |
|---|
|
|
P26-28. About the current situation and a problem of the calculation situation of the cancer instruction to patient management charges her cooperation full addition in our hospital 松尾昌治, 溝上和寿, 月原由華, 大野晃子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2021. |
|---|
|
|
P26-29. A viewpoint and problem of the drugstore pharmacist for the prescription of the foreign cancer chemotherapy 森山京英1, 金井良記2, 大熊祐美3, 石黒貴子4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1018-1018, 2021. |
|---|
|
|
P26-30. ... to think about from patients with inflection method - Palbociclib prescription of the side effect grade for the oral anticancer agent remedy patients 玉田麻利子1, 阿部真也2, 松井洸2, 山口浩2, 今野章之1, 吉町昌子2, 野村和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2021. |
|---|
|
|
P26-31. Usefulness of the telephone follow-up for patients with initial foreign cancer chemotherapy enforcement 上原弥未, 武由梨, 柳原桃子, 田中真紀子, 宮原奈央子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1020, 2021. |
|---|
|
|
P26-32. Obinutuzumab, investigation about the side effect of rituximab administration expression situation 宮崎公輔, 安江諒平, 伊藤健史, 眞野翔太, 田中佳子, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1021, 2021. |
|---|
|
|
P26-33. Making and use experience (case report) of the side effect evaluation tool of the kinase inhibitor 城守隆宏, 小野寺奈緒子, 石田千尋, 小竹未絵, 吉田綾那, 木村将綺 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1022, 2021. |
|---|
|
|
P26-34. The current situation and problem of the specific drug management instruction addition 2 calculation utilizing the regimen at the drugstore 小原将太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2021. |
|---|
|
|
P26-35. Efforts (case report) of the telephone follow-up for the oral anticancer drug remedy patients in the NIHON CHOUZAI Kitasato drugstore 坪井悠太, 櫻井七恵, 伊熊恵美, 根元明子, 渡邉道代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2021. |
|---|
|
|
P26-36. Efforts to medicine medicine cooperation by the cooperation full addition enforcement in the cancer chemotherapy 山田健太郎, 冨山成章, 田實裕介, 松ヶ野聡美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2021. |
|---|
|
|
P26-37. The situation of the efforts to cancer treatment of the drugstore pharmacist after the specific drug management instruction addition 2 new establishment 平井利幸, 寺門祐介, 高村優太, 秋山裕史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2021. |
|---|
|
|
P26-38. Medication counseling to the capecitabine remedy patients using the side effect confirmation sheet 澤田千惠1,2, 中村舞1, 高橋由梨1, 中村友香理1, 中川結稀1, 生田佳澄1, 中村光希1, 菅原章弘2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2021. |
|---|
|
|
P26-39. Attempt of the cooperation reinforcement of a health insurance pharmacy and the cancer practice cooperation base Hospital 森山健一1, 岩下知磨1, 内田貴之1, 西千春2, 佐藤みづき2, 井口有紀2, 遠山潤2, 中村初美2, 桜間啓基2, 近藤元三1,2,3, 天方奉子3, 稲葉一郎1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2021. |
|---|
|
|
P26-40. The repair of the instruction to patient paper making database for the purpose of the effective enforcement of the cooperation full addition duties and the evaluation 入佐俊弘, 南晴奈, 岩本茉樹, 渡部仁美, 池田宗彦, 池部美緒, 落合秀樹, 島内あかり, 高比良慎, 斎藤麻美, 末次王卓, 金谷朗子, 辻敏和, 江頭伸昭, 家入一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2021. |
|---|
|
|
P27-01. Examination about the expression situation and the antiemesis therapy of retching, vomiting in the HER2-positive inoperability with a history of the chemotherapy or T-DXd therapy for the recurrent breast cancer 足立紗知1, 北宅良祐2, 宮城和代1, 山下大輔1, 井上敦介1, 宮部貴識3, 吉野宗宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2021. |
|---|
|
|
P27-02. Examination of the antiemetic drug in the intractable multiple myeloma regimen (D-PACE therapy) 八幡静香1, 野尻雅人1, 高田昌季1, 清水雅子1, 高瀬美咲枝2, 清木ゆう3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1032, 2021. |
|---|
|
|
P27-03. Evaluation of the effectiveness and the economy of the antiemesis therapy standardization in the cancer chemotherapy 水津智樹, 小玉美希子, 鴨田夏実, 佃隆元, 山西香織, 田路章博, 粉川俊則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2021. |
|---|
|
|
P27-04. Effective evaluation of the antacids for the cisplatin-induced digestive organ symptom 谷口理1, 齋藤佳敬1, 武隈洋1, 品川尚文2, 木下一郎3, 秋田弘俊3, 菅原満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2021. |
|---|
|
|
P27-05. Investigation about the effect of the expression situation of nausea, vomiting in cisplatin hepatic artery chemistry embolus therapy (CDDP-TACE) and the antiemesis therapy 若松遼介1, 金子真弓1, 船田茜1, 櫻田啓介1, 宮村有貴1, 松本由香莉1, 須藤大雄1, 鈴木千波1, 小原秀治1, 柴波明男1, 樋浦一哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2021. |
|---|
|
|
P27-06. Examination about the tolerability of the day after day internal use of the 5-HT3 receptor blocker in the temozolomide combination radiotherapy 關谷久美子, 原田紗希, 後藤咲香, 藤井宏典, 飯原大稔, 小林亮, 鈴木昭夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2021. |
|---|
|
|
P27-07. Regarding adverse events and antiemetic therapy of trastuzumab deruxtecan at Osaka International Cancer Center 田中佐季, 中村さやか, 高木麻里, 藤田敬子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2021. |
|---|
|
|
P27-08. Comparison of the antiemesis effect of granisetron and palonosetron under the NK1 receptor blocker combination on retching, vomiting with oxaliplatin 三好孝法1, 宮下裕央2, 松尾尚美2, 小田原真希2, 堀南奈子2, 平木洋一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2021. |
|---|
|
|
P27-09. An antiemesis effect by the first generation 5-HT3 receptor blocker and NK1 receptor blocker combination on XELOX therapy and examination of the side effect 堀祐貴, 三坂恒, 嶋田努, 崔吉道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2021. |
|---|
|
|
P27-10. 1 case that alginate Na was effective for retching vomiting by the imatinib, but blood level of the imatinib decreased 富島喜朗, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1040-1040, 2021. |
|---|
|
|
P27-11. Randomized controlled trial of injection site reactions of aprepitant and fosaprepitant in TC+-Bev therapy for gynecological tumors 豊里星来1, 安藤洋介1, 鳥居裕2, 市川亮子2, 伊藤佳織3, 松田日出三1, 辻井奈保1, 柘植雅大1, 島戸茜1, 藤井多久磨2, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2021. |
|---|
|
|
P27-12. The current situation investigation of retching, vomiting in the AI therapy for malignant soft part tumor and search of the risk factor 加藤奈波, 熊倉康郎, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2021. |
|---|
|
|
P28-01. One case of patients with lung cancer that baclofen was effective for hiccups to develop for anticancer medicine administration 土本美咲, 福島隆宏, 宮本佳奈, 真志田絵美子, 佐伯康之, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2021. |
|---|
|
|
P28-02. One case that developed bullous pemphigoid in nivolumab 出町拓也1, 川端貢司1, 北山秀則1, 早坂州生1, 竹内公美1, 木村有貴2, 渡邉昭仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1050, 2021. |
|---|
|
|
P28-03. PBPM for construction and inflection of the system for the hepatitis B reactivation prevention with the cancer chemotherapy 流石智恵子1, 石橋正祥2, 小暮宗介1, 原澤秀樹1, 折井孝男3, 梅谷直亨4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2021. |
|---|
|
|
P28-04. The signal detection of the hyponatremia in the platinum system anticancer medicine administration using JADER 畠山史朗1,2, 加藤祐太3, 丘龍祥1, 志田敏宏1, 小倉次郎1,2, 山口浩明1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2021. |
|---|
|
|
P28-05. The study implementation situation investigation after the automatic alert system introduction for the hepatitis B reactivation prevention 西谷洋平1,2,3,4, 坂本健一1, 土井憲吾1, 西本沙央里1, 上野千奈美1, 角屋厚子2, 島川龍載3, 今井将洋4, 土井真一4, 谷口雅敏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2021. |
|---|
|
|
P28-06. Examination about the association between immune-mediated adverse event and neutrophilic/lymphocytes ratio with the immune checkpoint inhibitor for the non-small cell lung cancer 藤本愛理1, 高武嘉道1, 木村滋1, 花田聖典1, 川俣洋生1,2, 福石和久2, 橋本雅司1, 豊川剛二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2021. |
|---|
|
|
P28-07. One case that infliximab was effective for immune-mediated pulmonary disorder of the steroid refractoriness 今井雄介1, 藤井良平1, 田中雅幸1,2, 冨田詩織1, 打谷和記1, 村中達也1, 谷川昇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2021. |
|---|
|
|
P28-08. Efforts (case report) to nausea, a vomiting expression investigation and the intervention of the oral anticancer agent in the NIHON CHOUZAI Kumamoto drugstore 粟嶋敏, 吉中愛莉, 牛島健太郎, 芥川美波, 田中純怜, 徳岡安見 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2021. |
|---|
|
|
P28-09. Investigation about the expression of infusion related reaction with antiPD-L1 antibody pharmaceutical products 秦啓子1, 中村圭菜1, 宮本真由1, 犬飼萌乃1, 前田真一郎1,2, 前田真貴子1,3, 藤尾慈1,3, 廣部祥子1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2021. |
|---|
|
|
P28-10. The expression of infusion related reaction situation investigation by the Pembrolizumab 中村圭菜1, 秦啓子1, 宮本真由1, 犬飼萌乃1, 前田真一郎1,2, 前田真貴子1,3, 藤尾慈1,3, 廣部祥子1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2021. |
|---|
|
|
P28-11. Association between infusion related reaction expression and precaution at the second administration of rituximab 犬飼萌乃1, 深田耕司1, 宮本真由1, 前田真一郎1,2, 前田真貴子1,3, 藤尾慈1,3, 廣部祥子1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2021. |
|---|
|
|
P28-12. Fact-finding - second report - of the administration cancellation by irAE of the I-O combination chemotherapy in the lung cancer 早坂州生, 岩本浩史, 北山秀則, 竹内公美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2021. |
|---|
|
|
P28-13. It is ... mainly on research - lipid abnormality of the late adverse event after childhood cancer treatment 影山寛人1, 野井天音1, 松村泰志2, 橋井佳子3, 上田幹子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2021. |
|---|
|
|
P28-14. We look at the rear of the raw diet irrigation of eye protective efficacy for the eye manifestation with the Ara-C massive dose therapy and study a mark 角康隆1, 緒方憲太郎1,2, 佐藤啓介1, 佐藤陽菜3, 大倉野将広1, 中島勇太4, 知念祥太郎4, 後藤真喜4, 高松泰4, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2021. |
|---|
|
|
P28-15. Investigation about hydration and the adverse event expression in the cisplatin-based cancer chemotherapy 北澤沙英1, 中村真理子2, 吉見陽2,3, 肥田裕丈2,3, 宮崎雅之3, 山田清文3, 神野透人1, 野田幸裕2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2021. |
|---|
|
|
P28-16. An example with suspected Crizotinib and competitive inhibition of the combination drug 稲毛慶子, 溝口由梨香, 枦秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2021. |
|---|
|
|
P28-17. Cause analysis of the excretion delay in methotrexate large doses 金澤直子, 寺薗英之, 武田泰生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2021. |
|---|
|
|
P28-18. Examination of the prednisolone combination significance to castration-resistant prostate cancer docetaxel therapy 鈴木貴之, 岸高久, 猪野達也, 堀部聖, 池上幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2021. |
|---|
|
|
P28-19. irAE measures in the House of Prefectural University island disease 赤塚千文1, 有馬朱里1, 福山武敏1, 前田裕太1, 小田原正弥1, 中崎聖也1, 橋口雅和1, 右田裕二1, 川路智浩1, 元美江2, 柳田晶彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2021. |
|---|
|
|
P28-20. The case that a drugstore pharmacist taught early self-care to for edema by the docetaxel 中野雄介1, 末次加代子2, 吉岡聖子3, 藤田あゆみ3, 杉浦伸哉3, 杉浦克典3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2021. |
|---|
|
|
P28-21. Example that a drugstore pharmacist was able to contribute to supportive care reinforcement of the FOLFIRI therapy 田中越 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2021. |
|---|
|
|
P28-22. Ramucirumab for the non-small cell lung cancer in our hospital, examination of the Erlotinib combination therapy case 中西大介1, 牛田浩司1, 畑地治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2021. |
|---|
|
|
P28-23. Example that conducted side effect early detection of elevated blood pressure, hepatic dysfunction during pazopanib tablets internal use 笹野寿基1, 吉田貴大2, 安川徹1, 伊藤智平1, 高木亜由美1, 古瀬由奈1, 山田健人1, 渡邉悠花1, 岩渕有希子1, 小玉実佳1, 横田美沙1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2021. |
|---|
|
|
P28-24. Pharmacy pre-avoidance case for S-1 side effect lacrimation 丸尾俊博1, 浅野恭平2, 井上祥平3, 古川紗衣子4, 吉田絢5, 仙波瞳6, 片山珠季7, 永野悠馬8, 前田守8, 長谷川佳孝8, 月岡良太8, 森澤あずさ8, 大石美也8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2021. |
|---|
|
|
P28-25. The enforcement situation of the supportive care for the hand-and-foot syndrome in the capecitabine remedy patients 田村渓1, 政本康成2, 古川紗衣子3, 中村僚宏4, 山口弘5, 常世田京子6, 永野悠馬7, 前田守7, 長谷川佳孝7, 月岡良太7, 森澤あずさ7, 大石美也7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2021. |
|---|
|
|
P28-26. One patient who contributed to quantity of S-1 prescription adequacy in the cancer chemotherapy foreign the intervention of the drugstore pharmacist 浅野恭平1, 早笋奈美香2, 細谷晃3, 渡部貴子4, 深谷将司5, 金子裕介6, 原井厚子1, 佐藤展宏7, 永野悠馬8, 前田守8, 長谷川佳孝8, 月岡良太8, 森澤あずさ8, 大石美也8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2021. |
|---|
|
|
P28-27. The role that pharmacists should play in outpatient cancer chemotherapy, as seen in the case of pre-avoidance of patients taking abemaciclib after the Blue Letter was issued 芳賀文香1, 古川紗衣子2, 市ノ渡真史3, 永野悠馬4, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2021. |
|---|
|
|
P28-28. Display of the extensive pharmacy function based on the test value of the drugstore pharmacist in the foreign cancer chemotherapy 早笋奈美香1, 緒形富雄2, 伊藤秀剛2, 岡本怜子3, 佐藤展宏4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2021. |
|---|
|
|
P28-29. The role that a drugstore pharmacist should fulfil for prevention of side effect aggravation of foreign cancer chemotherapy patients 寺腰崇志1, 青木隆1, 長久保いぶき1, 齋藤希衣1, 川井亜由葉1, 本波茉耶香1, 深井麻利1, 保坂茂2, 小山貴史3, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2021. |
|---|
|
|
P28-30. One case that was able to evade aggravation of stomatitis just after the Everolimus start using the prescription notebook application with the chat consultation function 八木澤恭子1, 矢部和明2, 藤田あゆみ3, 杉浦伸哉3, 杉浦克典3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2021. |
|---|
|
|
P28-31. Look at the rear of the onset of vascular pain situation in the gemcitabine dosage form change; mark investigation 木村錦子, 松田早代, 村田政軌, 三上知佳, 岡田和也, 岡西康治, 治田匡平, 吉川一吾, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2021. |
|---|
|
|
P28-32. The making of the side effect evaluation tool of the oral anticancer agent and the use experience 安井法美, 坂本光次朗, 雄賀多健吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2021. |
|---|
|
|
P28-33. Example that the image transmission function of the electronic notebook was useful in a judgment of the consultation encouragement 梅山克寿, 岡部未来, 佐藤芽依 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2021. |
|---|
|
|
P28-34. One case that intervened in side effect management at CVD therapy enforcement for the malignant phaeochromocytoma 三瓶祐貴1, 奥田泰考1, 山口博紀2, 今井靖1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2021. |
|---|
|
|
P28-35. Examination of the factor associated with the effectiveness and the effect of the zinc acetate hydrate preparation on taste disturbance at cancer chemotherapy enforcement 竹迫秀和1, 瀬戸口誠1, 堀剛2, 有馬純子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2021. |
|---|
|
|
P28-36. The analysis of the risk factor to affect the onset of dermatopathy with the antiEGFR antibody medicine and examination about the workaround 高橋宏彰1,2, 三浦莉奈1, 山崎華1, 朝賀純一1,2, 平舩寛彦3, 氏家悠貴2,4, 松浦由紀子2, 二瓶哲2, 木村聡元5, 工藤賢三1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2021. |
|---|
|
|
P28-37. Analysis of the risk factor of the thrombocytopenia at the Azacitidine administration for patients with myelodysplastic syndrome 安田昌宏1,2, 舘知也1,2, 大澤友裕1, 渡邉久高1, 井上誠二1, 牧野哲平1, 長屋雄大1, 森田美穂1, 田中和秀1, 田中佑佳1, 青山智1, 笠原千嗣3, 寺町ひとみ2, 水井貴詞1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1085, 2021. |
|---|
|
|
P28-38. A factor and multicenter observational study about the treatment success period to influence the drug exposure to that mouth nib in patients with non-small cell lung cancer 梅原健吾1, 後藤桂輔2, 畠山智明3, 伊佐治麻里子4, 高田慎也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1086, 2021. |
|---|
|
|
P28-39. It is a one case using the tolvaptan for treatment of the syndrome of inapp ADH secretion (SIADH) with the cancer of the esophagus preoperative chemotherapy 星茜1,2, 百賢二2, 山崎公靖3, 大塚耕司3,4, 青木武士3, 村上雅彦4, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2021. |
|---|
|
|
P28-40. Adverse event investigation of the Lenvatinib administration in the unresectable hepatocellular carcinoma: Reproducible examination - first report - in a proper use assistance tool and the true clinical practice 朝岡裕樹1, 伊藤佳織2, 水野智博3, 宮本拓人1, 古川治郎1, 廣岡芳樹4, 山田成樹2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2021. |
|---|
|
|
P28-41. The effect that the supportive care of the rash gives to treatment continuation of the Osimertinib 緒形富雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1089, 2021. |
|---|
|
|
P28-42. See the rear about the risk factor of the cytomegalovirus infection when chemotherapy is given in the transplant non-adaptive ATLL patients; a mark investigation 津曲恭一1, 吉田裕生2, 福石和久3, 高田正温4, 川俣洋生5, 牛島知実6, 木村修徳7, 衛藤智章8, 斎田翌美9, 伊藤雄大10, 林稔展11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2021. |
|---|
|
|
P28-43. Search of the nourishment predicting neutropenia of the breast cancer FEC therapy and inflammatory marker ratio 中村俊貴1, 左右田和枝1, 松原肇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2021. |
|---|
|
|
P28-44. Case experience corresponding to the immune-mediated dermatopathy of the Pembrolizumab treated patients who complicated various skin disease 吉成宏顕1, 橋本竜1,2, 風岡真実1, 高岡栄一郎3, 佐藤淳也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2021. |
|---|
|
|
P28-45. Usefulness of the neutrophilic lymphocyte counts ratio as the predictor of the febrile neutropenia onset 熊澤里美1,2, 水野智博2, 村松直幸1,2, 古関竹直2, 松岡宏3, 須田康一3, 宇山一朗3, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2021. |
|---|
|
|
P28-46. Fact-finding of serum zinc levels and the taste disturbance in the treatment with 5FU system anticancer agent 戸塚孝治1, 田畑真一1, 高橋威洋2, 市川度2, 新井成俊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2021. |
|---|
|
|
P28-47. The effect that presence or absence of antidiarrheal drug, medicine for intestinal disorders combination prescription in the S-1 remedy patients gives to treatment continuation 村上紘世1, 田中直也2, 緒形富雄3, 片山珠季4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2021. |
|---|
|
|
P28-48. The effect that presence or absence of moisturizer combination prescription in the capecitabine remedy patients gives to treatment continuation 田中直也1,2,3,4,5, 村上紘世2, 緒形富雄3, 片山珠季4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1096, 2021. |
|---|
|
|
P28-49. Examination about the use of Palbociclib and the Abemaciclib which we saw from the viewpoint of side effect 中務ひとみ1, 高橋正也1, 高橋克之1, 高島勉2, 浅野有香2, 森崎珠実2, 柏木伸一郎2, 野田諭2, 中村安孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2021. |
|---|
|
|
P28-50. Association of peripheral neuropathy and the taste disturbance in patients who received oxaliplatin 河端真以, 田本光莉, 猪谷朱理, 久保萌美, 金澤沙衣, 蝦名勇樹, 村上智香, 晴山知拓, 石田陽美, 三本松泰孝, 佐藤弘康, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2021. |
|---|
|
|
P28-51. Search of the test value that is useful in side effect investigation of the nivolumab in the second treatment of the renal carcinoma and the early detection of the immune-mediated side effect 石田優理香1, 高崎新也1, 安藤咲弥香1, 諸角謙人2, 川崎芳英2, 前川正充1, 伊藤明宏2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2021. |
|---|
|
|
P28-52. One case of the breast cancer that was able to accomplish dose-dense AC therapy by the intervention of the pharmacist safely 石川雄大, 谷道あかり, 高橋則正, 格谷美奈子, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2021. |
|---|
|
|
P28-53. The osteoporosis therapeutic drug combination situation of the Abiraterone remedy patients 塩野美友紀1, 三宅祥太2, 小山貴史3, 永野悠馬4, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2021. |
|---|
|
|
P28-54. Examination of effect of treatment and the side effect of the IsaPd therapy for a recurrence, the intractable multiple myeloma 西村直朗, 柿原圭佑, 吉国健司, 小倉秀美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1102-1102, 2021. |
|---|
|
|
P28-55. One case that an antihistamine succeeded for hypersensitivity by the etoposide 寺坂裕希, 高野温志, 高野明香, 井上朋子, 伊賀正典, 町田充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1103, 2021. |
|---|
|
|
P28-56. Effect of the pharmacist intervention to give to the hand-and-foot syndrome of the capecitabine internal use patients 高橋恭平1, 福長豊己1, 森川記道1, 堀越友太1, 大山展弘1, 西倉教子1, 原田靖子1, 西原昌幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1104, 2021. |
|---|
|
|
P28-57. Look at the rear about the use of the peg filgrastim in the adjuvant chemotherapy after the lung cancer technique; mark investigation 佐多照正1, 末永尚輝1, 八汐祥恵1, 堀ノ内志織1, 堀内智裕1, 鶴永大貴1, 中村有莉恵1, 赤星真広1, 上原友美1, 池増鮎美1, 大塚綱志2, 西島浩雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1105, 2021. |
|---|
|
|
P28-58. One case of patients with lung cancer that caused sigmoid diverticulum perforation during Cisplatin+Vinorelbine radiation combination chemotherapy treatment 池下智之, 角川幸男, 野崎圭佑, 清水克次, 井上聡子, 高木麻里, 藤田敬子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2021. |
|---|
|
|
P28-59. The use situation and side effect report of the Lenvatinib in the Fukuoka Red Cross hospital 大石瑞紀, 川野昭, 大石裕樹, 福重昇吾, 杉慎介, 藤永理恵子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2021. |
|---|
|
|
P28-60. See the rear about the effect accompanied with changes from the first generation of the antihistamine which is the hypersensitivity reaction prevention in the cancer medical therapy to second generation; a mark investigation 柿本秀樹1, 大倉野将広1, 長郷あかね2, 内山将伸3, 川田哲史1, 真島宏太1, 角康隆1, 井上竜一1, 五十嵐保陽1, 武田佳子1, 池内忠宏1, 兼重晋1, 緒方憲太郎1,2, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2021. |
|---|
|
|
P28-61. The use actual situation of the Pembrolizumab in the non-small cell lung cancer and safe examination 藤本亜弓1, 石坂崚1, 山崎直樹1, 吉田徹也2, 中尾將彦1, 駄賀晴子3, 森宏幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2021. |
|---|
|
|
P28-62. Comparison of the diuretic tolerability with mannitol in the cancer of the esophagus FP (5-Fu+ cisplatin) therapy or furosemide 北本真一, 白木政博, 古谷智裕, 村上礼隆, 佐藤実由, 金田公平, 宮森伸一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2021. |
|---|
|
|
P28-63. Possibility of the protection effect with a risk factor and renin-angiotensin axis antihypertensive medications of the onset of proteinuria in patients with Axitinib remedy nephrocyte cancer 山岡健太1, 池末裕明1, 松本彩子1, 平畠正樹1, 室井延之1, 山崎俊成2, 川喜田睦司2, 橋田亨1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2021. |
|---|
|
|
P28-64. The difference in Carboplatin doses calculation method and relative examination of the thrombocytopenia 松浦徹, 與田賢作, 田中博和, 矢野洋平, 内山有理香, 奥野美和, 平川雅章, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1112, 2021. |
|---|
|
|
P28-65. Examination about the febrile neutropenia onset risk after the peg filgrastim administration using JADER 宗岡祐輔, 小山勝真, 伊藤麻結, 幸田恭治, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2021. |
|---|
|
|
P28-66. It is fact-finding of the febrile neutropenia in the docetaxel/5-fluorouracil/cisplatin therapy in becoming it peg filgrastim combination 松坂章也1, 橋詰淳哉1, 中川博雄1, 原澤仁美1, 中村忠博1, 小林和真2, 佐々木均1, 兒玉幸修1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2021. |
|---|
|
|
P28-67. Examination of the protective efficacy of the febrile neutropenia with administration of G-CSF preparation within 24 hours after the end of the administration in the cancer of the esophagus DCF therapy and the administration of antimicrobial 倉橋真弓1, 鎌田宏和1, 清水克次1, 高木麻里1, 辰見明俊2, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2021. |
|---|
|
|
P28-68. About effect on onset of febrile neutropenia in the combination therapy of the small cell lung cancer of immunity 八尾尚樹, 鎌倉政城, 竹内結香, 橋本智咲, 大堀健史, 近野祐里, 美濃部奈都, 庄司高明, 鍬田千草, 中村直美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2021. |
|---|
|
|
P28-69. Acute nephropathic evaluation associated with the anticancer medicine used in the stomach cancer in the adverse drug reaction database 内田まやこ1,2, 高野碧2, 近藤悠希3, 鈴木真也4, 細畑圭子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1117-1117, 2021. |
|---|
|
|
P28-70. Examination of the risk factor of the hypertensive expression with the pazopanib hydrochloride 國武正幸, 後藤綾, 酒井義朗, 樋口恭子, 三輪涼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2021. |
|---|
|
|
P28-71. Examination of the hepatic dysfunction risk factor with the pazopanib hydrochloride 後藤綾, 國武正幸, 酒井義朗, 樋口恭子, 三輪涼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2021. |
|---|
|
|
P28-72. Effect on protective efficacy by the magnesium oxide combination of the minocycline for the purpose of the acneform rash prevention in the colon cancer antiEGFR antibody therapy 小柴郁1, 渡部大介1, 大塚亮1, 橋本浩伸1, 齋藤義正1, 石川光信1, 赤木徹1, 山口正和2, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2021. |
|---|
|
|
P28-73. Use fact-finding of the peg filgrastim in our hospital 谷道あかり, 石川雄大, 高橋則正, 格谷美奈子, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1121, 2021. |
|---|
|
|
P28-74. The onset of dysfunction thyroid situation investigation with the immune checkpoint inhibitor 若井香鈴, 平手大輔, 今多亮介, 本郷文教 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2021. |
|---|
|
|
P28-75. About effect on renal function by the combination of bortezomib and aciclovir 今多亮介, 平手大輔, 若井香鈴, 大森悠翔, 本郷文教 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1123, 2021. |
|---|
|
|
P28-76. The change of the eosinophil count becomes the useful biomarker predicting the immune-mediated adverse event with the immune checkpoint inhibitor 奈良克彦, 苅谷嘉顕, 雨宮貴洋, 鈴木洋史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2021. |
|---|
|
|
P28-77. Examination about the onset of neutropenia in patients who received cisplatin + vinorelbine combination therapy 村山三佳, 丹羽洋介, 竹内佐織, 千崎康司, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2021. |
|---|
|
|
P28-78. 1 case of the sensitivity hepatic portal region cholangiocarcinoma which was able to continue gemcitabine + cisplatin therapy by having taken measures 金本卓1, 藤田強記2, 田中誠1, 中川義浩3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2021. |
|---|
|
|
P28-79. Examination about the risk factor of the taxane origin-related acute pain syndrome under the dexamethasone prophylaxis 坂本達彦1, 齋藤佳敬1, 武隈洋1,2, 小林正紀1,3, 山下啓子4, 菅原満1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1127-1127, 2021. |
|---|
|
|
P28-80. Exhaustive fixed-quantity evaluation of the patients quality of life by the pharmaceutical intervention to supportive care in the foreign cancer chemotherapy 上田祐稀乃1, 藤井宏典1,2, 廣瀬智恵美2, 大畑紘一2, 飯原大稔1,2, 鏑木美帆3, 松橋延壽4, 高橋孝夫5, 吉田和弘6, 鈴木昭夫1,2, 林秀樹1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2021. |
|---|
|
|
P28-81. Example that conducted antihypertensive agent adjustment for the high blood pressure that occurred after the Cabozantinib introduction, and was a treatment continuation possibility 末松耕輔1, 黒部健太郎1, 宮原強1, 水田秀貴1, 佐野雅彦1, 徳永晃1, 平井良樹2, 諸隈太2, 草葉一友1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2021. |
|---|
|
|
P28-82. The zinc level measurement of the patients who reported dysgeusia during chemotherapy and examination of the supplementary usefulness 伊東真由子1, 野原真吾1, 中村知子1, 山本和宜1, 瀬山厚司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2021. |
|---|
|
|
P28-83. Examination about the effect of the renal function on immune-mediated adverse event of the immune checkpoint inhibitor in urologic cancer 仲野宏紀1, 宮城和代2, 江原美里2, 山本友佳子2, 井上敦介2, 宮部貴識3, 山内一恭4, 福田利明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2021. |
|---|
|
|
P28-84. 2 cases that we introduced dabrafenib+trametinib combination therapy into as initial treatment for the unresectable progress non-small cell lung cancer with the BRAF V600E mutation in the gene 成田綾香1, 西辻雅2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2021. |
|---|
|
|
P28-85. Is the pattern of the UGT1A1 genetic polymorphism predictable by a total serum bilirubin level? 鈴川悠利愛, 福井梨乃, 槙原克也, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2021. |
|---|
|
|
P28-86. Urine qualitative analysis in Bevacizumab-related proteinuria and correlative evaluation of UPCR 鈴木直哉, 山田将悟, 藤林遼, 菊地義明, 高橋誠, 青田忠博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2021. |
|---|
|
|
P28-87. Side effect of family pharmacist measures of the cancer medical therapy using the nonprescription drug (case report) 正岡麻里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1135, 2021. |
|---|
|
|
P28-88. Attempt to neutropenic risk assessment of irinotecan by the classification of total bilirubin levels and the UGT1A1 genetic polymorphism 福井梨乃, 鈴川悠利愛, 槙原克也, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2021. |
|---|
|
|
P28-89. See the rear about the neutropenic expression risk factor of Grade3/4 in patients with breast cancer given eribulin; a mark investigation 高山俊輔1, 高山裕樹1, 松浦一生2, 牧野好倫1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2021. |
|---|
|
|
P28-90. modified Glasgow prognostic score (mGPS) in colon cancer adjuvant chemotherapy patients and investigation of the survival period 西和哉1, 川田彰彦1, 高橋舞1, 佐々木崇1, 佐賀利英1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2021. |
|---|
|
|
P28-91. About the effectiveness of mirogabalin and duloxetine for peripheral neuropathy that gynecologic TC therapy causes compare it directly 馬場華菜, 谷口潤, 尾之江剛樹, 山形真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2021. |
|---|
|
|
P28-92. Examination of the telephone follow-up using the tracing report for exclusive use of S-1 田村知子1, 都和彦2, 吉岡睦展3, 近藤万友美3, 澁谷奈穂3, 若松雄太3, 細見真世3, 高子優子3, 小溝優子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2021. |
|---|
|
|
P29-01. Usefulness of polypharmacy measures based on request for medicine that it decreased by it of patients in the palliative care unit 村上翔梧, 野村剛久, 佐古守人, 大西美香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2021. |
|---|
|
|
P29-02. Dose investigation at opioid preparation change in our hospital inpatient 田口諒, 元木孝, 澁谷基宏, 渡邊清人, 高柳昌宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2021. |
|---|
|
|
P29-03. One case of patients with rectal cancer that we conducted pain control with high-dose hydromorphone hydrochloride tablets 増田博也, 間千晴, 佐々木健志, 澤口友紀, 井上萌, 坪田美風, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1146, 2021. |
|---|
|
|
P29-04. Fact-finding of the use of nonopioid pain-killer at opioid introduction of our hospital 稲田佑亮, 立石朝子, 小倉絵里奈, 山下敦志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2021. |
|---|
|
|
P29-05. Efforts of the proper use promotion of the antiemetic drug for opioid-induced retching, vomiting utilizing the set prescription and the evaluation 杢保貴幸, 浜田真由子, 宮本彩, 徳竹裕貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2021. |
|---|
|
|
P29-06. Fact-finding survey regarding bisphosphonate injection drugs and dental consultations before first administration of denosumab in cancer patients 市原英則, 松田璃沙, 塚原優太, 中澤誉, 別府博仁, 丸山直岳, 土井敏行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2021. |
|---|
|
|
P29-07. Examination of the night delirium and sleep agent medication situation in our hospital palliative care unit 松岡未紗, 森戸敏志, 後藤義之, 角紀一郎, 岡田久美, 古本真由美, 茶野下貴恵, 島崎沙織, 青木理恵, 清水翔子, 梅下翔, 西川達也, 室田恵里, 橋本夏恵, 山下陽夏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2021. |
|---|
|
|
P29-08. Investigation about the effect to give renal function at the NSAIDs introduction 枝廣茂樹, 松波寿雄, 大川浩子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2021. |
|---|
|
|
P29-09. A comparison of the frequency of retching, vomiting at tramadol and oxycodone start and search of the risk factor 村上はる香, 澤昇平, 栗原啓輔, 飯塚美有, 古橋侑樹, 辻村行啓, 清水真弓, 荒川大輔, 山本圭祐, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2021. |
|---|
|
|
P29-10. About the interaction of the use of opioid preparation patients in the metropolitan east of the Sumida River hospital 黒木あかね1, 高木茂実1, 櫻井琴乃2, 太田博暁2, 丸藤義翔2, 白石麻由子2, 野村有加2, 安武夫2, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2021. |
|---|
|
|
P29-11. Efforts for the opioid weight loss in palliative care rounds 岩田一史, 合澤啓二, 土屋惠菜, 小野達昌, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2021. |
|---|
|
|
P29-12. The case that improved pain control and the compliance of patients with at-home cancer in cooperation with other types of job 鎌滝真永 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2021. |
|---|
|
|
P29-13. One case that the combination of the pain-killer was effective for Mohs ointment measures postoperative pain of the progress breast cancer 石坂真理1, 高木彩菜1, 長谷川章1, 早川裕二1, 間瀬広樹1, 生野仁美2, 川端康次3, 加藤浩充1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1156, 2021. |
|---|
|
|
P29-14. With this (drug for the medical care), can you go to Singapore? 藤村昭太1, 荒川昌史1,4, 野田達也1, 櫻木雅子2, 赤津理恵3, 清水敦4, 黒崎史朗4, 竹内瑞枝4, 丹波嘉一郎4, 今井靖1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2021. |
|---|
|
|
P29-15. About association with polypharmacy and the delirium before and after the palliative care unit hospitalization 野澤(石井)玲子1, 相沢健太1, 菅野智2, 荒井進3, 稲葉裕4, 加賀谷肇5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2021. |
|---|
|
|
P29-16. The use of opioid situation at head and neck cancer chemoradiotherapy enforcement in our hospital 林良亮, 江尻将之, 春日井悠司, 竹内正幸, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2021. |
|---|
|
|
P29-17. 1 case that it came to have difficulty with opioid analgesic remedy, and withdrawal sign appeared during chemotherapy 藤原麻衣1, 森脇崇1, 志方優子2, 井上敬之1, 中城宏子1, 岩崎輝夫3, 老田章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1160, 2021. |
|---|
|
|
P29-18. One case that combination of the agate Pross ton was useful in the constipation that accompanied oxycodone increase in quantity 宮田香織1, 渡部誠士2, 藤田あゆみ3, 市川隆之4, 杉浦伸哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2021. |
|---|
|
|
P29-19. The use situation of the constipation therapeutic drug for the use of opioid patients in our hospital inpatient 山野邉裕子1, 田村賢士1, 金子智一1, 金子誠1, 寺田伊知郎1, 立花栄三1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2021. |
|---|
|
|
P29-20. Use experience of hydromorphone at severe impaired renal function 佐藤和文, 船水祐里, 和賀信継, 佐山英明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2021. |
|---|
|
|
P29-21. Condition assessment reinforcement and improvement in medical treatment (the third report) by the Audit System introduction for patients with cancer 淡路健作, 深尾彰平, 阿部路, 竹下絵梨香, 近藤匡慶, 菅谷量俊, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1164, 2021. |
|---|
|
|
P29-22. 1 case that Kambakutaisoto was effective for pain of the opioid refractoriness 戸島心1, 角川幸男1, 神農理衣1, 西馬怜1, 迫田由佳梨1, 高木麻里1, 池田和世2, 藤田敬子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2021. |
|---|
|
|
P29-23. Use fact-finding of the laxative for the opioid-induced constipation (OIC) 三松史野, 實光由香, 佐分利美帆子, 内藤舞, 村岡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2021. |
|---|
|
|
P29-24. 1 case that a midazolam injection was effective for sufferings from treatment-resistant breathing 石川敬祐, 伊藤慎二, 磯貝潤一, 石川沙矢香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2021. |
|---|
|
|
P29-25. Examining the pain relief effect of combined use of strong opioid injection and tramadol hydrochloride injection 伊藤慎二, 石川敬祐, 磯貝潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2021. |
|---|
|
|
P29-26. 1 case that was able to reduce opioid by opioid switching for the use of high-dose opioid patients appropriately 竹田優作, 吉田昌子, 江崎宏樹, 大島有美子, 堀田敏之, 桜田宏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2021. |
|---|
|
|
P29-27. We look at the rear about the usefulness of the naldemedine prophylaxis to oxycodone-induced constipation and study mark Pilot 折笠瞬, 槙原克也, 嶽小原恵, 松野優紀, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2021. |
|---|
|
|
P29-28. The current situation of the opioid switch to a morphine hydrochloride note and safe inspection 大池貞治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2021. |
|---|
|
|
P29-29. The effectiveness of the Lidocain continuous intravenous infusion for the cancerous pain 原田沙枝子, 林洋平, 櫻井美由紀, 鹿間良弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2021. |
|---|
|
|
P29-30. Effect of the background factor giving it to the effectiveness of the delirium therapeutic drug of patients who received palliative care 佐藤淳也1,2, 梅田鈴香1,2, 塚越真由美2,3, 山田祐2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1173, 2021. |
|---|
|
|
P29-31. Confirmation of an effect of the naldemedine and the effect on retching and pain 渡部寿康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2021. |
|---|
|
|
P29-32. One case of patients with gastric cancer which we changed from a buprenorphine patch to an oxycodone sustained injection 大内竜介1,2, 薄井健介1,2, 倉田奈央子2, 鈴木清寿3, 長尾宗紀3, 児山香3, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2021. |
|---|
|
|
P29-33. The case that hydrozincite starch ad usum externum therapy was effective for breast cancer skin permeation 山崎美保1, 福田結彩1, 木村竜司1, 馬屋原慈理1, 一瀬貴史1, 二井久美2, 高橋護3, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2021. |
|---|
|
|
P29-34. Investigation about the use of fen toss tape (R) for the cancerous pain to opioid naive patients in our hospital 奥津雄人1, 江原純也1, 立田真也1, 矢野有紀2, 高橋尚子2, 細谷治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2021. |
|---|
|
|
P29-35. Investigation about the effectiveness and the safety of the morphine for a feeling of dyspnea in patients with cancer and non-cancer 内海尊雄1,2, 大久保正人1,2, 須藤知子1,2, 中村貴子2, 鈴木貴明2, 田口奈津子1,3, 石井伊都子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2021. |
|---|
|
|
P29-36. The role that the pharmacist fulfils in the medical care, the care in the final stage of the life 岩崎章吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2021. |
|---|
|
|
P29-37. 1 case that we made changes from sustained subcutaneous injection of the hydromorphone hydrochloride to internal use in the home care patient 原田寿1, 犬飼浩子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2021. |
|---|
|
|
P29-38. The case that a drugstore pharmacist prevented overdose at a route of administration change of the opioid 丸一泰雅, 折戸真澄, 藤丸知佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1181, 2021. |
|---|
|
|
P29-39. The at-home return in the palliative care unit admission patients and survival period comparison by the palliative care unit medical treatment 吉田健人1, 田辺公一1, 村上望2, 中嶋和仙3, 酒井隆全1, 大津史子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2021. |
|---|
|
|
P29-40. It is an example corresponding to the taking pain-killer difficulty in the childhood at-home mild medical care 辻裕太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2021. |
|---|
|
|
P29-41. It is ... for improvement in knowledge about the medical drug of questionary survey - inside the hospital staff in the palliative care class in inside the hospital 細田奈七恵, 松本晃一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2021. |
|---|
|
|
P29-42. Construction of the system for the inpatient drug self-care introduction 水谷彰史1, 久保淳一2, 高取士剛2, 高木明彦3, 板橋理絵4, 坂本健一3, 飛澤国広3, 鈴木千波1, 佐藤公人3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2021. |
|---|
|
|
P30-01. Investigation of doubt inquiry for the outside Parliament prescription of patients with cancer utilizing the clinical test value 仲尾洋子, 土井千亜紀, 森雅也, 三浦尚子, 良玄朋子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2021. |
|---|
|
|
P30-02. Examination of the factor having an influence on the treatment continuation of the S-1 monotherapy in the adjuvant chemotherapy after the pancreatic cancer technique 野口裕介1, 加藤良隆1, 大坪達弥1, 鹿浦香織1, 神田英一郎1, 小林大祐1, 眞釼彩子1, 江島智彦1, 豕瀬諒2, 村木優一2, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2021. |
|---|
|
|
P30-03. The current situation and problem of the cooperation full addition calculation in the foreign chemotherapy room 西上依里, 合澤啓二, 小野達昌, 岩田一史, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2021. |
|---|
|
|
P30-04. Fact-finding about the pharmacist duties of the cancer domain in the cancer practice cooperation base Hospital, and the like under the COVID-19 outbreak 櫻井洋臣1, 川澄賢司2, 佐々木駿一1, 脇本麻美3, 餅原弘樹4, 飯塚雄次5, 内坪敬太6, 田島亮7, 本田泰斗8, 石原由起子9, 濃沼政美10, 近藤直樹11, 青森達1,12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2021. |
|---|
|
|
P30-05. About the use situation of the CDK4/6 inhibitor in our hospital 長谷川豊則1,2, 窪田智行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2021. |
|---|
|
|
P30-06. The PBPM operation situation investigation associated with the cancer medical therapy in our hospital 羽生智宏, 尾形美絵, 近藤和宏, 中村槙一郎, 瀧内瑛輔, 長澤欣弘, 新関みどり, 田村和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1196, 2021. |
|---|
|
|
P30-07. The effect of menthol on doxorubicin killing effect with human liver cancer HepG2 cells: Possibility of the participation of the P-glycoprotein 長井克仁1, 内野友実子1, 瀬原菜津子1, 田畑竜也2, 山本洋平2, 福野修平1, 小西廣己1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2021. |
|---|
|
|
P30-08. Investigation of the factor about interruption, cancellation during the Durvalumab dosing period in patients with non-small cell lung cancer 樋口純一, 益本周治, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2021. |
|---|
|
|
P30-09. Look at the rear of the side effect of sunitinib in renal carcinoma first treatment and pazopanib; a mark investigation 安藤咲弥香1, 高崎新也1, 石田優理香1, 諸角謙人2, 川崎芳英2, 前川正充1, 伊藤明宏2, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2021. |
|---|
|
|
P30-10. About safety of VEGF inhibitor and the anticoagulant combination in patients with cancer with the thromboembolism 阿部多一, 住谷達也, 林哲哉, 井口恵美子, 猪股克彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2021. |
|---|
|
|
P30-11. Examination of drug continuation advisability when we used the UPC ratio as an evaluation standard of proteinuria in the bevacizumab administration for colon cancer and the tolerability 柴崎七海1, 金素安1, 大貫奏1, 太田茜1, 立沢正臣1, 宮野省三2, 須郷広之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2021. |
|---|
|
|
P30-12. Relative examination of the nutrition index and side effect expression in the EPOCH (-R) therapy and blood corpuscle ingredient ratio 菊池健1, 三坂陽菜2, 武田元樹1, 相馬貴史1, 鶴山辰1, 佐藤秀紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2021. |
|---|
|
|
P30-13. Drug-drug interaction between ixazomib/lenalidomide/dexamethasone (IRd) therapy and antacids - Possibility of attenuating the antitumor effect of IRd therapy - 北澤文章1, 中山優子3, 高良恒史4, 佐原敏之2, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2021. |
|---|
|
|
P30-14. Blood drug concentration analysis of the case that used clarithromycin together during hippopotamus diTaki cell administration 勝見重昭1,2, 八島秀明1, 荒木拓也1,2, 宮澤慶行3, 鈴木和浩3, 山本康次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1204, 2021. |
|---|
|
|
P30-15. Approach of the dose confirmation with the capecitabine inspection support paper in the health insurance pharmacy 吉田貴大1, 辻真利4, 山田裕介1, 笹野寿基2, 竹原美穂2, 安川徹2, 西阪宏彰3, 辻宗一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2021. |
|---|
|
|
P30-16. Investigation of the effect of the liver spare function to give the effectiveness of the paclitaxel 松田燦徳, 澤昇平, 北畠千種, 松川陽央, 都甲海, 山本圭祐, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2021. |
|---|
|
|
P30-17. The effectiveness of the gemcitabine + docetaxel combination therapy as the postoperative chemotherapy for the uterine leiomyosarcoma and safe examination 仁井寛彦1, 片山健太郎1, 後藤千尋1, 今村牧夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2021. |
|---|
|
|
P30-18. To offer cancer treatment reliable safely to the area 小野貴光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2021. |
|---|
|
|
P30-19. Good use of HBV infection screening - screening template (the fourth report) ... in the cancer chemotherapy 勝山繁佳1, 大久保真貴1, 渡邊雅明1, 中島正人1, 細野智美1, 土岐浩介1, 関根郁夫2, 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2021. |
|---|
|
|
P30-20. Questionary survey about the evaluation of the cooperation (Kagoshima cancer immune therapy support network: KISNet) between institutions for the irAE management reinforcement 松尾圭祐1, 鳥山陽子2, 谷本憲哉2, 谷口潤2, 平木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1210, 2021. |
|---|
|
|
P30-21. Evaluation of the quantity of S-1 prescription for the estimated renal function of foreign cancer chemotherapy patients 玉木麗花1, 伊藤学2, 竹村健志3, 永野悠馬4, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1211, 2021. |
|---|
|
|
P30-22. Consideration about the expiration date for use setting for Drug Vial Optimization introduction 濱宏仁1,2, 平畠正樹2, 池末裕明2, 室井延之2, 橋田亨2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1212-1212, 2021. |
|---|
|
|
P30-23. Investigation of an effect contracted at the preparation time by the agent type change to a bendamustine solution and the cost cut effect 種村繁人, 冨田敦和, 今井邦行, 小玉幸与, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1213, 2021. |
|---|
|
|
P30-24. It is a one case receiving the Osimertinib using the suspension method simple for patients with lung cancer with the oesophageal stenosis 江島智彦1, 松本有咲1, 古池志織1, 加藤良隆1, 大坪達弥1, 野口裕介1, 神田英一郎1, 岡橋孝侍1, 藤田敦夫1, 谷望未2, 竹田隆之2, 友金幹視2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2021. |
|---|
|
|
P30-25. The treatment continuation situation in the foreign cancer chemotherapy of the women using the cyclin-dependent kinase inhibitor 金井良記1, 大熊祐美2, 古川紗衣子3, 石黒貴子4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1215, 2021. |
|---|
|
|
P30-26. Prescription trend of the oral anticancer agent used by the outpatient department cancer chemotherapy of male elderly people 三宅祥太1, 塩野美友紀2, 黒川由紀子3, 永野悠馬4, 前田守4, 長谷川佳孝4, 月岡良太4, 森澤あずさ4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2021. |
|---|
|
|
P30-27. The treatment continuation situation in the foreign cancer chemotherapy using the pyrimidine system antimetabolite fluoride 田村真哉1, 津村直孝2, 正野隆3, 松野紀世彦4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1217-1217, 2021. |
|---|
|
|
P30-28. One case of colon cancer which caused chronic thrombocytopenia by oxaliplatin-related splenomegaly and liver damage 倉田玲奈1,2, 信岡祐2, 小島朋大1, 佐藤賛治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2021. |
|---|
|
|
P30-29. Case of pharmacy pre-avoidance of epidermal growth factor receptor tyrosine kinase inhibitors for skin disorders 伊藤学1, 芳賀文香2, 吉田亜紀2, 中村聡3, 森田晃子4, 原井厚子5, 玉木麗花6, 竹村健志7, 永野悠馬8, 前田守8, 長谷川佳孝8, 月岡良太8, 森澤あずさ8, 大石美也8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2021. |
|---|
|
|
P30-30. Starting doses design and examination about optimum doses based on the prescription situation of trifluridine Tipiracil hydrochloride combination tablets 小中健1,2, 斉藤辰彦1,2, 伊藤祥子1,2, 森本美由樹2,3, 黒田武志4, 都築大輔1, 伏谷秀治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1220-1220, 2021. |
|---|
|
|
P30-31. The treatment continuation situation in the foreign cancer chemotherapy using the aromatase inhibitor 正野隆1, 津村直孝2, 田村真哉3, 松野紀世彦4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1221, 2021. |
|---|
|
|
P30-32. The treatment continuation situation in the foreign cancer chemotherapy using the tyrosine kinase inhibitor 津村直孝1,2,3,4,5, 田村真哉2, 正野隆3, 松野紀世彦4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1222, 2021. |
|---|
|
|
P30-33. We support the medication on the nourishment side in adjuvant chemotherapy S-1 alone after the stomach cancer technique continuously 安川徹1,2, 笹野寿基1, 伊藤智平1, 高木亜由美1, 古瀬由奈1, 吉田貴大2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1223, 2021. |
|---|
|
|
P30-34. The effectiveness, safe examination of the immune checkpoint inhibitor in patients with old non-small cell lung cancer 宮下裕央1, 三好孝法2, 松尾圭祐1, 堀南奈子1, 松尾尚美1, 平木洋一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1224-1224, 2021. |
|---|
|
|
P30-35. With the skill necessary for the drugstore pharmacist corresponding to patients receiving foreign cancer chemotherapy 秋山真衣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1225, 2021. |
|---|
|
|
P30-36. Analysis (as part of reduction of the drug-related near miss) of anticancer agent-related doubt inquiry contents in our hospital 石崎文子, 相原敏彦, 増尾昌則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1226, 2021. |
|---|
|
|
P30-37. 3 cases that chills, fever developed after the oxaliplatin administration 里見眞知子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1227, 2021. |
|---|
|
|
P30-38. The effectiveness, safe examination of the mycophenolate mofetil for the steroid-resistant irAE liver damage 藤田敬子, 角川幸男, 野口大倭, 西馬怜, 木村美甫, 池下智之, 野崎圭佑, 高橋幸三, 鎌田宏和, 清水克次, 高木麻里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1228-1228, 2021. |
|---|
|
|
P30-39. The statin preparation combination situation of the aromatase inhibitor remedy patients 山口弘1, 田村渓2, 政本康成3, 常世田京子4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1229, 2021. |
|---|
|
|
P30-40. The enforcement situation of the supportive care for the osteoporosis accompanied with the use of aromatase inhibitor 青木香奈1, 丸尾俊博2, 井上祥平3, 片山珠季4, 永野悠馬5, 前田守5, 長谷川佳孝5, 月岡良太5, 森澤あずさ5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1230-1230, 2021. |
|---|
|
|
P30-41. Relation of the pharmacist to the patients whom hepatic dysfunction developed in by the immune therapy for unresectable hepatocytes cancer 臼井孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1231, 2021. |
|---|
|
|
P30-42. "The reactivation measures of HBV with the chemotherapy" are possible by the intervention of the pharmacist to here! 森井悠介1,3, 田井浩子1, 松井駿亮1, 山口唯1, 近谷仁志1, 大河万顕1, 阪口紀子1, 入潮佳子2, 西田升三3, 下村一徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1232, 2021. |
|---|
|
|
P30-43. Effect to give to renal function of the gemcitabine + cisplatin therapy in the biliary cancer 冨山成章, 山田健太郎, 田實裕介, 松ヶ野聡美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1233, 2021. |
|---|
|
|
P30-44. One case that produced immune thrombocytopenic purpura (ITP) by Durvalumab 永井道雄1, 岩本里味1, 辰巳真穂1, 松浦暢子1, 神山知也1, 藤井元1, 米田航佑1, 堀朱矢2, 北山翠3, 山根隆志3, 石坂忠博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1234-1234, 2021. |
|---|
|
|
P30-45. The effect that the administration of proton pump inhibitor gives to a vital prognosis on patients with metastatic or unresectable urothelium cancer which received Pembrolizumab therapy 國光葉子1, 森尾佳代子1, 平田佐智1, 山本和宏1, 大村友博1, 原琢人2, 原田健一2, 藤澤正人2, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2021. |
|---|
|
|
P30-46. Comparison of the side effect of pleural effusion retention expression of pemetrexed situation 大野裕之, 田中佳子, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1236, 2021. |
|---|
|
|
P30-47. Examination of the usefulness of the elderly people evaluation using the G8 score in the gastric cancer chemotherapy 鈴木喬也, 杉本智哉, 奥苑朱加, 山室栄一, 遠山幸男, 久田達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1237, 2021. |
|---|
|
|
P30-48. Example that gave ATRA+ATO therapy for elderly people APL with comorbidities, and achieved molecular biologic remission 宇佐美友佳子, 近藤篤, 三宅麻文, 尾上雅英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1238-1238, 2021. |
|---|
|
|
P30-49. Look at renal function at the denosumab administration in patients with solid carcinoma and the multicenter rear about the association of the hypocalcemia; a mark observational study 中村和代1, 嘉屋道裕1, 木苗あゆみ1, 久保田佳実1, 柳澤由紀2, 山本圭祐3, 高屋敷奈々4, 浮田浩利4, 名倉真理子5, 杉上香織6, 北島真利子7, 平野公美8, 石田紘基9, 小野田千晴10, 小林豊11, 中谷英仁12, 名波章子13, 小田切圭一14, 鈴木貴也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1239-1239, 2021. |
|---|
|
|
P30-50. Investigation of the potential drug interactions in the use of injectable anticancer medicine patients utilizing the drug interactions detection program 矢野洋平, 立石裕樹, 與田賢作, 大汐欣輝, 楢崎友理, 山本貴一, 田中博和, 松浦徹, 平川雅章, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1240, 2021. |
|---|
|
|
P30-51. Examination about myelosuppression of the amrubicin in the decreased renal function patients 重森美奈1, 根來寛1, 小島すみれ1, 渡邉享平1,2, 古俵孝明1, 塚本仁1, 矢野良一3, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1241, 2021. |
|---|
|
|
P30-52. It is the fact-finding about the S-1 internal use schedule of the adjuvant chemotherapy after the gastric cancer technique 小泉綾乃1, 堀之内藍2, 藤田翔平3, 大矢周一郎3, 椙田浩文3, 神山紗代1, 鍵山智樹1, 坂本寿博1, 牧野好倫1,4, 櫻本信一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1242, 2021. |
|---|
|
|
P30-53. About the critical care center consultation situation of the cancer chemotherapy enforcement patients in our hospital 小野裕紀, 鈴木薫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1243, 2021. |
|---|
|
|
P30-54. Construction ... of the system accompanied with the update of efforts - electronic medical chart of preventive measures against HBV reactivation with the chemotherapy in our hospital 山口雄士, 金森祐紀子, 新井大地, 安田翔, 近藤章吾, 芝祐輔, 松由幸司, 塚原民夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1244, 2021. |
|---|
|
|
P30-55. What is a factor influencing an excretion delay of the methotrexate therapy in large quantities? 上瀧喬仁, 杉山典子, 堤一貴, 樋口恭子, 三輪涼子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1245-1245, 2021. |
|---|
|
|
P30-56. Examination of the factor to give the cisplatin in patients with lung cancer, Carboplatin-induced hiccups 角南博子1, 田頭尚士2, 田坂友紀1, 唐川雅生1, 大山裕紀子1, 大倉裕祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1246, 2021. |
|---|
|
|
P30-57. Investigation of the adverse event expression situation of dose-dense EC therapy in the breast cancer perioperative period and the EC therapy 石井隆義, 松田亜希子, 藤谷千紘, 米谷頼人, 坂本佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1247, 2021. |
|---|
|
|
P30-58. Examination about the effect that antimicrobial gives on treatment with immune checkpoint inhibitor in patients with non-small cell lung cancer 片岡優太1, 佐竹真衣2, 後藤桂輔1, 岡崎泰香1, 岡山有希1, 原田直美1, 高力敦茂1, 橋野泰良1,2, 若本あずさ1, 初山多恵1, 佐藤秀紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1248, 2021. |
|---|
|
|
P30-59. After the CapeOX therapy technique about a change of the weight and the nutritional status at chemotherapy start and end in adjuvant chemotherapy patients 丸山昌広, 定盛理純 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1249, 2021. |
|---|
|
|
P30-60. Can GPS and PNI become the biomarker of the immune checkpoint inhibitor in lung cancer treatment? 小山田聡1, 久松直樹1, 小島純子1, 林士元2, 野村明広2, 原信田努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1250-1250, 2021. |
|---|
|
|
P30-61. Retrospective study on the efficacy and safety of lemborexant for insomnia in cancer patients 鈴木恵子1, 田中怜1,2, 新里馨3, 池内晶哉1, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1251, 2021. |
|---|
|
|
P30-62. It is tested the effect by suvorexant for the purpose of the delirium prevention and the ramified microglia combination after the operation of patients with cancer 池内晶哉1, 田中怜1,2, 杉浦禎一3, 新里馨4, 鈴木恵子1, 若林茜1, 篠道弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1252, 2021. |
|---|
|
|
P30-63. Various comparisons and convenience of the elderly people usability test to use at the chemotherapy of patients with old cancer 風岡真実1,2, 橋本竜1,2, 吉成宏顕1, 玉井一也1, 梅田鈴香1, 入野真紀1, 黒崎隆1, 吉田雄貴1,2, 佐藤淳也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1253-1253, 2021. |
|---|
|
|
P30-64. The enforcement situation investigation of the chemotherapy for patients with elderly people blood-forming organ tumor 東謙司朗1, 平川正宏1, 山田邦夫1, 高岡杏子1, 下村泰三2, 鈴島仁2, 森岡淳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1254, 2021. |
|---|
|
|
P30-65. Examination of the effect that a proton pump inhibitor gives to an effect of oxaliplatin 橋詰淳哉1,2, 里加代子1, 中川博雄2, 原澤仁美2, 中村忠博2, 兒玉幸修2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1255-1255, 2021. |
|---|
|
|
P30-66. Examination about the expression situation of the hypothyroidism with the nivolumab administration in patients with head and neck cancer and the association with the overall survival 池部美緒1, 秦晃二郎1, 益口賢2, 田川慎二1, 池田宗彦1, 松金良祐1, 小澤奈々1, 熊谷史子1, 近森綾子1, 辻敏和1, 渡邊裕之3, 安松隆治4, 松尾美央子4, 中川尚志4, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1256-1256, 2021. |
|---|
|
|
P30-67. An example of the Pembrolizumab treatment for colon cancer during haemodialysis 新美政樹1, 浅井暁2, 西川貴広3, 福元幸子1, 谷口結基1, 荒川真帆1, 田中美帆1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1257-1257, 2021. |
|---|
|
|
P30-68. Efforts of placement and the cooperation full addition of the working full time pharmacist in the foreign cancer chemotherapy room 神山知也, 藤井元, 松浦暢子, 永井道雄, 米田航佑, 石坂忠博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1258, 2021. |
|---|
|
|
P30-69. Making of "the side effect management book" for the purpose of the elimination of the local cancer medical therapy by the pharmacist team specialized in Ishikawa cancer 藺上圭子1, 宇夛裕基1, 石嶋麗2, 桂英之3, 北出絋規4, 久保杏奈5, 熊谷要6, 志村裕介7, 高橋喜統8, 高林真貴子7, 戸塚弘幸8, 原祐輔7, 平木祥子8, 北国憲剛9, 宮澤憲治10, 山田千代子11, 山本奈歩7, 吉田幸司7, 米澤美和5, 菅幸生12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1259-1259, 2021. |
|---|
|
|
P30-70. Efforts of a terrorism phone follow-up and the number of tracing reports increase for patients during treatment with anticancer agent to a medical institution 井澤佐知子, 安藤陽子, 前川佳子, 梶原理英子, 小針依里, 庄谷美沙, 園生渚, 近藤範子, 舩塚恵子, 相根千晶, 井上晋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1260-1260, 2021. |
|---|
|
|
P30-71. An evaluation of the calculation situation of the cooperation full addition in the foreign chemotherapy and questionary survey to the health insurance pharmacy about the specific drug instruction addition 2 acquisition situation 有原大貴, 宮澤憲治, 亀井裕明, 中出恵里奈, 間宮公教, 福島信一郎, 秋山哲平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1261, 2021. |
|---|
|
|
P30-72. Examination of the information that was an opportunity to judge a health insurance pharmacy to have a doubt in prescription of the antineoplastic 小竹優希, 向井淳治, 坂本竜平, 竹原涼子, 濱崎淳哉, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1262-1262, 2021. |
|---|
|
|
P30-73. The effect that acquisition of resistance gives to migration ability and permeation ability on PARP inhibitor in the human breast cancer cell line 湯浅遥菜, 峯垣哲也, 大西蘭, 宮谷茉莉, 木崎優, 新田郁穂, 的場麻知子, 阿部結衣, 中野裕介, 辻本雅之, 西口工司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1263-1263, 2021. |
|---|
|
|
P30-74. Atezolizumab for the unresectable liver cancer, examination about the safety of the bevacizumab combination therapy 山本友佳子1, 江原美里1, 仲野宏紀2, 宮城和代1, 畑裕基1, 山下大輔1, 井上敦介1, 宮部貴識3, 吉野宗宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1264-1264, 2021. |
|---|
|
|
P31-01. The second response situation and survey about the new corona vaccination in our hospital 中村和彦, 中村嘉孝, 塚本友紀江, 横井さおり, 小竹克博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1266-1266, 2021. |
|---|
|
|
P31-02. The current situation of the APTT measurement and the APTT prolonged by the prophylactic anticoagulation using unfractionated heparin in the southern part of Saiseikai Yokohama-shi Hospital 小林奈緒, 藤巻智則, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1267-1267, 2021. |
|---|
|
|
P31-03. Side effect investigation in the favipiravir non-loading dose case 長尾彰太1, 正置耕一1, 森田聡子1, 高子優子1, 太田宗幸2, 和智万由子2, 九鬼覚2, 吉岡睦展1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1268-1268, 2021. |
|---|
|
|
P31-04. Search of the internal change change factor of active metabolite GS-441524 of the rem decibuilding by the population pharmacokinetics analysis 助石有沙美1, 糸原光太郎1, 伊藤功朗2, 米澤淳1, 佐藤裕紀1, 松村勝之1, 片田佳希1, 中川貴之1, 井本英志5, 濱田哲2, 田辺直也2, 甲斐慎一3, 大鶴繁4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1269-1269, 2021. |
|---|
|
|
P31-05. The drug control system in safe examination and our hospital of the rem decibuilding in the COVID-19 case 岐部このみ1, 日高有美1, 中村大祐1, 吹上絵里香1, 菖蒲沙織1, 八板謙一郎2, 竹内宏樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1270-1270, 2021. |
|---|
|
|
P31-06. Preparation of role - vaccine of the pharmacist in the new coronavirus vaccination system construction 松林麻里子1, 初鹿野達也1, 菅原早織1, 廣瀬まい1, 佃征樹1, 田端祥子1, 井岡礼佳1, 鶴野結花理1, 須永雅恵1, 仁井田怜子1, 山村康比古1, 前田義治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1271-1271, 2021. |
|---|
|
|
P31-07. That it is sought to a ward charge drug in the medical treatment of the COVID-19 infection 牧田亮, 古谷一平, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1272-1272, 2021. |
|---|
|
|
P31-08. Use fact-finding of the new coronavirus infection therapeutic drug in our hospital 新崎孝夫1, 三箇山宏樹1, 山本知志1, 五代寛人1, 石田篤世1, 中森靖2, 関寿人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1273-1273, 2021. |
|---|
|
|
P31-09. The effect that renal function at rem decibuilding beginning to use gives to kidney, liver function 齋藤晶仁, 青島直也, 本田和照, 横山登英, 西村康孝, 石田耕太, 細谷治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1274-1274, 2021. |
|---|
|
|
P31-10. Efforts ... for the proper use of the therapeutic drug by the new coronavirus infection (COVID-19) - ward charge pharmacist 朽木絵美1, 増淵麻実1, 石渡宏平1, 疋田絵梨1, 安武夫1,2, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1275-1275, 2021. |
|---|
|
|
P31-11. Examination of the case that the dosing period of the rem decibuilding became within five days 池田久雄1, 平田貴宏1, 神原弘和1, 甲原雄平2, 足立充司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1276-1276, 2021. |
|---|
|
|
P31-12. An example of the patients on dialysis who received treatment with the rem decibuilding for COVID-19 infection 高見澤誠1, 箕輪勇紀1, 市川裕平1, 篠原徹1, 池田知也1, 宮下貴浩1, 嶋崎剛志2, 岡田邦彦2, 関戸大司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1277-1277, 2021. |
|---|
|
|
P31-13. Examination ... in the children utilizing pharmacokinetic - population pharmacokinetics model of the nucleic acid resemblance medicine 岡田章1,2, 中村友海1, 白土愛海1, 世良庄司1,2, 永井尚美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1278-1278, 2021. |
|---|
|
|
P31-14. Effect and evaluation of the effectiveness by the febuxostat to give to a rise in uric acid level of favipiravir 植田徹1, 中蔵伊知郎2, 柿花美沙紀1, 北澤文章1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1279-1279, 2021. |
|---|
|
|
P31-15. Safe investigation of the rem decibuilding in the single institution 磯崎僚1, 栗島彬1, 塩田朋子1, 臺裕子1, 清水秀文2, 溝尾朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1280-1280, 2021. |
|---|
|
|
P31-16. Effect of the tocilizumab on cytokine storm by COVID-19 田村賢士1, 金子智一1, 金子誠1, 寺田伊知郎1, 羽田憲彦2, 立花栄三1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1281-1281, 2021. |
|---|
|
|
P32-01. Efforts of the pharmacist in the ward (regular hospital) for exclusive use of COVID-19 in our hospital 山田直輝, 山本倫数, 福村真須美, 山本浩二郎, 前田晃佑, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1284-1284, 2021. |
|---|
|
|
P32-02. Efforts and second response investigation about corona vaccine storage, the filling in our hospital 木元慎一郎, 高橋杏奈, 望月保子, 加藤寛史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1285-1285, 2021. |
|---|
|
|
P32-03. A new coronavirus infection therapeutic drug and correspondence of the pharmacy 前田龍人1, 高田正弘1, 矢野圭悟2, 炭谷容子2, 國原将洋1, 松久哲章1, 田代裕尊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1286-1286, 2021. |
|---|
|
|
P32-04. Examination about the participation of the pharmacist for the use of favipiravir in COVID-19 中園裕利華1,2, 佐々木貴之1,2, 福本真己1,2, 森尚義3, 加藤恵一1, 白木克哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1287-1287, 2021. |
|---|
|
|
P32-05. Relation of the use of therapeutic drug situation and the pharmacist in the new coronavirus infection ward 楠本将裕, 喜多岡洋樹, 毛利昌平, 中村真希, 吉田愛, 橋本知佳, 田中由起子, 田中泉, 山室蕗子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1288-1288, 2021. |
|---|
|
|
P32-06. To conduct the bringing medicine for patients with COVID-19 differentiation safely 外山昌伸, 稲垣喬大, 山中友紀子, 澤田昌司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1289-1289, 2021. |
|---|
|
|
P32-07. The current situation investigation of the infection measures for the new coronavirus infection in the health insurance pharmacy of Akashi-shi 寺沢匡史1, 湊あゆみ2, 福島綾1, 國正淳一2, 笹部洋平3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1290-1290, 2021. |
|---|
|
|
P32-08. Efforts to the in-hospital steady supply by the re-preparation of the ethanol for disinfection donated under COVID-19 outbreak 奥真由1, 宇夛裕基1, 鳥羽英理子1, 奥野由美2, 藺上圭子1, 今井富紀子1, 下平彩乃1, 中野智尋1, 松永典子1, 竹田和喜1, 瀬野晶子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1291-1291, 2021. |
|---|
|
|
P32-09. About the new corona patients acceptance and infection measures in 57 beds (small scale) of hospitals 仲村裕子1, 澤本佳織1, 提箸純子1, 関根麻友美1, 大山実2, 岡田豪3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1292-1292, 2021. |
|---|
|
|
P32-10. Usefulness of the communication with the patients with evaluation of the pharmacist activity in slight illness, the moderate COVID-19 patients hospitalization ward and iPad (TM) 鈴木寛人1, 津曲恭一1, 山形真一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1293-1293, 2021. |
|---|
|
|
P32-11. Report - of the first -3 wave in role - Kobe Red Cross hospital of the hospital pharmacist for the new coronavirus infection 鈴木早苗1,2, 小玉博一1, 福徳美幸1, 赤石憲俊1, 大津佐和子1, 堀部正記1, 安藤和佳子1, 山岸雄幸1, 津村祐子2, 森下ひろえ2, 惠良有紀子2, 岡本貴大2, 杉本啓介2, 鹿島孝子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1294-1294, 2021. |
|---|
|
|
P32-12. About patients with pneumonia hospitalization turn of eventss accompanied with the new coronavirus infection spread 浅野嘉之1, 水草博希1, 鈴木大吾1, 田中伸明1, 中村敏史1, 坂田洋1, 服部芳明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1295-1295, 2021. |
|---|
|
|
P32-13. Investigation of the patients information for problem grasp in the telephone practice 栗原啓輔, 山本圭祐, 石塚友一, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1296-1296, 2021. |
|---|
|
|
P32-14. About correspondence of the pharmacy affecting new coronavirus practice 米田奈美1, 鶴崎泰史1, 小林弘美2, 田中将英2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1297-1297, 2021. |
|---|
|
|
P32-15. Intervention of the palliative care team to the COVID-19 patients who had the onset in diamond Princess number 辻茉莉香1,2, 佐藤弘子1, 吉村歩1, 五十嵐俊1,2, 高橋賢成1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1298-1298, 2021. |
|---|
|
|
P32-16. AntiSARS-CoV-2 antibody possession fact-finding of the healthcare worker of the first wave end time of COVID-19 in this country 下村夏穂1, 真野泰成2, 鈴木立紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1299-1299, 2021. |
|---|
|
|
P32-17. Relation of the pharmacist in the new coronavirus infection cluster generating institution support activity in Okayama 石橋真実1, 畑賢俊2, 杉原功3, 藤原敬作4, 齋藤博則5, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1300-1300, 2021. |
|---|
|
|
P33-01. AS activity by the ward pharmacist in the hospital where AST is not installed in 大塚登志喜, 中根望, 高橋正明, 富島淳司, 中村徹, 長澤法子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1304-1304, 2021. |
|---|
|
|
P33-02. An example of the infective endocarditis that suffered from an antimicrobial choice by an adverse event 塩田亮介, 柏原道志, 本田勝亮, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1305-1305, 2021. |
|---|
|
|
P33-03. Examination of the disease severity classification in the Clostridioides (Clostridium) difficile infection for Japanese 内田和葉, 柏原道志, 澤昇平, 本田勝亮, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1306-1306, 2021. |
|---|
|
|
P33-04. Intervention of the pharmacist for purulent spondylitis, the pacemaker infection of the community-associated MRSA origin 渡辺圭1, 三浦義彦1, 中村翔太郎1,2, 礒江雄人1, 小川惟弘1, 宮城泰雄3, 石井庸介3,4, 伊勢雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1307-1307, 2021. |
|---|
|
|
P33-05. 2 cases of a bone, the soft tissue infection with resistant Pseudomonas aeruginosa treated with a highly-concentrated antimicrobial local administration 玉造竜郎1, 田中道子2, 吉川泰司3, 杉田栄樹1, 阿部和正1, 岡田菜津美1, 関戸匡恵1, 縄田修一1, 佐々木忠徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1308-1308, 2021. |
|---|
|
|
P33-06. Approach for the antimicrobial proper use in our hospital 安田陽子1, 福山博務1,6, 小倉健一2,6, 眞柄雄樹3,6, 松元謙治3,6, 高田淳子4,6, 杉田知妹5,6, 塩地園代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1309-1309, 2021. |
|---|
|
|
P33-07. The use of cephamycin system medicine situation investigation after our hospital AS activity start 成島俊輔1, 鯉沼縁1, 青山美恵子2, 武藤博美3, 原信田努1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1310-1310, 2021. |
|---|
|
|
P33-08. Examination about the effect that a risk factor of the acute renal failure onset in the administration of the ST medical mixture and acute renal failure give to prognosis 清水優貴1, 平井利典2, 山田千祐1, 西野真紀1, 小林恵美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1311-1311, 2021. |
|---|
|
|
P33-09. A case of infection after joint replacement in which linezolid-induced neutropenia was controlled with tedizolid 小林俊介1, 加瀬雅士2, 安武夫3, 野上由佳1, 松原正明2, 北岡晃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1312-1312, 2021. |
|---|
|
|
P33-10. The effect that tazobactam/piperacillin at vancomycin combination gives for acute renal failure 柏木悠里, 伊部裕太, 石郷友之, 北川学, 木明智子, 藤居賢, 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1313-1313, 2021. |
|---|
|
|
P33-11. Effect ... of examination - fetal circulatory failure about the deviation factor of the Gentamicin blood level in neonates 本田勝亮1, 亀井七海1, 神谷早織1, 柏原道志1, 元重京子2, 杉浦弘2, 大木茂2, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1314-1314, 2021. |
|---|
|
|
P33-12. One case that suffered from treatment of MRSA osteomyelitis 赤星璃, 栗崎貴啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1315-1315, 2021. |
|---|
|
|
P33-13. The effectiveness every dose of the daptomycin for the gram-positive bacteria infection including the MRSA and safety assessment 田杭直哉1, 近藤匡慶1, 菅谷量俊1, 鈴木美子2, 丸山弘3, 高瀬久光1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1316-1316, 2021. |
|---|
|
|
P33-14. Examination about the administration of genetically-modified thrombomodulin preparation days for the disseminated intravascular coagulation syndrome associated with the infection in the intensive care unit 菅野雄太1, 向井潤一2, 鎌田裕介1, 菅原大輔1, 久保田理恵2, 尾鳥勝也3,4, 高岩徹幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1317-1317, 2021. |
|---|
|
|
P33-15. Efforts and evaluation of the antimicrobial proper use for the clarithromycin-resistant Helicobacter pylori infection 深津昌弘1, 水野貴仁1, 梅村拓巳1, 大口裕美1, 松本茂1, 岩津慎次郎1, 竹中宏之2, 黒岩正憲2, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1318-1318, 2021. |
|---|
|
|
P33-16. Example that was given vancomycin intrathecally for MRSA meningitis after VP shunts 安河内寿成, 中野祐樹, 大竹野久雄, 蓮輪博嗣, 横尾賢乗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1319-1319, 2021. |
|---|
|
|
P33-17. About the active intervention of the AST pharmacist in the middle scale hospital and the evaluation 栗崎貴啓1, 栗田澄香1, 川辺雅美2, 井上耕太郎3, 今村文哉4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1320-1320, 2021. |
|---|
|
|
P33-18. Antimicrobial early monitoring expansion and AST duties improvement effect by the cooperation with the specialist in infection 小川暁生1,2, 三上友寛1,2, 門居久嗣1,2, 淵上尚彦1,2, 桐畑美里2, 近澤秀己2, 伊庭雅代2, 瀬戸康子2, 遠藤正憲1,2, 伊藤貴優2, 高橋良一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1321-1321, 2021. |
|---|
|
|
P33-19. Attempt of the intervention to the blood culture-positive patients by our hospital pharmacist 城間盛彦1, 玉城哲子1, 武富美貴子1, 仲俣桃華1, 久場謙也2, 金城正樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1322-1322, 2021. |
|---|
|
|
P33-20. Comparison of the surgical-site infections protective efficacy by the difference of the perioperative antimicrobial in all total hip replacement 河原陽介1, 木内貴章1, 羽田野翔太1, 森川貴弘2, 加藤良治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1323-1323, 2021. |
|---|
|
|
P33-21. Examination of the acute renal failure (AKI) onset risk at vancomycin and tazobactam/piperacillin combination 崎山達矢, 硲貴和子, 井上咲那, 河口義隆, 幸田恭治, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1324-1324, 2021. |
|---|
|
|
P33-22. Usefulness evaluation ... of the support for patients with pharmacist-led antimicrobial proper use support team - yellow staphylococcemia 古川大樹1, 伊藤嘉英1, 大橋武司1, 林房江2, 菱田志乃3, 中尾彰宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1325-1325, 2021. |
|---|
|
|
P33-23. Usefulness ... of the long time administration in investigation - bacteremia treatment about the administration of beta-lactam derivative antimicrobial time 中谷亮介1, 岡田雅弥1, 三宅美有紀1, 野際俊希1, 稲葉静香1, 藤井美紀1, 奥野千晶2, 下川福子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1326-1326, 2021. |
|---|
|
|
P33-24. Fact-finding of the antimicrobial therapy for the infectious aortic aneurysm in our hospital 加戸義大1,5, 奥村佳史1,5, 平松梓1,5, 松本健佑4,5, 田村幸二2,5, 平田喜裕3,5, 森田孝子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1327-1327, 2021. |
|---|
|
|
P33-25. One patient who vancomycin moderate degree-resistant staphylococcus aureus was suspected as a causative organism of the purulent spondylitis, and chronically administered linezolid 大上亜樹1, 福原伸治1, 松田翔平1, 今津智子1, 山崎美保1, 小濱邦彦2, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1328-1328, 2021. |
|---|
|
|
P33-26. Investigation about the actual situation of the thrombocytopenia with the oxazolidinone system antiMRSA medicine 中川ちひろ1, 井出和男1, 岡村央3, 勝亦秀樹2, 川邉桂1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1329-1329, 2021. |
|---|
|
|
P33-27. Examination of impaired renal function frequency and the risk factor of tazobactam/piperacillin in patients with malignant tumor 有馬崇充1,2, 佐野智望1,2, 新藤美香1,2, 石川光信1, 赤木徹1, 橋本浩伸1, 山口正和3, 塩塚美歌2, 小林治2, 岩田敏2, 古川哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1330-1330, 2021. |
|---|
|
|
P33-28. Fact-finding ... based on administrative data using prescription situation - MDV analyzer of the oral antimicrobial for acute respiratory tract infection in the outpatient department and the acute diarrhea 椙山聡一郎1,3, 清水博之2, 比嘉令子3, 小杉三弥子1, 工藤誠3, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1331-1331, 2021. |
|---|
|
|
P33-29. Association with the MIC distribution rate for %T>MIC and Pseudomonas aeruginosa of the use of meropenem case 川崎祥平1, 小林義和1, 吉原基2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1332-1332, 2021. |
|---|
|
|
P33-30. Effect by the change on fosfomycin from perioperative infection prophylaxis antimicrobial cefazolin 古庄弘和, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1333-1333, 2021. |
|---|
|
|
P33-31. The antimicrobial proper use support activity evaluation that it is led by the AST working full time pharmacist in the scale hospital in infection specialist absence 沢田佳祐1,2, 中谷丈之1,2, 矢田真理1,3, 上山孝太1,4, 東新1,5, 福田康二1,6, 河野修治2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1334-1334, 2021. |
|---|
|
|
P33-32. Effect on surgical-site infections of the otolaryngology domain by the intervention of the pharmacist and antimicrobial consumption 石野清亮1, 柏原道志1, 本田勝亮1, 岡村純2, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1335-1335, 2021. |
|---|
|
|
P33-33. Intervention of our hospital AST accompanied with vancomycin supply restrictions and the clinical effect 青戸和宏, 幸前里奈, 小阪直史, 四方敬介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1336-1336, 2021. |
|---|
|
|
P33-34. A change of the foreign oral antimicrobial consumption and drug resistant bacterium rate of detection in our hospital and investigation about the correlation 平尾祐樹, 佐々英也, 内山耕作, 鈴川誠, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1337-1337, 2021. |
|---|
|
|
P33-35. One case of the infective endocarditis with the Lactobacillus genus 奥村佳史1,5, 加戸義大1,5, 平松梓1,5, 田村幸二2,5, 平田喜裕3,5, 松本健佑4,5, 森田孝子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1338-1338, 2021. |
|---|
|
|
P33-36. Rearward multicenter study about the effect of DAAs under the true clinical practice to the type 1 HCV patients 嘉屋道裕1, 中村和代13, 杉山恭平13, 木苗あゆみ13, 山口紘生2, 浮田浩利3, 氏家智香5, 加藤純6, 影山富士人7, 名倉真理子8, 松下久美9, 杉上香織10, 石田紘基11, 名波章子12, 小田切圭一4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1339-1339, 2021. |
|---|
|
|
P34-01. Efforts for a degree of purity evaluation and hygiene state maintenance of the in-hospital conveyance tray of the injection drug 池淵明美伽, 石原慎之, 高橋由, 山戸和美, 大仁田哲修, 岡崎美香, 尾村賢司, 玉木宏樹, 矢野貴久, 直良浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1342-1342, 2021. |
|---|
|
|
P34-02. Evaluation for improvement in hygiene state in the formulations environment 山戸和美, 岡崎美香, 高橋由, 石原慎之, 池淵明美伽, 亀井美穂, 泙誠一, 玉木宏樹, 矢野貴久, 直良浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1343-1343, 2021. |
|---|
|
|
P34-03. Efforts for the pneumococcal vaccine inoculation communalization in our hospital 岸本卓, 浜元善仁, 翁長真一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1344-1344, 2021. |
|---|
|
|
P34-04. Efforts for the antimicrobial proper use by the pharmacist in the intensive care unit 友納保幸, 曽我弘道, 福島将友, 町田聖治, 入江利行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1345-1345, 2021. |
|---|
|
|
P34-05. Introduction of the specimen culture test order by the pharmacist based on the protocol in the seriously disabled child person ward and the effect 森本真仁, 浜田茂明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1346-1346, 2021. |
|---|
|
|
P34-06. The current situation investigation of the infection with ward charge pharmacist treatment intervention and examination of the usefulness of the pocket edition tool 前田陽平1,2, 松澤弘志2, 菅原早織2, 石田留美2, 秦哲磨2, 梅川誠2, 木下理恵2, 小林崇史2, 丸山真依2, 諏訪淳一2, 大西真央2, 石井瑞2, 川島千夏2, 安田陽子2, 田中義幸2, 陣内博之2, 佐藤直行2, 石原溶子2, 八木原栄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1347-1347, 2021. |
|---|
|
|
P34-07. Prophylactic oral antimicrobial of mandibular extraction of impacted wisdom teeth in the dentistry outpatient department and the normal tooth extraction and clinical statistics investigation of surgical-site infections 吉田謙介1,2, 児玉泰光2, 永井孝宏2, 金子奨太1, 齋藤千愛1, 高木律男2, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1348-1348, 2021. |
|---|
|
|
P34-08. Questionnaire survey to a drugstore pharmacist in the antimicrobial proper use 青嶋瑞樹1, 笹野央1, 宿利美香1, 梛野健1, 月岡良太2, 宮野康央3, 佐藤卓也3, 荒川隆太郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1349-1349, 2021. |
|---|
|
|
P34-09. Examination of the risk factor about the change of a serum Na level with the antimicrobial administration and the blood pressure 緒方雅章, 井上玲子, 伊藤晴樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1350-1350, 2021. |
|---|
|
|
P34-10. Inflection of J-SIPHE data in the infection measures regional alliances network antimicrobial consumption surveillance 中島貴史1,2, 石田茂1, 山田孝明1, 佐々木恵一1, 山下祐二1, 要幸典1, 金谷朗子1, 辻敏和1, 廣田豪1, 江頭伸昭1, 下野信行2, 家入一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1351-1351, 2021. |
|---|
|
|
P34-11. Efforts for the prophylactic antimicrobial proper use in the larynx microdissection and the effect 鈴木悠斗1, 橋本詠次1,2, 松崎洋海3, 菊池憲和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1352-1352, 2021. |
|---|
|
|
P34-12. Inspection of the intervention effect on staphylococcus aureus bacteremia by the AST exclusive duty of the pharmacist 梶原敬悟1, 河田武志1, 濱岡照隆1, 相良義弘1, 守分正2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1353-1353, 2021. |
|---|
|
|
P34-13. The analysis of the risk factor for the Clostridioides difficile infection (CDI) onset reduction and future problem 守田侑真1,2, 大矢智則1,2,3, 大竹孝明2, 高橋和郎2, 西尾こゆる2, 宮田桃誉2, 佐藤淳也1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1354-1354, 2021. |
|---|
|
|
P34-14. The effect that antimicrobial proper use and the nutritional status of patients give for SSI development in the surgery 小関崇文1,2, 大貫敏明1,2, 日向早苗2,3, 足立智子2,3, 大場雄一2,4, 小舛修三2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1355-1355, 2021. |
|---|
|
|
P34-15. Inspection of the effect of the antimicrobial proper use support round that a pharmacist played a key role 大戸祐治1,2,3, 中田麻里1,3, 新井祐司2, 高久美穂2, 岡田壮令2, 田中克巳1,3, 佐々木忠徳3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1356-1356, 2021. |
|---|
|
|
P34-16. The intervention situation and effect in the bacteremia case of Kure medical center Antimicrobial Stewardship Team (AST) 高田正弘, 前田龍人, 坂井原美希, 星川果南, 川成昂, 田頭尚士, 國原将洋, 松久哲章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1357-1357, 2021. |
|---|
|
|
P34-17. It is ... through making, the operation of the list of efforts - oseltamivir prophylaxis patients of the pharmacist at seasonal flu outbreak 末永拓也, 岩尾恭寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1358-1358, 2021. |
|---|
|
|
P34-18. Exploration of factors for SHEA/IDSA severity classification in Clostridioides difficile infection 重成大介1, 岡野翔1, 北田衛1, 高橋詩織1, 太田明秀1, 前田孝則2, 本野純子2, 宮木未果2, 伊東敏弘2, 中田浩雅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1359-1359, 2021. |
|---|
|
|
P34-19. Change of consumption and resistant bacteria of the oral antimicrobial 石田茂伸1,2, 竹村陽介2,3, 藤原大亮1,2, 田川優介1, 眞野裕1, 多胡友絵1, 星育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1360-1360, 2021. |
|---|
|
|
P34-20. Usefulness of the early intervention of the pharmacist for blood culture-positive patients 福本真己1,2, 佐々木貴之1,2, 中園裕利華1,2, 海住博之3, 森尚義4, 加藤恵一1, 白木克哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1361-1361, 2021. |
|---|
|
|
P34-21. Adherence analysis of the oseltamivir in the influenza postexposure prophylaxis purpose in the healthcare worker 辻中海斗1, 岡田直人1,2, 藤原範子2, 合田光寛3, 八木健太3, 相澤風花1, 濱野裕章4, 櫻田巧1, 桐野靖1, 座間味義人1,4, 東桃代2, 石澤啓介1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1362-1362, 2021. |
|---|
|
|
P34-22. Report of the use situation according to the preventive measures against infection addition of the 2019 injection antimicrobial in infection measures cooperation common platform (J-SIPHE) 遠藤美緒1, 都築慎也1, 浅井雄介1, 田島太一1, 坂口みきよ1, 藤井直樹1, 松永展明1, 早川佳代子1,2, 大曲貴夫1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1363-1363, 2021. |
|---|
|
|
P34-23. The effect that the continuous intervention of the pharmacist gives for the treatment of patients with Escherichia coli bacteremia on injectable antimicrobial 篠田康孝, 大橋健吾, 松岡知子, 新井かおり, 堀田奈央, 浅野泉, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1364-1364, 2021. |
|---|
|
|
P34-24. Examination of the contribution of the risk factor in Clostridioides difficile infection recurrence 山根千尋, 岡冨大輔, 山西紀子, 樫本考司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1365-1365, 2021. |
|---|
|
|
P34-25. Improvement of the prophylactic antimicrobial administration timing before operation by the change of the clinical path 田中博和, 早志尚, 内川瞳, 山下大貴, 立石裕樹, 重松由加, 安永実沙, 宮津大輔, 渡邊裕之, 平川雅章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1366-1366, 2021. |
|---|
|
|
P34-26. For efforts - hepatitis B to vaccination of the staff, measles, rubella, epidemic parotitis, chickenpox - economical and effective vaccination 白川哲1, 山田ゆみ2, 武田朋子2, 中村忠之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1367-1367, 2021. |
|---|
|
|
P34-27. Examination of the risk factor of the patients that carbapenem-resistant Enterobacteriacae bacteria were detected 大石泰也1,2, 宮川雅行1, 佐伯めぐみ1, 山下世知子1, 石丸敏之2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1368-1368, 2021. |
|---|
|
|
P34-28. Comparison between cefmetazole and surgical site-related infection prophylaxis of the flomoxef in the large intestine-related surgery 濱田恵輔, 門口直仁, 田中広大, 濱本真歩, 田中聡, 段松雅弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1369-1369, 2021. |
|---|
|
|
P35-01. About efforts of our hospital for antiHIV Yakuin Todokoro 大道淳二1, 石橋真実1, 岡邊千聖1, 佐久川亮2, 宗好裕子3, 片山久留美4, 東郷和美5, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1371-1371, 2021. |
|---|
|
|
P36-01. Example that dysphagia was improved, and consisted of amantadine reduction if a diet intake was possible 伊東健一1,6, 細山田百梨2,6, 山崎里織3,6, 松尾剛志4,6, 白尾一定5,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1373-1373, 2021. |
|---|
|
|
P36-02. Fact-finding of the glycemic control in nondiabetic patients during hyperalimentation administration 江端祥世, 川上辰三, 田中智也, 村瀬博子, 新免徹, 樋本繭子, 高瀬尚武, 三木育子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1374-1374, 2021. |
|---|
|
|
P36-03. Investigation of the effect that the diet advice which a drugstore pharmacist receives gives in a potassium level 山下祥史1, 田口浩史1, 福井大樹1, 森岡美行1, 淺井季晴1, 河野未佑1, 小川愛2, 廣瀬隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1375-1375, 2021. |
|---|
|
|
P37-01. Fact-finding about delirium high risk patients care addition in our hospital 森川莉沙, 鶴崎大, 佐々木祐樹, 菊池憲和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1377-1377, 2021. |
|---|
|
|
P37-02. Efforts for the medical treatment investigation of patients with schizophrenia and the improvement in adherence by the pharmacist 石川晋平1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1378-1378, 2021. |
|---|
|
|
P37-03. Attitude survey about the medication counseling to patients with mental disorder for health insurance pharmacy pharmacists 福山雄卯介1,2, 宮崎敦2, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1379-1379, 2021. |
|---|
|
|
P37-04. Decrease of the sleeplessness medicine by the medication time change accompanied with the lights-out extension and the benzodiazepine system sleeping drug 青木竣哉1, 関千帆2, 石川蓮太郎2, 星野達也2, 佐藤尚子2, 高田勝利1, 須鎌建1, 君和田貢1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1380-1380, 2021. |
|---|
|
|
P37-05. About the efficacy and safety of nalmefene in the treatment of alcoholism 北侑未, 竹中克之, 森京子, 山田千代子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1381-1381, 2021. |
|---|
|
|
P37-06. Effect of brexpiprazole on antipsychotic-induced hyperprolactinemia 加藤美穂1, 肥田裕丈1, 小西郁代1, 松永安未1, 岩本邦弘2, 尾崎紀夫2, 山田清文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1382-1382, 2021. |
|---|
|
|
P37-07. Case report: The change that the antipsychotics reduction from multiple drug large doses gave in heart rate (RHR) at rest 津倉由里1, 宮嶋康人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1383-1383, 2021. |
|---|
|
|
P37-08. Usefulness inspection of the Clozapine TDM for treatment optimization 渡辺研弥1, 野崎啓子2, 陣野大輔1, 阿部裕也1, 平田祥一朗2, 鈴木二妙香2, 後藤將之2, 一瀬瑞絵2, 山本慎之助2, 堀越翔2,3, 金子春香2, 須藤孝浩1, 黒田純子1, 三浦至2, 矢部博興2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1384-1384, 2021. |
|---|
|
|
P37-09. 1 case that blonanserin tape was effective for the delirium in the patients who were hard to take medicine 中尾なつみ1, 田村安希1, 中島誠2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1385-1385, 2021. |
|---|
|
|
P37-10. The effect investigation that psychotropic drug weight loss gives to anxiety 五味和彦1, 山本和幸1, 田端真理生1, 福井將郎2, 鵜澤正寛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1386-1386, 2021. |
|---|
|
|
P37-11. Questionary survey (targeted for a staff of nurse, rehabilitation course) about the understanding degree of the psychotropic drug 清田晃司, 河野明子, 小林玲子, 越田朋美, 竹井純子, 和田こず恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1387-1387, 2021. |
|---|
|
|
P37-12. Efforts of the psychiatry liaison team in the acute phase hospital of the regular psychiatrist absence 山本浩二郎, 井上綾子, 山田直輝, 山本倫数, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1388-1388, 2021. |
|---|
|
|
P37-13. Examination of the effect that the difference of antipsychotics to use gives to subsequent schizophrenia treatment 河合真梨子1, 落合理路2,3, 榎本了三2, 梁川剛生2, 早坂俊亮4, 鈴木立紀1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1389-1389, 2021. |
|---|
|
|
P37-14. The significance that introduction of the sustained-release parenteral injection to schizophrenia treatment gives to the adequacy of the prescription dose 沖永慶太1, 落合理路2,3, 河合真梨子1, 榎本了三2, 梁川剛生2, 早坂俊亮4, 鈴木立紀1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1390-1390, 2021. |
|---|
|
|
P37-15. Early intervention example of the drug-induced extrapyramidal symptoms by the drugstore pharmacist 前原雅樹, 杉山正康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1391-1391, 2021. |
|---|
|
|
P38-01. Investigation about the consciousness to medication during the pregnancy, the nursing 田中優希, 赤坂寛子, 碁盤智子, 西川かおり, 西川須美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1393-1393, 2021. |
|---|
|
|
P38-02. Relation of the pharmacist to the lactational medical therapy in the maternity ward inpatient 田村美穂, 太田千絢, 石村光, 有近仁美, 坂井康仁, 幸田恭治, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1394-1394, 2021. |
|---|
|
|
P38-03. For each one case that a pharmacist intervened in for the AD/HD patients during atomoxetine methylphenidate remedy at the obstetrics and gynecology department clinic from early pregnancy 野口時恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1395-1395, 2021. |
|---|
|
|
P38-04. The case that resulted in neonates maladjustment syndrome to children as a pregnant woman took antidepressant in our hospital 蓮尾憲作1, 森侑治2, 藤井績3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1396-1396, 2021. |
|---|
|
|
P38-05. One patient who measured a milk concentration at perospirone internal use, and examined the effect on children 田川菜緒1,2, 小川泰葉1,2, 若林仁美1,2, 小林麻美1,2, 縄田修一1,2, 田中祥子3, 町田晃一4, 神谷太郎5, 佐々木忠徳1,2, 水野克己5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1397-1397, 2021. |
|---|
|
|
P38-06. The duties results of "the pregnancy and the medicine outpatient department" in the Kumamoto Red Cross hospital 秋吉明子, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1398-1398, 2021. |
|---|
|
|
P38-07. The in-hospital pharmacist duties in the pregnant woman nursing mother medical therapy domain and questionary survey of the Akashi district health insurance pharmacy 小川智孝, 川崎紀香, 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1399-1399, 2021. |
|---|
|
|
P38-08. Risk assessment for the use of drug during pregnancy using the case database in the pregnant woman 平澤裕美子1, 田頭尚士2, 上野杏菜1, 田坂友紀1, 山本宏3, 大倉裕祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1400-1400, 2021. |
|---|
|
|
P38-09. Examination of safety in administration of PROPESS vaginal preparation 川田希帆, 寺岡知香, 宮部祐子, 森井絵莉香, 山田敦子, 石川佳澄, 漆崎智香子, 下辻恒久, 山東真寿美, 坂上嘉浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1401-1401, 2021. |
|---|
|
|
P38-10. Theoretical consideration about the safety at mother's milk shift and nursing of loxoprofen 大久保正1,2, 田中真理子2, 大久保七枝3, 大久保節子4, 大久保美穂5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1402-1402, 2021. |
|---|
|
|
P38-11. Safe investigation in the polyethylene glycol preparation administration to a pregnant woman 福井幸, 宮越貴之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1403-1403, 2021. |
|---|
|
|
P38-12. Examination of the dose per weight of the zinc acetate hydrate in the premature baby 寺西真凜1, 先名健太2, 槙田芳1, 東修司1, 和泉秀明1, 田畑裕和1, 小原郁司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1404-1404, 2021. |
|---|
|
|
P38-13. Examination about a risk factor and the correspondence of the postpartum haemorrhage 木藤一美, 池森明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1405-1405, 2021. |
|---|
|
|
P39-01. Rearward observation of the hematopoietic effect with the SGLT2 inhibitor in type 2 diabetes 吉田雄貴1,2, 大矢智則1,2, 橋本竜1, 風岡真実1,2, 吉田明4, 佐藤淳也1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1408-1408, 2021. |
|---|
|
|
P39-02. About pharmacist-led carbohydrate counting introduction and operation (about carbohydrate counting education hospitalization and a setup of the carbohydrate counting outpatient department) 田中こずえ1, 山下恵梨香1, 上西咲穂1, 三宅はなこ2, 佐野結衣子2, 伊藤耕史2, 衛藤直子3, 串本真紀3, 本田友生1, 井戸垣融4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1409-1409, 2021. |
|---|
|
|
P39-03. Examination ... about the background of use situation - high dose patients of the liraglutide in the Komaki Municipal Hospital 水谷貴樹, 奥村允基, 岡村奈保, 戸田康裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1410-1410, 2021. |
|---|
|
|
P39-04. Examination - using search - MMAS-8 of the factor affecting the medication adherence of patients with diabetes 久保田樹, 津下遥香, 河野浩之, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1411-1411, 2021. |
|---|
|
|
P39-05. Investigation about the risk factor of the patients who presented with carbohydrate metabolism abnormality by inhalational steroid medicine administration for respiratory illness 竹内和貴子, 澤昇平, 内田和葉, 西村英子, 青木勇樹, 山本圭祐, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1412-1412, 2021. |
|---|
|
|
P39-06. Effect (the second report) that metformin and proton pump inhibitor combination give to glycemic control 石田翔1, 吉川明良2, 松本俊治1, 開浩一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1413-1413, 2021. |
|---|
|
|
P39-07. Examination - decreased renal function speed of the kidney protection of the drug in patients with diabetes for an index ... 守田彩文, 吉田陽, 西村博之, 塩山由紀, 高田雅文, 鈴木知子, 栗並昇, 梶原敬三, 陣内克紀, 稗島州雄, 杉山正悟, 陣内秀昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1414-1414, 2021. |
|---|
|
|
P39-08. Examination of the uric acid-lowering effect with the SGLT2 inhibitor in patients with hyperuricaemia merger diabetes 中嶋丈晴, 菅野和彦, 石本昌裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1415-1415, 2021. |
|---|
|
|
P39-09. Examination of the effect to give the early blood pressure, pulse after the Dulaglutide start 武藤崇, 下田賢一郎, 星野輝彦, 杉山留美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1416-1416, 2021. |
|---|
|
|
P39-10. The effectiveness of the SGLT2 inhibitor supplementation in patients with type I diabetes mellitus and safe examination 加藤芽生子1, 早川伸樹1,2, 津川透1,3, 福井愛子1, 亀井浩行1, 桑原宏貴3, 森川理佐2, 西田康貴2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1417-1417, 2021. |
|---|
|
|
P39-11. The effectiveness of the therapy with GLP-1 receptor agonist and sustained-release insulin preparation in patients with type 2 diabetes and safe examination 服部翔太1, 早川伸樹1,2, 津川透1,3, 福井愛子1, 亀井浩行1, 桑原宏貴3, 重康裕紀2, 轟木秀親2, 鈴木敦詞2, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1418-1418, 2021. |
|---|
|
|
P39-12. Examination of the usefulness in the continuation treatment long-term after GLP-1 receptor agonist liraglutide 1.8 mg/day increase in quantity 久嶋真紀子, 野口景子, 葛葉守, 中野玲子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1419-1419, 2021. |
|---|
|
|
P39-13. One case that dehydration of the lack of self-consciousness was hepatic dysfunction, the cause of the sudden rise of the blood glucose level 新井尚1, 八木澤恭子2, 藤田あゆみ3, 杉浦伸哉3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1420-1420, 2021. |
|---|
|
|
P39-14. Example that the medication follow of the pharmacist was able to contribute to prevention of exacerbation of diabetes 坂本和紀1, 藤田あゆみ2, 杉浦伸哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1421-1421, 2021. |
|---|
|
|
P39-15. 2 cases that the multi-type of job cooperation and medicine medicine cooperation in the diabetes education hospitalization brought the effective medical therapy after the discharge 土屋貴1,2, 倉田賢生2, 安河内尚登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1422-1422, 2021. |
|---|
|
|
P39-16. The coronary heart disease incidence prediction-style development of patients with type 2 diabetes and inspection 山下康也1, 野崎洋一1, 北島里奈1, 井上岳1,2, 松原聖1,3, 堀井剛史4,5, 毛利順一4,5, 厚田幸一郎4,5, 松原肇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1423-1423, 2021. |
|---|
|
|
P39-17. Patients questionary survey about usability and the behavior modification of the FreeStyle livret 喜友名侑舞, 田仲祐子, 久田潤平, 喜多洋嗣, 白木萌 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1424-1424, 2021. |
|---|
|
|
P39-18. Examination of the result of a measurement of free-style livret and the POCT apparatus in the blood sugar determination of patients with postoperative diabetes of the view on femur fracture blood 豊田愛恵, 見尾谷昇, 細野真吾, 堀浩子, 山崎崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1425-1425, 2021. |
|---|
|
|
P40-01. Usefulness of the dose evaluation of the antivirus chemotherapeutant by the pharmacist 霍間尚樹, 金子睦志, 池田考介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1427-1427, 2021. |
|---|
|
|
P40-02. Investigation to interview form about the phosphorus content out of the preparation and a manufacturer 鈴木寛1,2, 小川裕子1, 漆畑理帆1, 佐橋貴美子1, 柏倉康治2, 田中紫茉子2, 内田信也2, 並木徳之2,3, 影山慎二4, 山内克哉1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1428-1428, 2021. |
|---|
|
|
P40-03. Search of the factor affecting the medication adherence of patients with chronic kidney disease using MMAS-8 河野浩之, 津下遥香, 久保田樹, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1429-1429, 2021. |
|---|
|
|
P40-04. Relative examination of the use situation and P, the Ca of the laxative in patients on dialysis and the phosphate binder 内田朱美1, 續政哉1, 門脇大介2, 奥田佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1430-1430, 2021. |
|---|
|
|
P40-05. Examination of the factor affecting the multiple drug remedy in foreign haemodialysis patients 永野浩之1,2, 櫛山暁史2, 小岩まの1, 高橋雅弘2, 眞壁秀樹1, 友利浩司3, 岡田浩一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1431-1431, 2021. |
|---|
|
|
P40-06. An example of patients in CKD during the eldecalcitol internal use that developed a high Ca blood symptom as Ca intakes derived from a diet increased 藤巻宥紀1, 藤巻浩子1, 松永千広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1432-1432, 2021. |
|---|
|
|
P40-07. Examination of the copper deficiency risk by zinc deficiency and the supplement in haemodialysis patients 菱田啓介, 中島里菜, 松井治幸, 植優衣, 田村友香, 米澤彩, 末次悠衣, 倉田裕美, 岡田悠子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1433-1433, 2021. |
|---|
|
|
P40-08. Medical treatment evaluation by changes from amino acid preparation for the renal failure in patients on dialysis to general amino acid preparation 花木真美子1, 高橋仁美1, 江尻朋子2, 成山真一2, 澁谷浩二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1434-1434, 2021. |
|---|
|
|
P40-09. Role elucidation of the indoxyl sulfate in the kidney condition of a patient extension of the ischemic acute renal failure concurrence diabetes model rat 道脇なつみ1, 鵜木隼平1, 小山直子1, 下河優奈1, 桑原孝成2, 向山政志2, 成田勇樹1,3, 城野博史1,3, 齋藤秀之1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1435-1435, 2021. |
|---|
|
|
P40-10. About high blood pressure prevalence, the association between decreased renal function disease severity and remedy antihypertensive medications for patients with coronary disease 町田聖治, 曽我弘道, 友納保幸, 富田敏章, 入江利行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1436-1436, 2021. |
|---|
|
|
P40-11. Examination of timing for determining anemia improvement effect in dialysis patients taking roxadustat 篠原慶次1, 續政哉1, 門脇大介2, 奥田佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1437-1437, 2021. |
|---|
|
|
P40-12. Elucidation of the molecular toxicologic role of the indoxyl sulfate in the kidney fibrosis formation 侯慧嫻1, 薮内希実1, 郡田菜緒1, 成田勇樹1,2, 城野博史1,2, 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1438-1438, 2021. |
|---|
|
|
P41-01. Fact-finding of the polypharmacy intervention situation judging from the calculation results of the drug global assessment adjustment addition 森崎崇文, 星野輝彦, 下田賢一郎, 杉山留美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1440-1440, 2021. |
|---|
|
|
P41-02. Investigation about the intervention effect by the dementia care team in patients with stroke 林太祐1, 西野拓也2, 飯田謙司1, 藤村由梨香1, 吉田綾奈1, 庄司知紘1, 伊勢雄也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1441-1441, 2021. |
|---|
|
|
P41-03. Regarding the relationship between drug reduction and readmission rate in geriatric hospitals 片原憂斗1, 小原朋也1, 瀧川美和1, 大堀薫1, 島崎良知1, 石川譲治2, 岩切理歌3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1442-1442, 2021. |
|---|
|
|
P41-04. About an association between drug and injury showing frequent use drug investigation of the fragile bone fracture injury patients, use 益成宏1, 山本学2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1443-1443, 2021. |
|---|
|
|
P41-05. A role and efforts of the pharmacist in the elderly people medical therapy 高吉未奈, 真鍋扶美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1444-1444, 2021. |
|---|
|
|
P41-06. Change of disintegration and the drug release behavior when we used thickness adjustment food at tablet remedy 下山哲哉, 賀好玲奈, 上田菜々子, 伊藤邦彦, 小林道也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1445-1445, 2021. |
|---|
|
|
P41-07. About the activity of the dementia care team in our hospital 磯田祥, 上ノ段友里, 縄田好一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1446-1446, 2021. |
|---|
|
|
P42-01. Two cases that we changed from other antiepileptic drugs to Perampanel hydrate monotherapy 石原慎, 吉年正宏, 岩崎浩子, 竹上学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1449-1449, 2021. |
|---|
|
|
P42-02. Efforts for the polypharmacy improvement in our hospital 辻屋朝美, 尾上雅英, 三宅麻文, 上ノ山和弥, 日高貴生, 岡田麻佑, 野村勇太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1450-1450, 2021. |
|---|
|
|
P42-03. One patient who received clindamycin primaquine combination therapy for pneumocystis pneumonia 梅田鈴香1,2,3, 吉成宏顕1, 入野真紀1, 吉田明2, 佐藤淳也1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1451-1451, 2021. |
|---|
|
|
P42-04. The effect of the RAS inhibitor giving it to anemia of patients with heart failure that a left ventricular ejection fraction was kept: Look at the single institution rear; a mark cohort study 馬橋美由季, 堀内望, 奥川寛, 土手賢史, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1452-1452, 2021. |
|---|
|
|
P42-05. Examination about the effect factor to give to the effectiveness of the disseminated intravascular coagulation syndrome therapeutic drug recombinant thrombomodulin 朝居祐貴, 山本高範, 阿部康治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1453-1453, 2021. |
|---|
|
|
P42-06. An association between low density lipoprotein cholesterol level and re-treatment at follow-up coronarography after the acute coronary syndrome: Case-control study 奥川寛, 堀内望, 土手賢史, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1454-1454, 2021. |
|---|
|
|
P42-07. Examination for the pneumocystis pneumonia onset of patients receiving rheumatoid arthritis therapeutic drug 畝知己1, 前田和彦1, 森脇順子1, 松原菜美1, 渡部里香2, 茂久田翔3, 荒木慧4, 岡井由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1455-1455, 2021. |
|---|
|
|
P42-08. A case of a familial hypercholesterolemia homozygote who achieved LDL-C control goals with lomitapide low-dose escalation 水谷雅子1, 上原明彦2, 飯塚修3, 田中ありさ4, 高岡弥央子1, 坂口綾香1, 山崎涼也1, 高橋直樹1, 山本秋美1, 有田育子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1456-1456, 2021. |
|---|
|
|
P42-09. The effect that the interview by the multi-type of job gives to a treatment continuance rate of self-injection preparation (dTPTD) on teriparatide day after day 川田暁1, 船木麻美1, 川上由美2, 安藤羽純2, 石川修平3, 児玉照光4, 相田桃子4, 舟越亮寛1, 久保田基夫5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1457-1457, 2021. |
|---|
|
|
P42-10. Investigation of the antithrombotic therapy in patients who underwent PCI 宗岡美紗1, 前田和彦1, 森脇順子1, 寺川宏樹2, 岡井由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1458-1458, 2021. |
|---|
|
|
P42-11. Pharmacist intervention in the treatment of the infants hemangioma 森兼愛実, 持田裕子, 上條真菜実, 浅井翔子, 清水祐一, 甲斐維子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1459-1459, 2021. |
|---|
|
|
P42-12. Safety evaluation based on actual usage survey of sacubitril valsartan sodium hydrate tablets at Gifu Prefectural General Medical Center 西尾洋平, 古谷一平, 関谷泰明, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1460-1460, 2021. |
|---|
|
|
P42-13. The effectiveness and safety of the denosumab in patients with male osteoporosis 安土菜美1, 丸井万由香1, 櫻田啓介2, 川口翔平1, 車塚千穂1, 今井隆人1, 小林龍1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1461-1461, 2021. |
|---|
|
|
P42-14. The use situation investigation of the denosumab for patients with male osteoporosis that took advantage of pharmaceutical products risk management plan カワセ彩1, 中島美治1, 佐藤愛1, 内田裕之1, 八木仁史1, 満田正樹1, 東川晶郎2, 河井良智1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1462-1462, 2021. |
|---|
|
|
P42-15. Example that ceftriaxone and gentamicin succeeded for patients on dialysis of recurrent infective endocarditis suspicion by Klebsiella pneumoniae 石井俊一1,2, 宮本渚2,3, 渡邊徹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1463-1463, 2021. |
|---|
|
|
P42-16. The effect that high fat diet gives to the microRNA expression of mouse liver 柴山良彦, 中川勉, 久保義忠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1464-1464, 2021. |
|---|
|
|
P42-17. The nalfurafine prescription for the itch and examination of the zinc deficiency 見元尚, 筒井由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1465-1465, 2021. |
|---|
|
|
P42-18. 2 cases that was able to evade remedy method improvement and drug exposure by a medication follow-up and a tracing report 白鞘裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1466-1466, 2021. |
|---|
|
|
P42-19. It is the medicine charge to a substitute of chronic constipation therapeutic drug magnesium oxide! Choice called DSS 酒向聡子1,4, 亀山聡美1,4, 今西正人1,4, 松井一樹2,4, 岩井雄司3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1467-1467, 2021. |
|---|
|
|
P42-20. Examination of the effects and side effects of Movicol-containing oral preparation LD for patients with chronic constipation in a ward for severely mentally and physically disabled patients 鶴崎泰史1, 上野知香3, 古川淳2, 陣内紀子2, 丸小野まゆみ2, 江崎由佳1, 山本晃大1, 山本修一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1468-1468, 2021. |
|---|
|
|
P42-21. Investigation about the administration situation and dermatitis of zinc acetate in the premature baby 末長芽以1, 木村滋1, 藤本愛理1, 川俣洋生1, 福石和久2, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1469-1469, 2021. |
|---|
|
|
P42-22. The glutathione drying up with the glutamic acid out of the nerve cells induces nitrosylation of Protein disulfide isomerase 小倉次郎1,2, 小野慎司3, 杉浦弘樹3, 山内碧4, 佐藤紀宏2, 前川正充2,3,4, 山口浩明1,2, 眞野成康2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1470-1470, 2021. |
|---|
|
|
P42-23. About the effectiveness and safety of the Pemafibrate 坂東香織1, 菊田絵梨華1, 先名健太1, 道貝優太1, 小笠原綾香1, 水谷彰史1, 北川裕也1, 中村裕一1, 鈴木千波1, 小原秀治1, 柴波明男1, 樋浦一哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1471-1471, 2021. |
|---|
|
|
P42-24. The effect that the combination of diuretics and SGLT2 inhibitor gives to renal function 伊藤和, 荻原友里, 吉原正和, 鈴木知則, 楠見彰宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1472-1472, 2021. |
|---|
|
|
P42-25. Effect of the actual situation and the drug of the salivation in patients with intractable neuromuscular disorders 大野隼輔1, 石田奈津子1, 座光寺伸幸2, 鈴木亮平3, 野尻桂2,4, 大月慎之助5, 菅幸生1, 石崎純子1, 松下良1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1473-1473, 2021. |
|---|
|
|
P42-26. The effectiveness, safe comparison of Linaclotide and the Elobixibat 下坪達人, 石郷友之, 北川学, 木明智子, 藤居賢, 福土将秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1474-1474, 2021. |
|---|
|
|
P42-27. One patient whom we were able to save from poisoning by the colchicine excessive quantity internal use 馬替仁1, 小林正人1, 竹内崇浩1, 宮内秀典1, 野口周作1, 城戸教裕2, 大嶽康介2, 田上隆2, 松田潔2, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1475-1475, 2021. |
|---|
|
|
P42-28. Examination about the taking aspirin period in patients with Kawasaki's disease 山田敦子, 寺岡知香, 川田希帆, 漆崎智香子, 石川佳澄, 森井絵莉香, 宮部祐子, 岩崎瑛子, 中野寛之, 下辻恒久, 山東真寿美, 坂上嘉浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1476-1476, 2021. |
|---|
|
|
P42-29. Examination of the liver function improvement effect with the Pemafibrate administration 大谷綾1, 金秀基2, 川瀬愛香1, 亀井健人1, 西條由夏1, 上田愛梨1, 中尾啓子1, 笹瀬典子1, 金守良2, 金啓二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1477-1477, 2021. |
|---|
|
|
P43-01. Efforts in our hospital pharmacy about the study drug management support in the clinical studies that a physician leads 遠又未佐子1, 後藤洋仁1,2, 松井周一1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1479-1479, 2021. |
|---|
|
|
P43-02. Fact-finding about the exhibition of the clinical study information by the pharmaceutical company on the Internet 石橋春奈, 原梓, 漆原尚巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1480-1480, 2021. |
|---|
|
|
P43-03. Evaluation of CubixxCT in the clinical experimental medicine management 齊田翌美1,2, 宮本聖子1,2, 浮池香奈子1,2, 白澤宏美4, 佐々木幸作2, 中川義浩5, 湊本康則1,2, 富田正郎3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1481-1481, 2021. |
|---|
|
|
P44-01. It is visit instruction and enforcement ... of the pharmacist outpatient department after efforts - discharge of the ward pharmacist who fixed the eyes on the home care after the discharge 岡田雅弥1, 満田正樹2, 中谷亮介1, 大本奈緒子1, 尾崎加織1, 瀧浪靖子1, 富山志帆1, 細直子1, 下川福子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1484-1484, 2021. |
|---|
|
|
P44-02. Examination of the factor contributing to the burden of pharmacist duties in the treatment at home 市橋菜月1, 柴田賢三1,2, 室谷健太3, 坂巻弘之4, 亀井浩行1, 半谷眞七子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1485-1485, 2021. |
|---|
|
|
P44-03. Usefulness of the drug reporting book making between the institutions at hospital transfer by the pharmacist and the evaluation 伊藤有美, 柴田大地, 滝本典夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1486-1486, 2021. |
|---|
|
|
P44-04. Example that we transfused it and prescribed it and suggested at-home based on the information of the community medical care cooperation network 中川友之1,2, 草場大作1, 木村安佳莉1, 丸一泰雅2, 折戸真澄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1487-1487, 2021. |
|---|
|
|
P44-05. Inquiry analysis about the TPN infusion from the ethical pharmacy 掛水瑞芳, 星泉, 吉岡小都子, 竹林佑花, 松田直子, 佐々木美由紀, 福田まゆみ, 河野裕則, 岩原良晴, 沢田憲彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1488-1488, 2021. |
|---|
|
|
P44-06. Aiming for a regional formulary - Awareness survey results report - 森英樹, 花房伸幸, 小池彩子, 大道淳二, 横田幸子, 石橋真実, 諏訪耕三 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1489-1489, 2021. |
|---|
|
|
P44-07. Effect inspection to the local inhabitants health enhancement of the locomotive syndrome prophylactic activity to be carried out at a drugstore 藤井優里菜1, 菊池千草2,3, 浅井治行4, 大竹芳房5, 大庭紀宏6, 佐々木豊7, 佐藤裕美8, 清水一希9, 供田将志10, 中尾理香11, 藤井麻由12, 松岡良典9, 水野輝雄13, 山本加奈子14, 小嶋雅代15, 鈴木匡2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1490-1490, 2021. |
|---|
|
|
P44-08. 1 case that cooperated with the multi-type of job with at-home PCA introduction 志田友美1,5, 豊田清子2,5, 浮海利枝2,3, 太田学4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1491-1491, 2021. |
|---|
|
|
P44-09. Problem - in the hospital transfer support of patients with relation - new model coronavirus infection of the community medical care cooperation center pharmacist to the hospital transfer suffering case in the acute phase hospital 三沖大介1, 山本晴菜1, 池末裕明1, 米谷久美子2, 橋田亨1, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1492-1492, 2021. |
|---|
|
|
P44-10. One case that was able to start transvenous lipid microsphere administration by the treatment at home by the multi-type of job cooperation and the maneuver instruction to patients family smoothly 伊津田知樹1, 藤田あゆみ2, 川崎優人3, 岡本優也3, 中村友洋3, 杉浦伸哉2, 杉浦克典2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1493-1493, 2021. |
|---|
|
|
P44-11. Fact-finding to evaluate the at-home pharmacy administrative task that a drugstore pharmacist conducts in the nursing facility 遠田宙1,2, 山村恵子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1494-1494, 2021. |
|---|
|
|
P44-12. Study on efficiency improvement of pharmacist duties by the information sharing between a physician, the pharmacists using the glaucoma seal 大迫翔平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1495-1495, 2021. |
|---|
|
|
P44-13. Approach to the epoprostenol continuous intravenous infusion therapy introduction for patients with pulmonary artery-related pulmonary hypertension in the district hospital 高見澤美紀1, 篠原徹1, 橋詰さやか1, 高見澤誠1, 土屋ひろみ2, 飯島実和子3, 矢崎善一2, 関戸大司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1496-1496, 2021. |
|---|
|
|
P44-14. For medical garbage mixture zero and needle pad accident zero to classification of plastic 磯貝一成1,2,3, 江島姿子1, 細谷雄二2, 井上泰芳2, 高尾満3, 三國貴子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1497-1497, 2021. |
|---|
|
|
P44-15. The current situation investigation about the at-home intravenous alimentation infusion preparation in the Osaka lower dispensing pharmacy 大石雅子1,2, 渡邊梓2, 井上善文3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1498-1498, 2021. |
|---|
|
|
P44-16. The example analysis that "cannot swallow up the medicine" that was taken up in patients consultation desk combination conference 久岡清子1, 増田博也1, 日下部紗穂2, 鹿島由美子3, 下地朝秀4, 城戸あゆみ5, 伊藤克樹4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1499-1499, 2021. |
|---|
|
|
P44-17. Efforts of the information sharing between a drugstore, the hospital pharmacist at hospitalization and release of patients 大内友季江, 安達寛成, 佐藤千穂, 佐伯里紗, 正垣耕, 遠藤武弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1500-1500, 2021. |
|---|
|
|
P44-18. Development of Quality Indicator measuring the characteristic of the drugstore service 加藤寛菜, 酒井隆全, 田辺公一, 大津史子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1501-1501, 2021. |
|---|
|
|
P44-19. Search of the stressor becoming the stressor of the pharmacist in the treatment at home 淺野七海1,2, 亀井浩行1, 室谷健太2, 半谷眞七子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1502-1502, 2021. |
|---|
|
|
P44-20. Investigation about the number of the staff of the drugstore pharmacist and the at-home duties enforcement situation 上山碧1, 玉木啓文1, 長内理大1, 伊野陽子1, 岩田麻里2,3, 松永俊之4, 中村光浩3, 井口和弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1503-1503, 2021. |
|---|
|
|
P44-21. Significance to accept the outside Parliament prescription of the emergency visit at a health insurance pharmacy 林田大輝1, 天方奉子1, 沼田朋和1, 牛濱直樹1, 佐々木雄一2, 稲葉一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1504-1504, 2021. |
|---|
|
|
P44-22. One case that caused somnolence when we finished passing through oral from hypodermic injection and exchanged hydromorphone 天方奉子, 沼田朋和, 本山有佳子, 稲葉一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1505-1505, 2021. |
|---|
|
|
P45-01. The prescription situation investigation after the discharge of the patients who intervened pharmaceutical in our hospital 中村豪志, 岡田淳芳, 神原康佑, 石井一也, 大塚識稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1510-1510, 2021. |
|---|
|
|
P45-02. Investigation, analysis about the discharge drug information cooperation addition in the Oiso Hospital attached to the Tokai University faculty of medicine 横山直, 奥村伊代, 千葉詩織, 岡安弘樹, 山縣彩, 矢野忠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1511-1511, 2021. |
|---|
|
|
P45-03. Efforts ... to medicine medicine cooperation in the cottage-hospital out of modi operandi and calculation situation ... of the drug control summary by the discharge drug information cooperation addition new establishment 岩崎有可里, 奥村謙一, 吉村直人, 野村真里, 藤原洋介, 山田憲和, 中村智子, 吉川知世, 吉田明弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1512-1512, 2021. |
|---|
|
|
P45-04. Community medical care cooperation ... at new efforts - hospitalization for the seamless patients support 澤口友紀, 増田博也, 合田さやか, 大荒政志, 川村大輔, 鹿沼奈央, 坂本真衣, 吉川真央, 井上萌, 小滝亜梨紗, 梶貴裕, 青柿和樹, 黒田悠加, 坪田美風, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1513-1513, 2021. |
|---|
|
|
P45-05. The current situation investigation for the efforts of a medication reporting book (drug summary) and the writing a postscript 阿部響, 福島奈津美, 大上寛子, 起塚美沙, 中村美樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1514-1514, 2021. |
|---|
|
|
P45-06. Survey on the current status of admission phone calls to family pharmacy pharmacists at Rakuwakai Marutamachi Hospital 大村真里奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1515-1515, 2021. |
|---|
|
|
P45-07. Active intervention to the discharge medication counseling utilizing the discharge drug reporting book and the effect 荒木遼太, 譲原千広, 小川紗知, 波多晶子, 中澤美樹子, 橋爪和恵, 窪田真弓, 鶴居勝也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1516-1516, 2021. |
|---|
|
|
P45-08. Efforts for the effective discharge drug information cooperation addition calculation 花房伸幸, 甲元大樹, 小池彩子, 大道淳二, 森英樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1517-1517, 2021. |
|---|
|
|
P45-09. Medicine medicine cooperation ... with pharmaceutical intervention of the hospital pharmacist using the tracing report in the foreign cancer chemotherapy and the drugstore in evaluation - site 金剛圭佑1, 刈谷美里1, 井上祥平2, 岡奈津美2, 脇下大樹1, 小寺克典1, 松田ゆかり1, 横町朋子1, 岡田秀明3, 橋本泰明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1518-1518, 2021. |
|---|
|
|
P45-10. It is questionary survey ... to ... drugstore for improvement in quality of the foreign cancer chemotherapy 黒部健太郎, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1519-1519, 2021. |
|---|
|
|
P45-11. The current situation report fourth report of the foreign inhalational instruction in the Komaki Municipal Hospital 河野美来, 水谷貴樹, 水野彩花, 戸田康裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1520-1520, 2021. |
|---|
|
|
P45-12. The introduction of the tracing report in the Osaka University faculty of medicine hospital and evaluation of the usefulness 大西絵梨1, 有持潤子1, 山本智也1, 門脇裕子1, 竹屋泰2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1521-1521, 2021. |
|---|
|
|
P45-13. Construction of the foreign inhalational instruction follow-up system by the medicine medicine cooperation reinforcement 佐々木陽一, 原大真, 高橋恭平, 長田一晃, 西倉教子, 横山匠太, 原田靖子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1522-1522, 2021. |
|---|
|
|
P45-14. Analysis of issuance of the summary for the prescription notebook using the commercial documentation support system and the writing a postscript from the health insurance pharmacy 下田賢一郎, 星野輝彦, 木村美紗子, 森崎崇文, 杉山留美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1523-1523, 2021. |
|---|
|
|
P45-15. The use situation investigation of the cooperation document between the institutions in the local basic hospital under Kyoto 三浦誠1,2, 石橋直哉1,3, 板倉祥嗣1,4, 加藤良隆1,5, 楠川侑吾1,6, 田渕祐輔1,7, 伴具也1,2, 岩根裕紀1,8, 土下喜正1,9, 深津祥央1,3, 友沢明徳1,10, 四方敬介1,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1524-1524, 2021. |
|---|
|
|
P45-16. One patient who was able to evade the becoming severe of the side effect by the illness medicine cooperation through the tracing report 本田修一, 牛島智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1525-1525, 2021. |
|---|
|
|
P45-17. One case that was able to prevent a dangerously ill low K blood symptom by medicine medicine cooperation 阿部華奈1, 正置耕一2, 西山祐美2, 下村美穂2, 森田聡子2, 高子優子2, 吉岡睦展2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1526-1526, 2021. |
|---|
|
|
P45-18. Efforts (the second report) for the cooperation full addition in the corona evil 上淵未来1, 土井裕美子1, 志間裕介1, 泉勇成1, 金森陽子1, 中村拓真1, 大岡建太郎1, 守田尚史1, 本村美穂1, 西村秀洋2, 市川康子1, 藤井憲一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1527-1527, 2021. |
|---|
|
|
P45-19. The case that was able to confirm an adherence drop of the double cancer internal use treatment by a tracing report 松本美紅1, 桑村恒夫1, 原田智子1, 平田仁美2, 田尻健亮1, 中川義浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1528-1528, 2021. |
|---|
|
|
P45-20. Example avoiding aggravation of pneumonia drug-related by the inflection of the oral anticancer agent fixed form check-type tracing report by the physician starting point 西上真1, 三坂恒1, 志村裕介1, 原祐輔1, 坪内清貴1, 嶋田努1, 石川聡子2, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1529-1529, 2021. |
|---|
|
|
P45-21. Efforts for the cooperation full addition calculation of the Osaka Red Cross hospital and evaluation from the neighborhood health insurance pharmacy 山瀬大雄, 野村加奈子, 原田慶子, 仲里泰太郎, 林淳雄, 谷大輔, 安田成男, 門馬佳代子, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1530-1530, 2021. |
|---|
|
|
P45-22. Analysis of the approach situation about the medicine medicine cooperation for improvement in quality of the foreign cancer chemotherapy in Kanagawa 田口真穂, 高橋健太, 阿部竜大, 畚野海, 日原慧, 山田博章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1531-1531, 2021. |
|---|
|
|
P45-23. We investigate a problem in the current situation confirmation of the foreign chemotherapy regimen joint ownership and the operation at the health insurance pharmacy 西村碧1, 奥埜早紀1, 藤井友美1, 大西優里1, 加藤良子2, 吉留実慧子3, 三宅麻文4, 近藤篤4, 尾上雅英4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1532-1532, 2021. |
|---|
|
|
P45-24. Efforts of the good use of cancer chemotherapy information sharing sheet reinforcement 柴山はる子1,2, 後藤愛実2, 西原雅美2, 服部有紀1, 長田英子1, 家崎加奈1, 鶴田花奈1, 奥本貴廣1, 川端麻衣子1, 國井久美子1, 家里夏子1, 奥田菜由子1, 神吉麻美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1533-1533, 2021. |
|---|
|
|
P45-25. ... which thinks about the way of the cooperation of hospital pharmacist for the "drugstore vision for patients" promotion and the family pharmacist through ... case 村田夕起子1, 向井光一朗2, 濱田健人3, 村本慎悟2, 大山高廣1, 政賢悟1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1534-1534, 2021. |
|---|
|
|
P45-26. Efforts of the medicine medicine cooperation more satisfying by "the cooperation full addition" 川原裕, 田中亮輔, 佐野雅昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1535-1535, 2021. |
|---|
|
|
P45-27. Analysis of contents of the reporting using the information sharing sheet for exclusive use of the Lenvatinib with the University of Miyazaki faculty of medicine hospital 上運天玲子, 櫻井京子, 比惠島有香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1536-1536, 2021. |
|---|
|
|
P45-28. One case that good pain control was got from by the cooperation of community pharmacy, a door front drugstore, the medical institution 林優希1, 吉留実慧子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1537-1537, 2021. |
|---|
|
|
P45-29. Evaluation of the usefulness of the tool to use for medicine medicine cooperation in the foreign cancer chemotherapy 疋田絵梨1, 大崎真美1, 黒木あかね1, 秦哲磨1, 浦山泰典1, 村上菜月1, 賀川智子2, 安武夫3, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1538-1538, 2021. |
|---|
|
|
P45-30. Questionary survey about the medicine medicine cooperation of the anticancer medicine for health insurance pharmacies of the East Tottori area 廣岡賢輔, 清水浩幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1539-1539, 2021. |
|---|
|
|
P45-31. Side effect follow-up investigation of the anticancer agent in the medicine medicine cooperation 山本浩之, 出口桃子, 堀田千里, 河野修治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1540-1540, 2021. |
|---|
|
|
P45-32. Efforts for the cooperation full addition in the Hekinan Municipal Hospital 伊藤昌美1, 片山広美1, 後藤整一2, 小竹千秋3, 伊藤弥生3, 鈴木崇太4, 鈴木厚志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1541-1541, 2021. |
|---|
|
|
P45-33. Efforts to the cooperation full addition acquisition 米谷頼人, 松田亜希子, 藤谷千紘, 石井隆義, 坂本佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1542-1542, 2021. |
|---|
|
|
P45-34. Evaluation about the efforts of the medicine medicine cooperation using "information sharing paper" in the foreign cancer chemotherapy 竹本将士1, 近藤勝弘1, 川出義浩1, 外海友規1, 伊豆田美晴1, 手崎世織1, 井口裕美子1, 後藤佳奈1, 中村大学1, 木村和哲1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1543-1543, 2021. |
|---|
|
|
P45-35. The actual situation grasp of the telephone practice accompanied with the prevention of COVID-19 infection spread in the pediatric special hospital and creation of useful data for the medicine medicine cooperation 長沼明子1,3, 大和由佳1, 郭義胤2,3, 安河内尚登1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1544-1544, 2021. |
|---|
|
|
P45-37. Economic effect in the Residual medicine intervention using a doubt inquiry simplification protocol and the spreading effect 十亀裕子, 西村光子, 小杉奈緒, 野村政子, 柏川紗希, 森加也, 高橋典子, 佐々木尚美, 岸本仁文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1545-1545, 2021. |
|---|
|
|
P45-38. Questionary survey for the purpose of stocktaking and the cooperation reinforcement of the medicine medicine cooperation 白石貴寿, 小西裕二, 坂本拓也, 青柳晴彦, 井上優子, 山田智栄子, 奥田和貴, 渡邊卓巳, 川村ひとみ, 小澤明日香, 小松浩大, 小川実華, 金城俊之介, 井口舞香, 鈴木美和, 荒井宏人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1546-1546, 2021. |
|---|
|
|
P45-39. Efforts (suggestion to medicine medicine cooperation) as the family drugstore for the discharge prescription that it is hard to take of patients on dialysis 山内牧子1, 山邊健司1, 田中みずき1,2, 坂口眞弓1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1547-1547, 2021. |
|---|
|
|
P45-40. Introduction of the case that information sharing with a drugstore pharmacist and the hospital pharmacist led to improvement in adherence of patients 牛尾彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1548-1548, 2021. |
|---|
|
|
P45-41. Content analysis of the drug control summary of the Tohoku University Hospital and investigation about the usefulness 小林大典, 黒澤桂子, 田中里奈, 高橋茜, 森下啓, 佐藤稔之, 高崎新也, 佐藤祐司, 松浦正樹, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1549-1549, 2021. |
|---|
|
|
P45-42. Change of tracing report contents before and after the medicine machine law revision 高子優子, 吉岡睦展, 土田裕貴, 石津智司, 下村美穂, 正置耕一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1550-1550, 2021. |
|---|
|
|
P45-43. Efforts for the community medical care cooperation reinforcement using the drug control summary 大竹野久雄, 蓮輪博嗣, 松野知寛, 井上和洋, 辻村啓史, 北村憲雅, 中野祐樹, 安河内寿成, 猪口陽子, 秀島久美子, 横尾賢乗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1551-1551, 2021. |
|---|
|
|
P45-44. The effect that renal excretion type drug inquiry standard introduction by the medicine medicine cooperation gives to drugstore pharmacist checking prescription duties 高村優太1, 平井利幸1, 佐藤和人1, 秋山裕史1, 名越ソッヴィリヤック ヴァッティ3, 大橋雅人4, 樗木昭5, 関利一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1552-1552, 2021. |
|---|
|
|
P45-45. The illness medicine cooperation that a pharmacist of the local government Hospital conducts 片山広美1, 加藤直紀1, 鈴木めぐみ1, 天野哲史1, 鈴木裕之1, 八並ゆかり1, 伊藤昌美1, 加藤奈美1, 渡邉香織1, 山崎典子2, 山端二三子3, 奥村晋平4,6, 板倉由縁1,5, 鈴木厚志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1553-1553, 2021. |
|---|
|
|
P45-46. Consideration for the actual situation and the medicine medicine cooperation of the receipt situation of the drug control summary in the health insurance pharmacy 鈴木すみれ, 佐々木麻里, 須藤寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1554-1554, 2021. |
|---|
|
|
P45-47. About the operation of the tracing report aiming at the establishment of the polypharmacy community medical care model 天白宗和, 溝神文博, 間瀬広樹, 加藤浩充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1555-1555, 2021. |
|---|
|
|
P45-48. It is ... using intervention situation investigation - medicine questionnaire by the regional alliances team 石原瑛太郎1, 大嶋成奈優1, 石井照樹1, 沖廣絵里子1, 高橋公子1, 篠永浩1, 原田典和1, 加地努1, 石山晃子2, 中津守人3, 矢野禎浩4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1556-1556, 2021. |
|---|
|
|
P45-49. Inflection of the tracing report in the medication management of the perioperative patients 石原慎之, 玉木宏樹, 望月優里, 大仁田哲修, 北郷真史, 後藤貴樹, 矢野貴久, 直良浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1557-1557, 2021. |
|---|
|
|
P45-50. Efforts and problem to the online workshop holding of the medicine medicine cooperation promotion workshop 鶴居勝也, 荒木遼太, 小川紗知, 譲原千広, 波多晶子, 中澤美樹子, 橋爪和恵, 窪田真弓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1558-1558, 2021. |
|---|
|
|
P45-51. Having been able to see it from the setup of the in-hospital system for the cooperation full addition calculation and the questionnaire to the health insurance pharmacy 原田哲彦, 坂野博紀, 村上仁志, 足立翼, 冨山麻里子, 石川元章, 柳沼妙子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1559-1559, 2021. |
|---|
|
|
P45-52. Usefulness of the cooperation with the drugstore judging from the calculation situation of the cooperation full addition 外山智章1, 五月女拓也1, 日向野理輝1, 大塚瑠里1, 篠崎圭子1, 臼井悟1, 五十嵐爽2, 小貫佐和子2, 木名瀬直樹2, 石濱洋美3, 本田雅巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1560-1560, 2021. |
|---|
|
|
P46-01. About a problem of the storage pharmaceutical products operation thought about through an in-hospital disaster prevention drill 森川祥彦, 川瀬亮介, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1562-1562, 2021. |
|---|
|
|
P46-02. Development of the disaster application using package insert computerization for medical care 木村敦1, 松本利恵1, 深澤真吾2, 草深裕光2,3, 松波和寿4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1563-1563, 2021. |
|---|
|
|
P46-03. Effect of the Iburi eastern part earthquake to give change of prescription of the psychiatry 矢田山瑞稀, 大野奈子, 荒井理乃, 喜多力, 真井雄規, 越野早紀, 能登数馬, 門脇督, 田中悠季, 三本松泰孝, 佐藤弘康, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1564-1564, 2021. |
|---|
|
|
P46-04. National survey about the introduction situation of the disaster-response pharmaceutical products supply vehicle and the use actual situation 岡村佳奈1, 羽山希1, 生木庸寛1,3, 河合琢良1,3, 小原道子1,3, 林秀樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1565-1565, 2021. |
|---|
|
|
P46-05. It is the lesson from Fukushima offing earthquake happened in the tenth year from the Great East Japan Earthquake 須藤孝浩, 永島久義, 渡辺研弥, 石井重亮, 吉田裕美, 鈴木優佳, 五十嵐暁子, 塩谷真奈美, 星正弘, 鳥羽衛, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1566-1566, 2021. |
|---|
|
|
P47-01. Contents and tendency analysis of doubt inquiry in inside the hospital 土井加奈子, 高武嘉道, 鶴山萌子, 永石浩貴, 坂口晋哉, 河野なるみ, 中原萌子, 花田聖典, 川俣洋生, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1569-1569, 2021. |
|---|
|
|
P47-02. Dispensing error generating inhibitory effect by the picking support system introduction 宇根良祐, 白木萌, 長濱藍, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1570-1570, 2021. |
|---|
|
|
P47-03. Efforts of our hospital about the HBV reactivation prevention in the steroid therapy 高橋真一, 桝早紀子, 四方公亮, 伊東充, 佐藤香織, 勝俣はるみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1571-1571, 2021. |
|---|
|
|
P47-04. Development and evaluation of in-hospital operation procedures of the propofol 龍田涼佑1, 山村亮太1, 中原良介1,3, 衛藤大輝1, 森永裕子1, 田中遼大1, 北野敬明2, 平松和史3, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1572-1572, 2021. |
|---|
|
|
P47-05. Confirmation duties of the cancellation medicine before surgery, examination and the evaluation 柏原由佳, 柘植縁理佳, 伊波樹, 江畠麗, 佐伯美沙, 田中章久, 前田絵里加, 松崎あい理, 田中克巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1573-1573, 2021. |
|---|
|
|
P47-06. Our hospital's efforts toward the proper use of omidenepag isopropyl ophthalmic solution 柴谷直樹1, 宮坂萌菜1, 平野達也1, 奥吉博之1, 大江泰2, 藤原雅史3, 室井延之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1574-1574, 2021. |
|---|
|
|
P47-07. About the response to medication incident in the internal use self-care patients 川崎文雄1,2, 瀬戸梓1, 山ノ内芹南1, 平松美早1, 与那城知夏1, 奥西美奈1, 小室寿子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1575-1575, 2021. |
|---|
|
|
P47-08. Trends in the use of sleeping pills and effects on falls due to the introduction of an insomnia indicator formulary among hospitalized patients 小池彩子1,2,3,4,5, 原田亮2, 畑賢俊3, 山田美智子4, 中島誠5, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1576-1576, 2021. |
|---|
|
|
P47-09. The current situation and problem of a fall, the fall in the Hokuriku center Hospital 守内匡1, 秋元恵子2, 中山詠美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1577-1577, 2021. |
|---|
|
|
P47-10. Operation of the cancellation medicine before effective and safe hospitalization using the protocol 伊藤隆哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1578-1578, 2021. |
|---|
|
|
P47-11. Examination of the information sharing method by the registration situation investigation of the allergy to patients information 保戸塚里美, 疋田絵梨, 城田幹生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1579-1579, 2021. |
|---|
|
|
P47-12. About the injection drug bar code authentication system introduction in ward/emergency room and the usefulness 福長豊己1, 田辺友也1, 高橋恭平1, 原田靖子1, 西原昌幸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1580-1580, 2021. |
|---|
|
|
P47-13. Examination of the current situation investigation and measures about the registration that an alert of the drug allergy does not function 小澤明日香, 渡邊卓巳, 坂本拓也, 白石貴寿, 荒井宏人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1581-1581, 2021. |
|---|
|
|
P47-14. Introduction effect of the mark to alert on drug requiring attention at a decreased renal function 東春奈, 淺津裕子, 片岡憲昭, 柿迫大樹, 牧野順子, 西原雅美, 内山和久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1582-1582, 2021. |
|---|
|
|
P47-15. ... to look back on from bar code use and application - incident report aiming at medical security and duties efficiency 鈴木良1,2, 折井孝男1, 山口智史2, 杉田匡聡2, 加藤敏明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1583-1583, 2021. |
|---|
|
|
P47-16. Difference in depiction by plain radiography and CT taking picture of drug and PTP sheet 宇野尭1, 高橋庄太1, 田浦将明2, 米田瑞輝2, 薄井健介1,3, 千葉浩生2, 大原貴裕4, 岡田浩司1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1584-1584, 2021. |
|---|
|
|
P47-17. Fact-finding about the misunderstanding of similar pharmaceutical products in clinical settings and the measures 小林彩乃1, 佐藤宏樹2,3, 柳奈津代2, 澤田康文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1585-1585, 2021. |
|---|
|
|
P47-18. Effect by the efforts of the sleeplessness instructions adequacy 伊藤匡伸1, 寺村由枝1, 西川裕美1, 和田侑輝人1, 足立康則2, 杉浦洋二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1586-1586, 2021. |
|---|
|
|
P47-19. Fall fall risk factorial experiments using the on admission evaluation score, Nested case-control study 石田亮1,3, 赤木晋介2,3, 塩津昭子3,4, 西出康晴3,4, 徳増裕宣1,3, 橋本徹3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1587-1587, 2021. |
|---|
|
|
P47-20. Making of the citrus fruits eating and drinking advisability card to use for the Erlotinib remedy patients 西川直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1588-1588, 2021. |
|---|
|
|
P47-21. Duties improvement from the position of the development situation and the pharmacist of the drug-related incident in the southern part of Saiseikai Yokohama-shi Hospital 深沢貴志1,2, 上原美佐2, 澤田真実1, 関根美保1, 南太一1,3, 鈴木康太郎1, 猿渡力1, 加藤一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1589-1589, 2021. |
|---|
|
|
P47-22. Evaluation using the development of the pharmacy student medical care safety education program that adopted active learning and the text mining 木下徳康1,3, 新谷拓也1,3, 廣部祥子1,2, 中村京太3, 前田真一郎1,2, 奥田真弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1590-1590, 2021. |
|---|
|
|
P47-23. Production (the second report) of reporting 4, Tours top comics about the proper use of pharmaceutical products 丸山凜七1, 徳永仁1, 河田実優1, 帳智香1, 園田純一郎1, 興梠靖幸2, 緒方賢次2, 高村徳人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1591-1591, 2021. |
|---|
|
|
P47-24. Production (the second report) of the animation for the purpose of the improvement in medication adherence 河田実優1, 徳永仁1, 帳智香1, 丸山凜七1, 園田純一郎1, 興梠靖幸2, 緒方賢次2, 伊藤寛3, 高村徳人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1592-1592, 2021. |
|---|
|
|
P47-25. An effect and problem of the workshop that took in the short play of the pharmaceutical products-related incident example 齊藤直美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1593-1593, 2021. |
|---|
|
|
P47-26. About pharmacist intervention to discontinuation confirmation before surgery in the outpatient department 安田郁稀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1594-1594, 2021. |
|---|
|
|
P47-27. QI activity with the number of incident reports as an index 山本倫数, 前田晃佑, 山本浩二郎, 濱田達志, 山田直輝, 森下夏伎, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1595-1595, 2021. |
|---|
|
|
P47-28. Usefulness of the e- learning teaching materials about the oral medicine transluminal administration which we made by the multi-type of job collaboration 新谷拓也1,2, 木下徳康1,2, 百田真弓1, 徳永あゆみ1, 新開裕幸1, 北村温美1, 奥田真弘2, 中村京太1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1596-1596, 2021. |
|---|
|
|
P48-01. Attempt - to ward remote training using the pharmacy school long-term business training - online system in the corona evil 曽根千晶, 角野雄亮, 渡辺瑞貴, 久保有佳梨, 吉年正宏, 岩崎浩子, 藤原季美子, 竹上学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1599-1599, 2021. |
|---|
|
|
P48-02. The effect that contents change of the pharmacy business training in the corona evil gives to a self-assessment arrival degree 青井博志, 岡田和也, 大西健太, 谷田彩, 小川恵美子, 吉川一吾, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1600-1600, 2021. |
|---|
|
|
P48-03. Maintain the satisfaction of the student how while combining business training - remote training under the new coronavirus infection outbreak that conducted in our hospital; or ... 善積美佳1, 熊久保さえ香1, 大久保淳史1, 立沢正臣1, 下泰司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1601-1601, 2021. |
|---|
|
|
P48-04. Extraction of the improvement item by a learning effect and the satisfaction questionnaire of the ward business training under the new coronavirus infection outbreak 道場勇真, 高野明香, 高野温志, 伊賀正典, 町田充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1602-1602, 2021. |
|---|
|
|
P48-05. Correspondence of the long-term business training in our hospital under the new coronavirus infection outbreak and inspection of the usefulness in the hybrid training 近藤昭志, 成田勇樹, 城野博史, 三宅俊介, 山川祐可子, 大坪謙一, 池田瑞季, 山下諒祐, 清住友香, 末永安司, 成田さわな, 嶋村桃子, 政賢悟, 田中順子, 齋藤秀之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1603-1603, 2021. |
|---|
|
|
P48-06. Business training curriculum corresponding to the clinical practice in the corona evil 大久保有起, 風岡典子, 國廣志保美, 福田英克, 南波勝栄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1604-1604, 2021. |
|---|
|
|
P48-07. Evaluation by the pharmacy student to the business training in the corona evil 佐々木紀彰, 古元俊徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1605-1605, 2021. |
|---|
|
|
P48-08. It is ... through change of the business training contents accompanied with the corona evil and evaluation - questionary survey 奥野昌宏, 田中詳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1606-1606, 2021. |
|---|
|
|
P48-09. Questionary survey about the hospital business training under the new coronavirus infection outbreak 久賀谷幸昌1, 西園寺真二1, 中村護1, 濱崎浩一1, 覚前美希2, 田山剛崇2, 三宅勝志2, 山崎美保1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1607-1607, 2021. |
|---|
|
|
P48-10. Efforts of the hospital training under the new coronavirus infection spread 安達るい, 西田初博, 三嶋一登 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1608-1608, 2021. |
|---|
|
|
P48-11. Inspection of the study Osamu effect that assumed evaluation of achievement of the pharmacy business training under COVID-19 pandemic an index 鈴木小夜1, 平賀ゆい1, 岩田紘樹2, 地引綾1, 横山雄太1, 河添仁1, 小林典子2, 藤本和子2, 中田英夫3, 青森達3, 山浦克典2, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1609-1609, 2021. |
|---|
|
|
P48-12. Inspection of the effect on medication counseling training of 8 representative diseases in the business training under COVID-19 pandemic 岩田紘樹1, 地引綾2, 鈴木小夜2, 横山雄太2, 平賀ゆい2, 河添仁2, 小林典子1, 藤本和子1, 中田英夫3, 青森達3, 山浦克典1, 中村智徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1610-1610, 2021. |
|---|
|
|
P48-13. Effect of the corona evil analyzed than questionary survey about the drugstore business training 吉田都1, 小島穂菜美1, 宇野莉央1, 内田享弘1, 大川恭子1, 笠井眞二1, 政田啓子1, 池上咲枝里1, 井上智咲1, 波多江崇2, 森山賢治1, 中村一基1, 篠塚和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1611-1611, 2021. |
|---|
|
|
P48-14. Effect of the corona evil analyzed than questionary survey about the hospital business training 小島穂菜美1, 吉田都1, 宇野莉央1, 内田享弘1, 桑原晶子1, 豊原朋子1, 濱宏仁1, 辻本勉1, 片岡和三郎1, 田崎眞生1, 波多江崇2, 森山賢治1, 中村一基1, 篠塚和正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1612-1612, 2021. |
|---|
|
|
P48-15. Efforts of the pharmacy business training acceptance in the corona evil 新井由希, 伊東充, 高澤千重理, 桝早紀子, 成田瞳, 佐藤香織, 勝俣はるみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1613-1613, 2021. |
|---|
|
|
P48-16. Inspection of the effect of COVID-19 pandemic in the domain evaluating by the business training record 地引綾1, 横山雄太1, 鈴木小夜1, 岩田紘樹2, 平賀ゆい1, 河添仁1, 小林典子2, 藤本和子2, 中田英夫3, 青森達3, 山浦克典2, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1614-1614, 2021. |
|---|
|
|
P48-17. The change of training contents in the trial secretariat and the future prospects 綿貫陽一, 白根尚子, 日浦寿美子, 小林秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1615-1615, 2021. |
|---|
|
|
P48-18. The visualization of the problem point of the harmful effect education using the text mining and examination 大和幹枝1, 松野純男2, 土肥弘久1, 長南謙一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1616-1616, 2021. |
|---|
|
|
P48-19. Establishment of the education situation grasp system using the duties check seat 土居紋子, 安藤洋介, 上野美幸, 森万奈, 浅井遥, 川波恭子, 太田秀基 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1617-1617, 2021. |
|---|
|
|
P48-20. Where is the charm, the fun of situation - hospital pharmacist of the stature of the student judging from an arrival degree (outline) evaluation in the hospital training? ... 渡邉正教, 中沢修司, 日比徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1618-1618, 2021. |
|---|
|
|
P48-21. We can measure the performance level of the trainee using the outline evaluation of the lube Rick pattern in the business training in conformity with revision core Cali 河添仁1, 鈴木小夜1, 平賀ゆい1, 横山雄太1, 地引綾1, 岩田紘樹2, 小林典子2, 藤本和子2, 中田英夫3, 青森達3,4, 山浦克典2, 中村智徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1619-1619, 2021. |
|---|
|
|
P48-22. Evaluation of the online training accompanied with the outbreak of COVID-19 judging from the questionnaire results of a student, the pharmacist 石橋正祥, 飯村洋平, 入江杏奈, 伊地知由樹, 古川直樹, 吉森瞳, 石井英里, 山村実佳, 福司佳穂里, 中原規容子, 黒田誠一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1620-1620, 2021. |
|---|
|
|
P48-23. Remoteness in the 2020 hospital business training and efforts about the training with the high Bullitt pattern of the meeting 石原祥子, 大谷寧次郎, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1621-1621, 2021. |
|---|
|
|
P48-24. The consciousness change investigation of the student by the prevention of drug abuse class and evaluation of the class teaching materials 赤松祐介1, 赤松路子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1622-1622, 2021. |
|---|
|
|
P48-25. Student independent participation type hospital business training and satisfaction investigation 橋本竜1,2, 栃木恵里1, 高橋彩花1,2, 玉井一也1, 宮内輝人1, 吉成宏顕1, 久保倫美1, 鈴木優子1, 大矢智則1,2, 佐藤淳也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1623-1623, 2021. |
|---|
|
|
P48-26. Evaluation of the bedside teaching pattern that used the on-demand teaching materials together 片岡憲昭1, 倉地果純1, 遠藤久美子1, 坂井紀水1, 畑武生1, 鈴木典子1, 角山香織2, 羽田理恵2, 中村敏明2, 西原雅美1, 内山和久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1624-1624, 2021. |
|---|
|
|
P49-01. Development and evaluation of the material for the self-learning for the purpose of the basic knowledge acquisition of the checking prescription in a tumor, the immune center 奥村洋平1, 櫻井洋臣1, 笠井雄佑1, 野々宮菜彌1, 吉田加奈1, 津田壮一郎1, 山吉康子1, 村松博1, 青森達1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1626-1626, 2021. |
|---|
|
|
P49-02. The current situation and problem of the pharmacist resident system in our hospital 山本幸二郎1, 畠山成寛1, 岡村央1,2, 川邉桂1, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1627-1627, 2021. |
|---|
|
|
P49-03. Introduction effect of the lube Rick evaluation on pharmacist resident training 綿本有希子, 伊藤雄大, 清水倫子, 栗村朋子, 松本久美子, 谷藤亜希子, 飯田真之, 大本暢子, 久米学, 山本和宏, 大村友博, 矢野育子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1628-1628, 2021. |
|---|
|
|
P49-04. The present situation of the medical therapy workshop by University of Shizuoka, hospital, the community pharmacy cooperation 大澤隆志1, 賀川義之1,2, 伊藤邦彦2, 山田浩2, 森本達也2, 黒川絢子2, 並木徳之2, 矢部勝茂2, 河西きよみ2, 鈴木貴也2, 青島弘明2, 櫻井和子2, 松山耐至2, 井上達秀2, 山田静雄2, 真鍋敬2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1629-1629, 2021. |
|---|
|
|
P49-05. Efforts using the lube Rick evaluation of the compounding of medicines duties in the pharmacist resident 渡邉美菜子, 宮崎典子, 戸嶋彩乃, 田中理子, 矢田郁実, 亀島理沙, 太田小織, 千崎康司, 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1630-1630, 2021. |
|---|
|
|
P49-06. Carrier design result report of the Hekinan Municipal Hospital pharmacy 渡邉香織1, 片山広美1, 天野哲史1, 石井彩子1, 伊藤昌美1, 八並ゆかり1, 加藤奈美1, 鈴木めぐみ1, 鈴木厚志1, 板倉由縁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1631-1631, 2021. |
|---|
|
|
P49-07. Examination - of the high performer image in the construction (the second report) - pharmacist version clinical ladder making of the hospital pharmacist staff education system 小山郁美1, 稲野寛1, 婦川貴博2, 坂倉智子1, 近藤留美子1, 谷口陽子3, 厚田幸一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1632-1632, 2021. |
|---|
|
|
P50-01. Final report of the identification results of bacteria detected in the surface of the formulations instrumentation 佐藤亜希子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1634-1634, 2021. |
|---|
|
|
P50-02. It is examination about the reflection to the current situation and the safety measures of the investigation after the production and sales by the all cases investigation in Japan 中尾美波, 前田英紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1635-1635, 2021. |
|---|
|
|
P50-03. Shortening of the doubt inquiry correspondence time by the efforts outside Parliament prescription doubt inquiry simplification protocol (PBPM procedure) introduction to duties improvement 高木洋明1, 鬼窪利英1, 中野和佳1, 三浦篤史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1636-1636, 2021. |
|---|
|
|
P50-04. Efforts ... for stocktaking and the improvement of the muscat drugstore made from ... drugstore KPI for achievement of drugstore vision for patients of 2 years 高橋正志1, 安倉央1,2, 守安洋子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1637-1637, 2021. |
|---|
|
|
P50-05. Examination about the change factor between the individual of the placebo effect 間宮桐子1, 新井菜々美1, 井澤美苗1, 石川春樹1, 中田英夫2, 青森達1,2, 望月眞弓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1638-1638, 2021. |
|---|
|
|
P50-06. Pharmaceutic approach for the delirium risk reduction that a dementia care team conducts 瀬古高裕, 辻内喜久雄, 山名知子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1639-1639, 2021. |
|---|
|
|
P50-07. Usefulness evaluation of the intestinal tract organoid derived from human iPS cells for the inflammatory bowel disease healing 渡邊ちひろ1, 中西杏菜2, 小野里太智2, 奥村啓樹2, 坡下真大2, 岩尾岳洋2, 松永民秀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1640-1640, 2021. |
|---|
|
|
P50-08. A BLS class for citizens and the result 比嘉耕基1, 齋藤靖弘2, 田中寿和1, 木下隆市1, 染谷光洋1, 谷口亮央1, 中島史雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1641-1641, 2021. |
|---|
|
|
P50-09. Effect of the comprehensive prior agreement protocol introduction in the outside Parliament prescription 萩原大樹1, 永江寛子1, 江藤浩平2, 小松公秀2, 兼重晋3, 神村英利3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1642-1642, 2021. |
|---|
|
|
P50-10. Approach - from enforcement and education effect - economic aspect of the cancer education for the high school student 横山郁子1, 河内正二1, 園部愛梨1, 渡邊理乃1, 藤本佳昭2, 沼田千賀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1643-1643, 2021. |
|---|
|
|
P50-11. Quantity of duties evaluation after the flex time introduction accompanied with the work-style reform 立沢正臣1, 下泰司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1644-1644, 2021. |
|---|
|
|
IP-01. Pregnancy and Infant Outcomes for Golimumab Therapy for Ulcerative Colitis During the Pregnancy and Lactation Periods : A Retrospective Report Ayami Miyai1, Kozo Tatsumi1, Minoru Kawai1, Hiroyuki Miyazaki2, Kyosuke Takeuchi2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1648-1648, 2021. |
|---|
|
|
IP-02. Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database Mitsuhiro Nakamura1, Junko Abe1,2, Ryogo Umetsu1, Hiroaki Uranishi1, Honami Suzuki1, Yuri Nishibata1, Yamato Kato1, Natsumi Ueda1, Sayaka Sasaoka1, Haruna Hatahira1, Yumi Motooka1, Mayuko Masuta1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1649-1649, 2021. |
|---|
|
|
IP-03. Role of symptoms cluster using EORTC QLQ-C15-PAL scores and inflammatory biomarkers in predicting survival in terminally ill patients with cancer Chikako Matsumura1, Nanako Koyama1, Morito Sako2, Hideo Kurosawa2, Takehisa Nomura2, Yuki Eguchi2, Kazuki Ohba2, Yoshitaka Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1650-1650, 2021. |
|---|
|
|
IP-04. Occurrence of encephalitis due to immune checkpoint inhibitors : A pharmacovigilance study Yugo Chisaki1, Hiroki Hata1,2, Chikako Matsumura1, Yoshitaka Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1651-1651, 2021. |
|---|
|
|
IP-05. Risk factors associated with the development of hepatic dysfunction during teicoplanin administration in pediatric patients Kazumasa Narita, Erina Motoki, Akira Mimura, Shusuke Ozawa, Satoshi Yamaori Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1652-1652, 2021. |
|---|
|
|
IP-06. Evaluation of risk of long QT syndrome caused by drug-drug interactions using a spontaneous reporting system Jun Matsuo1,2, Satoshi Yamaori1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1653-1653, 2021. |
|---|
|
|
IP-07. Impact of substrates and inhibitors of breast cancer resistance protein on apixaban pharmacokinetics in Japanese patients with atrial fibrillation Satoshi Ueshima1, Daiki Hira1,2,3, Karin Hirata1, Yohei Tabuchi2, Tomoya Ozawa1, Hideki Itoh4,5, Yoshihisa Nakagawa4, Minoru Horie4, Tomohiro Terada2,3, Toshiya Katsura1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1654-1654, 2021. |
|---|
|
|
IP-08. Impact of silicone oil tamponade on intraocular vancomycin pharmacokinetics after intravitreal injection in cynomolgus monkeys Daiki Hira1,2,3, Tomoya Kitagawa1, Taku Imamura4, Masashi Kakinoki4, Satoshi Ueshima1, Tomonobu Okano1, Masahito Ohji4, Mikio Kakumoto1, Tomohiro Terada2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1655-1655, 2021. |
|---|
|
|
IP-09. A preliminary trial for developing the methodology intended to broaden pharmacy students? global horizons Yoshimi Tomita1, Kinko Tamamaki2, Shoji Kawauchi1, Yoshihiko Tauchi1, Junichi Kunimasa1, Okiko Miyata1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1656-1656, 2021. |
|---|
|
|
IP-10. Predictors of the onset of type 1 diabetes obtained from real-world data analysis in cancer patients treated with immune checkpoint inhibitors Shinya Takada1, Hirokazu Hashishita1, Kayo Yamagishi1, Hideki Sato0, Kozo Mino1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1657-1657, 2021. |
|---|
|
|
IP-11. Evaluation of Appropriateness of Changing Intravenous ImmunoglobulinAdministration Schedule in Pediatric Recipients of Hematopoietic Stem Cell Transplantation Sorah Lee1, Hee Young Geum1, Ae Ryoung Park1, Jeong Yi Yoon1, Jin Suk Kang1, Jae Wook Lee2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1658-1658, 2021. |
|---|
|
|
IP-12. Impact of a multidisciplinary antimicrobial stewardship program for decreasing the duration of prophylactic antibiotic use Atsushi Uda1,2, Kei Ebisawa1,3, Mari Kusuki1, Rie Izuta1, Mariko Yahata1, Kayo Osawa4, Ikuko Yano2, Takayuki Miyara1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1659-1659, 2021. |
|---|
|
|
IP-13. Effects of concomitant use of antiemetic drugs on cisplatin-induced renal injury Mitsuhiro Goda1,2,3, Masaya Kanda2,3, Toshihiko Yoshioka2,3, Ami Yoshida2, Takahiro Niimura3, Yoshito Zamami2,3, Fuka Aizawa2,3, Yuki Izawa-Ishizawa4, Kenta Yagi1, Masayuki Chuma5, Hirofumi Hamano2, Naoto Okada3, Keisuke Ishizawa0 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1660-1660, 2021. |
|---|
|
|
IP-14. Revision Pharmaceutical and Medical Device Act, and Pharmaceutical GS1 barcodes utilization for patient safety in Japan Takao Orii1,2, Koichi Uemura3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1661-1661, 2021. |
|---|
|
|
IP-15. P38 MAPK, NF-κB and JAK-STAT3 signaling pathways promoted IL6 or IL8 abnormal expression contributed in capecitabine-induced hand-foot-syndrome Yan Lou, Jiali1, Wang Xiaoyang Lu2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1662-1662, 2021. |
|---|
|
|
IP-16. Clinical applicability of renin-angiotensin system inhibitors in cancer treatment Huirong Jiang1,2,3,4, Zongguang Tai11,2,3, Zhongjian Chen2, Quangang Zhu2, Leilei Bao1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1663-1663, 2021. |
|---|
|
|
IP-17. Huperzine A provides retinal neuroprotection via the M1 mAChR Ping Yu, Wen-Pei Dong, Ya-Bin Tang, Hong-Zhuan Chen, Yong-Yao Cui, Xiao-Lan Bian Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1664-1664, 2021. |
|---|
|
|
IP-18. Construction and validation of real-time PCR based measurement of NUDT15 gene polymorphism Tetsuichiro Isono1, Daiki Hira1,2, Masahiro Kawahara3, Akira Andoh3, Tomohiro Terada1,3, Shin-ya Morita1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1665-1665, 2021. |
|---|
|
|
IP-19. SGLT2 inhibitors in patients with cardiovascular disease or cardiovascular risk : a systematic review and meta-analysis of cardiovascular outcome trials Zinan Zhao1, Yatong Zhang1, Pengfei Jin1, Xin Hu1, Chao Tian3, Deping Liu2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1666-1666, 2021. |
|---|
|
|
IP-20. Presentation of chemotherapy options in cachexia in the literature : a scientometric evaluation Mingnan Cao1, Jingxuan Wu2, Li Wang3, Ruihua Dong2, Zhigang Zhao1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1667-1667, 2021. |
|---|
|
|
IP-21. Correlation between Clock gene methylation and therapeutic effect in patients with depression disorder Ou Yaqing1,2, Zhang Yuan1, Lu Chen1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1668-1668, 2021. |
|---|
|
|
IP-22. The effect of liposomal doxorubicin on liver and renal function in patients with breast cancer Du Jie, Gong Zhicheng Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1669-1669, 2021. |
|---|
|
|
IP-23. Evaluation of a Pharmacist-led Remote Warfarin Management Model Using a Smartphone Application (Yixing) in Improving Patients' Knowledge and Outcomes of Anticoagulation Therapy Pan Chen1, Shudan Jiang1,2, Qiuyi He11, Jiajia Yan1, Liyan Zhao1, Yifan Zheng1, Xiao Chen1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1670-1670, 2021. |
|---|
|
|
IP-24. The design and establishment of prescription pre-examination system based on DRG payment platform Sichao Yan, Jiang Dechun Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1671-1671, 2021. |
|---|
